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ABSTRACT
Heavy and light chain cDNAs that encode for a bovine anti-testosterone 
monoclonal antibody have been cloned and sequenced. Testosterone binding by the 
antibody encoded by the cDNAs has been verified by expression in COS-1 cells and 
subsequently identifying bovine anti-testosterone IgG in transfected cell culture 
media. The cDNAs are the first to be described for functionally rearranged bovine 
Ig genes. The heavy and light chains were identified as C-gamma-1 and lambda 
respectively. The coding region of the V-domains include J-regions which suggests 
that the germline organisation and the mechanisms of V-exon assembly in cattle 
are likely to be similar to those of other mammalian species. The derived protein 
sequence of the heavy chain has been compared with those of bovine IgG2 and human 
and rabbit IgGs, in order to identify potential binding site(s) for Fc-gamma-1 
receptors and complement on bovine IgGl.
A three-dimensional molecular model of the antigen binding site of the bovine 
anti-testosterone antibody has been constructed. The major structural feature of 
the model is a cavity formed by residues from five of the CDRs. Based on the 
model, testosterone is predicted to bind into the cavity and establish a hydrogen 
bond through the D-ring hydroxyl with CDR-H3 Tyr-97. Site-directed mutagenesis at 
CDR-H3 Tyr -97 confirmed the importance of this residue for the high affinity of 
the antibody. Substitution o f phenylalanine at this site resulted in an antibody 
with an affinity reduced by nearly three orders of magnitude , whereas 
substitution of glutamate resulted in an antibody that still binds testosterone, 
but with a greatly reduced affinity. The reduction in binding energy associated 
with the replacement of phenylalanine for CDR-H3 Tyr -97 was calculated to be 3.7 
kcal moP'., which is consistent with the loss of a single hydrogen bond. The model 
has been used to propose specific amino acid substitutions design to enhance the 
antibodies affinity for testosterone.
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CHAPTER 1. 
INTRODUCTION.
CHAPTER 1.
INTRODUCTION.
1.1 Antibody Structure and Function: General Introduction.
The immunological importance of antibodies has been recognised since 1890 when 
von Behring and Kitasato demonstrated that resistance to diphtheria toxin could be 
transferred between animals by serum containing anti-toxins. The anti-toxins they 
described are now known to be antibodies, or immunoglobulins (Ig).
Antibodies are produced by B-cells and fulfil their immunological role as the 
effector molecules of humoral immunity. They function as adaptor molecules that 
enable the invariant killing mechanisms of the immune system to recognise the 
enormous antigenic variation of pathogenic microorganisms. Binding to antigen is 
achieved through binding sites, located on the variable domains of the molecule 
(section 1.3.3), which bind specific antigen (Inbar et al., 1972; Amit et al., 
1986; Colman et al., 1987; Sheriff et al., 1987; Padlan et al., 1989). The 
antibody-antigen complex is then able to bind effector molecules o f the immune 
system (section 1.5), including cell receptors (Duncan et al., 1988; Helm et al., 
1988) and complement (Duncan and Winter, 1988).
Antibody molecules consist of 4 polypeptide chains, 2 identical light chains of 
approximately 220 amino acids, and 2 identical heavy chains of 450-475 amino 
acids. The chains are linked by interchain disulphide bonds which give antibodies 
a Y-shaped structure. The structure of a monomeric IgG molecule is diagramatically 
represented in Figure 1.
1.2 Immunoglobulin Classes and Subclasses.
Five distinct classes of antibody have been recognised in mammalian species, 
designated by the Greek, mu (IgM), gamma (IgG), alpha (IgA), epsilon (IgE), and 
delta (IgD). Antibody classes are further divided into subclasses, and the number 
of subclasses within each class varies between species. The class/subclass of an 
antibody is determined by the sequence o f the heavy chain (section 1.3). Each 
heavy chain is encoded by a distinct gene which is referred to as an isotypic 
variant. Unique structural features of each heavy chain isotype allow the 
different antibody classes/subclasses to mediate distinct biological effector 
functions.
Antibody light chains are also divided into classes, namely kappa and lambda.
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Figure 1. Structure of monomeric IgG.
Monom eric Igs consist of 4  polypeptide chains:
2 identical heavy chains and 2 identical light chains held together by 
interchain disulphide bonds.
IgM and IgE antibodies have a  fourth C-dom ain (C H 4) at the C-term inus  
of each heavy chain.
Fab =  fragm ent antigen binding V-region = variable region 
Fc = fragm ent crystaiizable C-region = constant region
LC = light chain V L  = light chain V -dom ain
H C  =  heavy chain V H  = heavy chain V -dom ain
C H O  = carbohydrate FR =  fram ew ork regions
H 1 , H2 and H3 = heavy chain C D R s L 1 , L2 and L3 -  light chain C D R s
(C D R  = Com plem entarity Determ ining Region)
C H 1 , C H 2 , C H 3  and C L  = C onstant region dom ains.
  Indicates positions of interchain disulphide bonds
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The number of isotypic variants of each class is also species dependant. The mouse 
has a single kappa and three lambda isotypes and each isotype has been found in 
association with each of the heavy chain isotypes, although the kappa light chain 
isotype predominates in murine Igs i.e. approximately 95% of murine Igs have kappa 
light chains. In cattle, this situation is reversed and antibodies with kappa 
light chains have not been found. Man is intermediate with approximately 60% of 
Igs having light chains of the kappa class.
1.2.1 IgA.
The mouse has only a single alpha isotype, whereas in man two isotypic variants 
have been identified (Takahashi et al., 1982). IgA is the major antibody class 
found in external secretions where they perform a protective role by coating 
pathogens, thereby preventing their cellular attachment and entry into the body 
(Underwood and Schiff, 1986). IgA is predominantly found as a dimer, linked by a 
joining (J) chain. Dimerisation of IgA is essential for association with secretory 
component (SC), on the surface of epithelial cells which allows for IgA transport 
into external secretions.
1.2.2 IgM.
Monomeric IgM (and IgD), on the surface of B-cells, function as antigen 
receptors. Surface expression requires association with membrane proteins and is 
dependant on a transmembrane tail (Hombach et al., 1990). Membrane IgM is involved 
in regulating the immune response. Crosslinking of membrane IgM on immmature B- 
cells results in cell inactivation, a mechanism believed to be responsible for 
eliminating B-cells capable of producing auto-antibodies (Nossal, 1983). By 
contrast, crosslinking membrane IgM on mature B-cells promotes clonal activation 
and cell differentiation into antibody secreting plasma cell (DeFranco, 1987; 
Cambier and Ransom, 1987).
IgM is secreted as pentamers in association with a joining (J) chain. 
Pentameric IgM, therefore, has multiple antigen binding sites which increases the 
avidity o f the molecule for antigen. Similarly, pentameric IgM has multiple 
binding sites for effector molecules, such as complement, which allows for 
interactions with greater affinity than the monomeric form (Burton, 1985). For 
this reason, pentameric IgM is the most effective Ig molecule that activates 
complement via the classical pathway.
3
1 .23  IgD.
IgD also functions as an antigen receptor on the surface of B-cells and 
crosslinking of membrane IgD has also been implicated in immune regulation and the 
development of immunological tolerance (see IgM above). IgD is associated in the 
membrane with a protein heterodimer, one subunit of which is homologous to a 
subunit of the IgM complex (Hombach et al., 1990).
1.2.4 IgE.
IgE binds to receptors (Fc-epsilon-R) on the surface o f mast cells and 
basophils (Helm et al., 1988). Antigen crosslinking of IgE bound to mast cells and 
basophils stimulates the release o f histamine and other chemical mediators of 
inflammation resulting in the clinical symptoms of hypersensitivity (Ishizaka and 
Ishizaka, 1967). The main physiological role of IgE is to protect external mucosal 
surfaces by local recruitment of plasma factors and effector cells by triggering 
an accute inflammatory reaction.
1.2.5 IgG.
In general, IgGs function as opsonins. When aggregated on the surface of 
microorganisms, they trigger their engulfment via simultaneous binding to 
receptors (Fc-gamma-R) on the surface of phagocytic cells. Aggregated IgG also 
activates complement via the classical pathway (Burton, 1985). Soluble IgG binds 
and neutralises bacterial toxins before they can have their harmful effects. IgG 
bound to antigen on the surface of virusinfected cells mediates antibody-dependant 
cell-mediated cytotoxicity (ADCC) by simultaneous binding to cells with natural 
killing activity (Karpovsky et al., 1984). Crosslinking of IgG on the surface of 
platelets stimulates the release o f several factors important to the development 
o f an acute inflammatory response. Through its ability to bind placental 
trophoblasts, IgG is transported across the placental barrier (Neizgodka et al., 
1981; Brown and Johnson, 1981) and provides a major defence against pathogenic 
microorganisms in the first few weeks of the life of a human baby.
In man and mouse, there are 4 IgG subclasses. These are designated IgGl, IgG2, 
IgG3 and IgG4 in man, and IgGl, IgG2a, IgG2b, and IgG3 in mouse. In cattle, 2 
subclasses of IgG (IgGl and IgG2) have been recognised, with the possibility of 
the IgG2 subclass being further divided into IgG2a and IgG2b (Butler et al., 
1987). Recently, a third bovine IgG subclass (IgG3) has been proposed (Knight et 
al., 1988), which may account for the apparent divison of IgG2. The IgG subclasses
4
mediate distinct, but overlapping biological effector functions (section 1.5); 
however, IgGs from different species with the same designation are not usually 
functionally equivalent.
1.3 Immunoglobulin Structure.
The overall structure of the Ig molecule (Figure 1) was elucidated in the early 
1960s from several lines of evidence. Edelman and Poulik (1961) demonstrated that 
chemical reduction of Igs yields 4 polypeptide chains, two of approximately 55 kd 
and two of approximately 22 kd. Porter (1962) demonstrated that protease digestion 
o f IgG results in fragments with different properties. Digestion with papain 
results in three fragments; two identical Fab fragments (Fab; fragment antigen 
binding) which bind, but fail to precipitate antigen, and a Fc-fragment which is 
readily crystallized (Fc; fragment crystallisable). Digestion with pepsin results 
in cleavage of the Fc-fragment into several small molecular weight species and 
leaves the Fab arms covalently linked by the hinge region as a single F(ab')2 
fragment. The F(ab')2 fragment is able to bind and precipitate large molecular 
weight antigens. Together, these observations implied that antibody molecules 
possess two antigen binding sites, one on each Fab arm.
The bivalent nature of antibodies was confirmed by the studies of Valentine 
and Green (1967) who obtained electron micrographs o f antibodies bound to a 
divalent antigen and identified geometric structures (triangular trimers, square 
tetramers, and pentagonal pentamers) consistent with the binding of Y-shaped 
molecule with an antigen binding site located at the end of each arm.
The studies of Valentine and Green also supplied the first evidence o f the 
flexible nature of the molecule as the angle between the Fab arms was seen to 
vary. Relative movement between the Fab arms and the Fc region is now known to 
result from the flexible nature of the hinge region (section 1.4). In addition to 
conferring flexiblility on the molecule, the hinge region supplies cysteine 
residues that form inter-heavy chain disulphide bonds (Marquart et al., 1980).
Knowledge of the three-dimensional structure of Igs at atomic resolution has 
been predominantly supplied by X-ray crystallography of IgG fragments (Table 1). 
Crystallographic data for intact antibody molecules is limited to the IgG KOL 
(Marquart et al., 1980) and hinge-depleted antibody variants MCG (Rajan et al.,
1983) and Dob (Sarma et al., 1971). In the case of IgG KOL, the Fc region could 
not be assigned significant electron density as this region occupies more than one 
position in the crystal lattice resulting from the flexible nature o f the
5
molecule. In the hinge-depleted antibodies MCG and Dob, loss of the hinge region 
results in reduced flexibility, which has enabled the Fc region to be located in 
their respective electron density maps.
Table 1. Crystal structures of Ig fragments.
Fabs
NEW
KOL
McPC603
J539
R19.9
Gioop-2
4-4-20
HyHEL-5
HyHEL-10
D1.3
NC41
NC.10
Saul et al., (1978); * Amzel et al., (1974) 
Marquart et al., (1980)
* Segal et al., (1974); Satow et al., (1986)
* Suh et al., (1986)
Lascombe et al., (1989)
Jeffrey et al., unpublished
* Herron et al., (1989)
* Sheriff etal., (1987)
* Padlan et al., (1989)
* Amit et al., (1986); * Bhat et al., (1990)
* Colman et al., (1987)
* Colman et al., (1989)
Fv fragment
D1.3 * Bhat et al., (1990)
Light chain dimers
RHE
Rei
Loc
Furey et al., (1983) 
Epp et al., (1975) 
Chang et al., (1985)
Fc-region
Human IgG Deisenhofer et al., (1981)
Intact Ig
KOL Matsushima et al., (1978)
Hinge-depleted Igs
Dob
MCG
Sarma et al., (1971) 
Rajan et al., (1983)
* indicates structure determined in the presence of antigen.
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1.3.1 Immunoglobulin Domains.
Immunoglobulin chains fold into a series of distinct domains. Light chains are 
formed by two domains: an N-terminal variable domain (VL) and a C-terminal 
constant domain (CL), Heavy chains fold into an N-terminal variable domain (VH) 
and three or four C-domains (CHI, CH2, CH3 and CH4) depending on the class of the 
antibody. The heavy chains of IgA, IgD and IgG have 3 C-domains (except for murine 
delta-chains which have only 2 C-domains), whereas the heavy chains of IgE and IgM 
have four.
As the name implies, the amino acid sequence of VL and VH domains vary between 
chains, including those of the same isotype, whereas the amino acid sequence of C- 
domains are identical for chains of the same isotype (and allotype) (Kabat et al., 
1987). The divison of the chains into V and C-domains reflects the functional 
division of the molecule. V-domains include the regions of the molecule that make 
molecular contact with the antigen (the paratope) to which they are directed, 
whereas the C-domains have binding specificities for effector molecules o f the 
immune system.
The first evidence that antigen combining sites are formed by the V-domains was 
presented by Inbar et al., (1972) and Hochman et al., (1973). They demonstrated 
that isolated VL and VH-domains could reassociate, in equimolar proportions, to 
form functional antigen binding sites. This implied that the C-domains o f an 
intact antibody molecule are neither required for, nor interfere with, antigen 
binding. This observation has been confirmed by the expression of VL and VH 
domains, which associate to form functional antigen binding sites with identical 
affinity as the parent antibody (Skerra et al., 1988), and by the expression of 
recombinant antibodies with interchanged V-domains (i.e. antibodies with heavy 
chains with a VL-domain and visa versa) that retain the antigen binding 
specificity of the wild type antibody (Simon and Rajawsky, 1990).
The biological effector functions of the Ig classes/subclasses have been 
identified to reside on the Fc region of the molecule by comparing the activities 
of isolated Fc fragments with intact antibodies (Burton, 1985).
In the Ig crystal structures (Table 1), V and C-domains are seen to share 
considerable structural homology, despite extensive sequence variation (Lesk and 
Chothia, 1982). They consist of two large anti-parallel beta-sheets packed face 
to face and stabilised by a conserved disulphide bond. The basic structure 
o f an Ig domain, as represented by a C-domain (Figure 2), consists o f 7 beta
7
Figure 2. Diagramatic representation of the structure of an Ig domain.
CDR-i
An Ig C-domain consists of 7 15-strands labelled A, B, C, D, E, F and G from the N- 
terminus. V-domains are characterised by the addition of 2 extra 15-sheets , labelled Cl and 
C2. Structural alignment of the domains shows that the additional J3-sheets are inserted 
between C and D.
A & B = Framework region 1. C & C = Framework Region 2.
C2, D & E = Framework 3. G = Framework Region 4.
CDR = Complementarity Determining Region.
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strands formed into two beta-sheets o f 3 and 4 strands respectively. V-domains 
are characterised by the addition of two extra beta-strands. Optimal alignment of 
V and C-domains has demonstrated that the two additional strands are inserted into 
die three stranded sheet to form a sheet of 5 strands (Colman, 1988 and Figure 2).
A common core structure, formed by 17 homologous residues, has been found at 
the centre of V and C-domains, which has been proposed to be primarily responsible 
for the conserved structure (Lesk and Chothia, 1982). This region includes the 
conserved disulphide bond, and hydrophobic residues that pack between the double 
beta-sheet structure.
1.3.2 Variable-domains.
V-domains are themselves divided into subregions. The division is made on the 
basis of sequence homology and reflects the functional divison of the domain.
A sequence alignment o f several Bence-Jones proteins (light chain dimers) 
identified three linear regions within VL-domains that varied in length and 
sequence (Wu and Kabat, 1970). A comparison of VH-domains similarly identified 
three regions of variable length and sequence (Kabat and Wu, 1971). These regions 
were termed the hypervariable regions (or hypervariable loops, Wu and Kabat, 
1970; Kabat and Wu, 1971) and were proposed as the regions involved in antigen 
binding. In addition, the above sequence comparisons identified two conserved 
cysteine residues within both VL and VH-domains that were proposed to facilitate 
the association of the hypervariable regions within a V-domain by the formation of 
a intra-chain disulphide bond (Kabat and Wu, 1971). These observations led Kabat 
and Wu (1971) to propose that the hypervariable regions of a VL- and a VH-domain 
associate in the tertiary structure of the molecule to form an antigen combining 
site.
The crystal structures of Fabs complexed with antigens (Table 1) have confirmed 
the predicted role for the hypervariable loops: the hypervariable loops associate 
to form a surface complementary to the surface that they bind (the epitope). The 
term complementarity determining regions (CDR) was therefore introduced to 
describe the functional role of the hypervariable loops.
The remaining regions of V-domains display less sequence variation, and V- 
domains have been grouped into families according to their homology over these 
regions (Kabat et al., 1987). These regions are referred to as the framework 
regions (FR) and are considered in the Fab crystal structures to serve as a
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structural support for the hypervariable loops: The CDRs form exposed loops that 
link strands of the framework beta sheets (Figure 2). CDRs L2, L3, H2, and H3 link 
adjacent strands, whereas CDRs LI and HI link strands from different sheets.
The linear arrangement of the hypervariable and framework regions in V-domains 
is schematically represented in Figure 1.
1.3.2.1 The Framework Regions.
The framework regions (FR) of V-domains form highly conserved structural 
supports for the hypervariable loops. Investigations into the nature o f the 
homologous structure of V-domains have identified several key structural residues 
responsible for their conserved fold.
Saul et al., (1978) predicted a common structural fold for V-domains on the 
basis of identifying the same or similar amino acids in the sequences o f V- 
domains of other immunoglobulins, to those found at key structural residues in the 
crystal structure NEW.
Novotny and Haber (1985) superimposed the side chain atoms of conserved 
residues of isolated V-domains of three crystal structures KOL, NEW and McPC603 
(Table 1), and identified regions within each V-domain type that almost overlayed 
exactly.
Chothia and Lesk (1987) superimposed the main chain atoms of the FRs of 
isolated VL-domains (KOL, McPC603, NEW, J539, RHE and REI. Table 1), and isolated 
VH-domains (KOL, McPC603, NEW and J539. Table 1), and identified 69 light chain 
and 79 heavy chain residues that occupy homologous positions.
The above analyses demonstrated that the structural homology of the FRs extends 
to those residues immediately adjacent to the hypervariable loop and as a 
consequence the loops occupy a relatively fixed position within the domains.
1.3.2.2 The Complementarity Determining Regions.
The main chain conformations o f the CDRs display a remarkable similarity 
despite considerable sequence variation.
Kabat (Kabat et al., 1977; Kabat, 1978) examined the CDR sequence of antibodies 
with widely different antigen spec'ficities and argued that an amino acid seen at a
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particular residue with a high frequency would be expected to be involved in 
determining the structure of the CDRs rather than binding specificity. On this 
basis, they predicted that 7 light chain, and 10 heavy chain CDR residues would 
play such a structural role. In support o f their prediction, Padlan (1979) 
examined the available crystal structures and concluded that the amino acids at 
several of these residues have side chains that are buried within the domains, in 
positions inaccessible for antigen binding.
de la Paz et al., (1986) observed that CDRs of the same length may share 
similar main chain conformations, despite low sequence homology, and used these 
observations to construct molecular models of Fv fragments (section 1.8).
Chothia and Lesk (1987), and Chothia et al., (1989) examined the CDR 
conformations of several crystal structures and identified key structural 
residues within the CDRs, and interacting residues within the FRs, that are 
primarily responsible for their main chain conformations. Furthermore, they 
compared the published CDR sequences and showed that several CDRs, which are the 
same length as those o f a crystal structure, have identical amino acids at these 
sites, and that CDRs with different amino acids display a different pattern of 
conserved residues (Chothia and Lesk, 1987). These observations led Chothia and 
Lesk (1987) to propose that for five of the CDRs (excluding H3), the repertoire of 
main chain conformations available is limited to a small number of types which 
they call canonical forms. Their analyses involved the optimal alignment of 
corresponding CDRs of crystal structures and demonstrated that residues at the N 
and C terminals of the CDRs as defined by Kabat and Wu (1971), have virtually 
identical main chain conformations. This observations led Chothia and Lesk (1987) 
to propose different boundaries between the CDRs and the FRs on the basis of 
structural variability. For each CDR, except CDR-H1, they define a subregion of 
the region defined by Kabat and Wu (1971); however, in crystal structures of Fabs 
complexed with antigens (Table 1), several residues that lie outside the CDRby
boundaries defined Chothia and Lesk, but inside those defined by Kabat, make 
contact with the antigen.
1.3.4 Immunoglobulin Modules.
In intact antibody molecules, the domains of Ig chains associate to form 
domain pairs or modules. The V-domains of a heavy (VH) and light chain (VL) 
associate to form a V-module or Fv fragment. The light chain C-domain (CL) 
associates with the heavy chain C-domain, proximal to the VH domain (CHI), to form 
a CL:CH1 domain dimer. In IgG, the CH2 and CH3 domains associate to form CH2:CH2
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and CH3:CH3 domain pairs (Deisenhofer, 1981). Except for a CH2 domain pair domain 
association is achieved through extensive, lateral non-covalent interactions 
between several hydrophobic residues.
1.3.4.1 C-modules.
The association of CH3 domains resembles that between CL and CHI (Deisehnhofer, 
1981) in that virtually all the residues involved in CH3-CH3 contacts are in 
positions homologous to those that participate in CH1:CL contacts. The 
association of the CH2 domains of IgG molecules is different to that observed 
between CHI and CL, and that of a CH3 domain pair. This results from the presence 
o f carbohydrate chains attached to Asn 297. The carbohydrate forms extensively 
branched structures that fill the interface between the domains such that 
protein:protein contacts are not made (Deisenhofer, 1981).
1.3.4.2 V-modules.
V-modules share considerable structural homology which results from the highly 
conserved structure of V-domains. Most of the structurally conserved residues of 
V-domains identified by Novotny and Haber (1985) have hydrophobic side chains and 
are buried within the domains. However, they also identified several structurally 
conserved residues, with hydrophobic side chains, that are located at the surface 
of the domains. These residues were found to be the most stringently conserved in 
V-domains, and become buried at the VL:VH interface on domain association. They 
concluded that these residues were important in determining the conserved 
quaternary structure of V modules.
A similar analysis (Chothia et al., 1985) identified 20 residues (10 on each 
chain) which are involved in the conserved packing at the VL:VH-domain interface. 
Twelve o f these residues are absolutely or very strongly conserved in all Ig 
sequences. These residues form the central and lower regions (towards the C- 
domains) o f the interface. The remaining eight residues display greater varia­
bility and form the upper region of the interface. Approximately one-quarter of 
the interface involves packing between residues in the CDRs and it is in this 
region that the remaining eight residues are found.
The above analyses identified virtually the same residues as being responsible 
for the overall conserved architecture of an Fv module. The beta sheet packing of 
V domains and the assocation of V domains in V modular formation of the more 
recently resolved crystal structures conform to the conserved pattern seen in
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the earlier resolved structures (references later than 1985 cited in table 1).
1.4 Segmental Flexibility.
A feature of immunoglobulin molecular design is the ability of different parts 
of the molecule to move relative to each other, a phenomenon termed 'segmental 
flexibility’ . Two flexible regions have been observed: a ’hinge region’ between 
the Fab arms and the Fc region (Noelken et al., 1965; Valentine and Green, 1967; 
Silverton et al., 1977; Marquart et al., 1980), and an ’elbow region’ between the 
domain pairs (VL:VH and CL:CH1) of an Fab fragment (References cited in Table 1). 
Flexibility about these regions facilitates bivalent binding o f antibodies to 
polyvalent antigens, by allowing the position of the antigen combining sites to 
adjust, to match the pattern of repeated epitopes on the surface of foreign 
antigens. In addition, hinge flexibility controls the ability o f the different IgG 
subclasses to activate complement (Oi et al., 1984).
1.4.1 The Hinge Region.
Under the scanning electron microscope, the angle between the Fab arms of a 
myeloma protein, when complexed with a divalent antigen, is seen to vary over a 
range of approximately 180° (Valentine and Green, 1967). This observation led 
Valentine and Green (1967) to propose that a molecular hinge mechanism operatesL
between the Fab arms and the Fc region. This proposal has since been supported by 
a variety of studies and observations. In the crystal structure o f an intact IgG 
KOL (Marquart et al., 1980), significant electron density could not be assigned to 
the Fc region, as this part of the molecule appeared disordered. Crystal 
structures of hinge-depleted variants show antibodies as T-shaped molecules, and 
the Fc region has been located in their respective electron density maps (Sarma et 
al., 1971; Rajan et al., 1983). These observations are consistent with loss of 
molecule flexibility in the hinge- depleted Ig, which permits the Fc region of KOL 
to occupy more than one position in the crystal lattice.
Genetically engineered IgGs, with identical binding specificities, have been 
used to obtain a more precise understanding of the structural features that 
control hinge flexibility (Dangl et al., 1988; Schneider et al., 1988).
The length o f the 'upper hinge', (defined as the region between the last 
residue of the CHI domain and the first cysteine residue of the hinge that forms a 
interchain disulphide bond), correlates with the observed flexibility of IgG 
subclasses (Dangl et al., 1988). Murine IgG3 was found to be an exception to the
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above correlation. This antibody is of intermediate flexibility, despite the upper 
hinge region being 14 amino acids long, which is consistent with substantial 
flexibility. The amino acid sequence of the upper hinge of murine IgG3, proximal 
to the disulphide bond, contains a polyproline core sequence. This region is 
proposed to act as a restricting element, thereby effectively reducing the upper 
hinge from 14 to 9 amino acids, consistent with the observed flexibility of this 
isotype.
Q
Nanosecond fluores^nce measurments, using recombinant antibodies with 
identical antigen binding sites for epsilon-dansyl-L-lysine, and hybrid CHI 
domains have implicated a continuous polypeptide loop (131-139) to be important 
in the control of hinge flexibility (Schneider et al., 1988). Replacement o f this 
loop in murine IgGl with that of IgG2a, and vice versa, renders both molecules 
more rigid. In the crystal structure o f the intact IgG KOL (Marquart et al., 
1980), the upper hinge region is seen to lie close to the 131-139 loop (NAT). 
This has led Schneider et al., (1988) to propose that interactions between this 
loop and the hinge must be properly matched and act to further influence hinge 
flexiblity. These studies also demonstrated that different IgG isotypes display 
differing degrees of flexibility.
1.4.2 Elbow Motion.
In Fab fragments, the VL:VH and CL:CH domain pairs are related by a two-fold 
axis of symmetry, and the angle between these two axes varies over a range of 50°. 
The ability o f the Fab domain pairs to change their positional relationship is 
referred to as 'elbow motion'. The Ig crystal structures show that the angle at 
the 'elbow' results from a different conformation of the switch peptides. Switch 
peptides are short regions o f the heavy and light chains that link V and C- 
domains. Lesk and Chothia (1988) have identified highly conserved residues that 
make longitudinal interactions between VH and CHI which facilitate 'elbow motion' 
and propose that these residues form the molecular equivalent o f a 'ball-and- 
socket' joint.
1.5 The Fc-region of IgG.
The Fc region o f IgG includes binding specificities which allow for 
interactions with several cell receptors (Fc-gamma-receptors) and complement 
(Burton, 1985; Duncan et al., 1988; Duncan and Winter, 1988).
14
1.5.1 Complement Activation.
IgG subclasses activate the complement cascade via the classical pathway and 
display a range of complement fixing activity (Bruggemann et al., 1987; Oi et al.,
1984). Human IgGl and IgG3, murine IgG2a and IgG2b fix complement the most 
efficiently. Murine IgGl is less efficient, whereas human IgG2 and IgG4, and 
murine IgG3 fail to activate complement. IgG subclasses from other species also 
activate complement, and in general IgG and complement derived from different 
species usually interact (Burton, 1985).
The first step in activating the complement cascade via the classical pathway 
is binding of Clq to aggregated antibody (Burton, 1985). Clq is a subunit of the 
first active component of the classical pathway, Cl. The binding site for Clq was 
localised to the C-gamma-2 domains by Yasmeen et al., (1976) who demonstrated that 
isolated C-gamma-2 domains could bind Clq with a comparable affinity to isolated 
Fc-fragments and intact IgG molecules. The binding site on C-gamma-2 domains has 
subsequently been identified (Duncan and Winter, 1988) and is formed by residues 
Glu-218, Lys-220 and Lys-222. This site is conserved in all human and murine IgGs, 
except for murine IgGl. The presence of a Clq binding site on human IgG4 explains 
the observation that isolated Fc-fragments derived from this subclass bind Clq and 
activate complement as well as isolated Fc regions o f IgG subclasses that fix 
complement well (Yasmeen et al., 1976). Human IgG4 is a relatively inflexible 
molecule (Dangl et al., 1988) and the inability of this isotype to bind Clq 
results from steric hindrance o f the C lq binding site by the Fab arms. This 
explanation is supported by the inability o f hinge-depleted IgGs to activate 
complement despite these molecules being variants o f antibody subclasses that 
normally activate complement (Klein et al., 1981). A strong correlation between 
hinge flexibility of IgG subclasses and the ability to activate complement has 
been found (Oi et al., 1984; Schneider et al., 1988), with the most flexible 
subclasses being the most effective. Thus the degree of hinge flexibility 
modulates the ability of IgG molecules with Clq binding sites to activate 
complement.
1.5.2 Fc-receptor Binding.
IgG binds Fc-gamma receptors that are expressed on a variety o f cell types, 
including mononuclear cells, granulocytes, lymphocytes, platelets and trophoblasts 
(Anderson and Looney, 1986). Three types of Fc-gamma receptors (FcRI, FcRII and 
FcRIII) have been identified on human leucocytes, which are expressed in different 
combinations on distinct cell populations (Anderson and Looney, 1986; Hogg, 1988
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). In addition, Fc-gamma-receptor expression may be induced on some cell types by 
gamma-interferons (Hogg, 1988). Each receptor type possesses a distinct 
specificity for IgG subclasses and the receptors are characterised by their 
different affinities for IgGs. Human FcRI is expressed on human monocytes and 
binds monomeric IgG with relatively high affinity (Ka = 1 x 108-109 M-1 ). The 
other Fc-gamma receptor types bind monomeric IgG with weak affinity (Ka = 1 x 105 
M-1), which increases for aggregated IgG (Ka = 1 x 107 M” 1).
The binding site on human IgGl for human FcRI was shown to reside on the Fc- 
region by Frangione and Milstein (1967). They demonstrated that isolated Fc 
regions of human IgGl are able to inhibit the interaction between human IgG and 
human monocytes, whereas Fab fragments had no effect. Several further studies 
localised the binding site to the C-gamma-2 domains (Klein et al., 1981; 
Ratcliffe and Stanworth, 1983; Woof et al., 1984; Leatherbarrow et ai., 1985; 
Partridge et al., 1986). The ability o f various proteolytic fragments o f human 
IgGl to bind human monocytes has been assessed and the results obtained strongly 
implicated the N-terminus of the CH2-domains as the site of receptor binding (Rat­
cliffe and Stanworth, 1983). These studies demonstrated that the Fc region 
(prepared by papain digestion which cleaves above the hinge interchain disulphide 
bonds) and the CH2-domains still covalently linked in the hinge region were able 
to bind human monocytes, whereas Fab, the CH3-domains and, more significantly, 
thermolysin prepared Fc fragments (which cleaves below the hinge interchain 
disulphide bonds, in the hinge-CH2 link region) were unable to do so. Hinge- 
depleted IgGs retain the ability to bind Staphylococcal protein A, but no longer 
bind human monocytes (Klein et al., 1981; W oof et al., 1984). The protein A 
binding site has been located and is formed by the lower part of the C-gamma-2 
domain (towards the C-gamma-3 domain) and the upper part of the C-gamma-3 domain 
(Deisenhofer, 1981). The lower region of the C-gamma-2 domains and the C-gamma-3 
domains in hinge-depleted IgG are therefore available for interactions with other 
proteins which suggested that these regions do not include the human FcRI binding 
site. Woof et al (1984) and Leatherbarrow et al (1985) found no evidence for the 
involvement of the C-gamma-3 domain of human IgG in binding human monocytes. 
Partridge et al., (1986) used monoclonal antibodies, specific for individual C- 
gamma domains, to show that only antibodies against C-gamma-2 were able to inhibit 
the interactions between IgG and monocytes. A sequence comparison of C-gamma-2 
domains, and their binding specificity for human IgGl (Woof et al., 1986), led to 
the proposal that the human FcRI binding site was located at the hinge-C-gamma-2 
link region, involving the sequence 234-Leu-Leu-Gly-Gly-Pro-238. This sequence has 
been confirmed as the FcRI binding site by the introduction of site-directed muta­
tions (Duncan et al., 1988). Murine IgG2b has a near identical sequence over this
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region (Gly-235 replaces Leu-235), but does not bind human FcRI. Gly-235 in 
murine IgG2b has been changed to leucine, resulting in a 100 fold increase in 
affinity for human FcRI.
The binding sites on IgG for the other human Fc-gamma receptor types (FcRII and 
FcRIII) are as yet unknown; however, it is likely that these receptors bind 
different parts of the molecule. Barnett-Foster et al (1982) demonstrated that the 
B-fragment of Staphylococcus aureus protein A, inhibits the interactions of rabbit 
IgG-sensitised sheep erythrocytes with human monocytes (FcRI), but not with human 
neutrophils, which normally express FcRII or FcRIII (Anderson and Looney, 1986; 
Hogg, 1988). Similarly, the use of anti-NIP monoclonal antibodies has shown that 
human IgG4 binds FcRI, but not FcgRII (Hogg, 1988). The binding site on human IgG4 
for FcgRII could be the FcRI binding site identified by Duncan et al., (1988), 
with the failure of FcRII binding resulting from steric obstruction as is the case 
for the C lq binding. However, the molecular weight of the human FcRII is 
significantly smaller than FcRI (FcRI 71 kDa, FcRII 40 kDa. Anderson and Looney,
1986), which suggests that FcRII should have unrestricted access to the hinge link 
region.
1.5.3 CH-2 N-linked Carbohydrate.
A common structural feature of IgGs is the presence of carbohydrate chains 
attached to Asn-279 of each of the C-gamma-2 domains. An assesment of the solvent 
accessibility of the C-gamma 2 carbohydrate (Burton, 1985) shows that the 
terminal residues of the chains are available for interactions with proteins; 
however, attributing functions to the carbohydrate is complex as a large number of 
carbohydrate structures have been proposed to exist on IgG antibodies of a 
conventional subclass (Rademachr and Dwek, 1984) creating 'sub-subclasses'.
1.6 Antibody-antigen Complexes.
The molecular details of the interactions between an antibody and its antigen 
have confirmed the role of the CDRs in antigen binding (Amit et al., 1986; Colman 
et al., 1987; Sheriff et al., 1987; Padlan et al., 1989; Bhat et al., 1990). The 
CDRs associate to form a surface (the paratope) complementary to the region of the 
antigen to which the antibody binds (the epitope). For large antigens, such as 
proteins, all of the CDRs make contact with the epitope, whereas for relatively 
small molecules, such as haptens, not all of the CDRs are involved (Amzel et al., 
1974; Segal etal., 1974).
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1.6.1 Antibody Binding to Haptens.
The antigen combining site o f the phosphorylcholine (PC)-binding antibody 
McPC603 (Segal et al., 1974) forms a cavity, the walls of which are formed 
exclusively by residues o f the CDRs (CDR-L2 was the only loop found not to 
particpate in formation of the cavity walls). PC occupies only a small part of the 
cavity and makes contact with residues of four CDRs. The choline moiety is buried 
at the interface with the phosphate group positioned within hydrogen bonding 
distance to heavy chain residues Arg-52 and Tyr-33.
The surface presenft by the hydroxy-vitamin K1 binding antibody NEW is 
relatively flat with a shallow groove between the two domains (Saul et al., 1978). 
On complex formation, the 2-methyl-1,4-napthoquinone moiety of hydroxy vitamin K1 
binds into the groove. The phytyl chain of hydroxy-vitamin K1 runs along the 
surface of the antibody combining site and makes contact with residues o f the 
antibody (Amzel et al., 1974).
The CDRs of a fluorescein binding antibody, 4-4-20 (Herron et al., 1989) 
present a deep slot formed by a network of tryptophan and tyrosine side chains. On 
complex formation, approximately 90% of the fluorescein molecule is buried by 
interactions with the antibody through contacts with five o f the CDRs. The 
contacts between the two molecules includes a single hydrogen bond and one salt 
bridge.
It appears that small molecules, such as haptens, bind antibodies by binding 
into pockets (cavities or grooves) that are formed by the CDRs and that not all of 
the CDRs make contact.
1.6.2 Antibody Binding to Large Antigens.
The structures of 4 Fab fragments complexed to epitopes found on relatively 
large proteins have also been determined (D1.3, Amit et al., 1986; Bhat et al., 
1990; NC41, Colman et al., 1987; Hy-HEL-5, Sheriff et al., 1987; Hy-HEL-10, Padlan 
et al., 1989). Three of these structures are complexed with epitopes on lysozyme 
(D1.3, HyHEL-5 and HyHEL-10), whereas the other complex is with an epitope on 
influenza virus neuraminidase (NC41). These complexes provide information as to 
the likely nature o f antibody-antigen interactions that occur in an immune 
response to foreign antigens, such as a bacterial or viral proteins. Many common 
features are shared by these complexes.
18
In each case, the antibody binds a discontinuous epitope (Van Regenmortel,
1986) through extensive contacts between 16-20 residues on the antibody and a 
similar number on the antigen. With the exception of the Fab fragment NC41, in 
which the involvement of CDR-L2 has not been clarified, all six CDRs make contact 
with the epitope. Residues assigned by Kabat et al (1987) as framework residues 
(FR) make contacts with the epitope. Three FR residues make contact in NC41, two 
in D1.3, and one in both HyHEL-5 and HyHEL-10. In NC41, D1.3 and HyHEL-10, heavy 
chain FR Thr-30 makes contact and, in the case of D1.3, through formation of a 
strong hydrogen bond.
On complex formation, greater than 700 A sq of solvent accessible surface on 
both the antibody and antigen, becomes buried at the interface. The interacting 
surfaces display good complementarity. In NC41, HyHEL-5 and HyHEL-10, the surfaces 
interact to exclude water molecules from the interface completely. However, in 
the case of D1.3, some imperfections in complementarity are observed resulting in 
small regions (or holes) that may be occupied on complex formation by water 
molecules. This observation has been suggested to contribute to the lower binding 
affinity of D1.3 for lysozyme compared with HyHEL-5 and HyHEL-10. Similarly, it 
may also explain the phenonemen of heteroclitic antibodies (i.e antibodies that 
bind with a higher affinity to a closely related antigen) as such holes may be 
filled with atoms of the related antigen at the expense o f water molecules, 
allowing for a closer fit between the antibody and the epitope.
HyHEL-10 presents a different type of surface to the antigen when compared with 
those of other known Fab structures. The surface is relatively flat, except for a 
large protrusion consisting largely o f the side chains of heavy chain residues 
Tyr-33 and Tyr-53 which fit into a cleft on lysozyme. The other Fabs of known 
structure present either flat surfaces, or relatively flat surfaces with shallow 
grooves or cavities.
In each complex, many van der Waals contacts are made across the interface. 
Several hydrogen bonds are also made and some involve amino acid side chains of 
the antigen and main chain atoms of the antibody, and vice versa. A high proporton 
o f aromatic residues are found at the interface, presenting a large hydrophobic 
surface to the antigen. Several tyrosine residues contribute and participate in 
both general hydrophobic interactions, as well as specific hydrogen bonds through 
the hydroxyl group. The contribution of electrostatic interactions in each complex 
is relatively small involving 3, 1, 1, and 0 ion pairs for HyHEL-5, HyHEL-10, NC41 
andD1.3 respectively.
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1.6.3 Conformational Change.
Antigen binding leads to interactions involving the complexed antibody with 
other components of the immune system (Burton, 1985). These interactions usually 
involve the Fc region of the antibody. Initial explanations as to why these events 
take place after antigen binding included the possibility of an antigen-induced 
conformational change occuring in the V-domains, which is transmitted to the C- 
domains, thereby activating the biological effector functions associated with 
these regions (Huber et al., 1976).
Colman (Colman. et al., 1987; Colman, 1988), has determined and analysed the 
structure of the Fab fragment of a monoclonal antibody NC41, complexed with 
influenza virus neuraminidase. They compared the relative spatial arrangments of 
the CDRs of each V-domain of NC41 with the CDRs of other Fab crystal structures 
determined in the absence of antigen and found no significant difference in their 
positions; however, they extended their analysis to include a comparison of the 
rotational and translational movement required for optimal alignment of alpha 
carbon atoms of selected VH residues after this procedure had been applied to the 
VL-domains. They had previously applied this procedure to the Fabs of KOL, NEW and 
McPC603 and found small alterations in V-domain pairing, resulting in a slightly 
different spatial arrangement o f the CDRs, which they attributed to the 
contribution of CDR residues to the VL:VH interface. When NC41 was included in the 
comparison, larger differences of up to 4 A in the positions o f the CDRs were 
observed. These observations led the authors to propose that in the 
NC41:neuraminidase complex, the spatial arrangment of the CDRs results from slid­
ing o f the V domains, in response to antigen binding, to induce a better fit 
between the surfaces of the paratope and the epitope. Furthermore, they proposed 
that the VL:VH domain interface plays a critical role in determining the 
specificity of the antibody by controlling the spatial arrangement of the CDRs 
in a V-module and that the degree of domain slide could represent an additional 
level of antibody diversity.
A subsequent, and more extensive analysis of the spatial arrangement of the 
CDRs in crystal structures of Fabs determined either in the absence or presence of 
antigen (i.e KOL, NEW, McPC603 and R19.9 determined without antigen, and HyHEL-5 
and D1.3 determined in the presence of antigen) found no correlation between the 
relative postions of the V-domains and antigen binding (Lascombe et al., 1989).
Direct evidence to confirm that the exact complementarity between an antibody 
paratope and its epitope is facilitated by the ability o f the V-domains to move
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relative to each other has recently been obtained. Crystal structures of the Fab 
fragment of the anti-lysozyme monoclonal antibody D1.3 have been determined in 
the absence and presence of lysozyme (Amit et al., 1986: Bhat et al., 1990). In 
addition, the structure of the Fv fragment of D1.3 complexed with lysozyme has 
also been determined (Bhat et al., 1990). A comparison of these structures found 
no evidence for a conformational change having occurred within the individual V- 
domains; however, an antigen-induced repositioning of the V-domains was observed. 
In the complexed structures, the VH-domain has moved closer to lysozyme, such that 
the antibody-antigen contact distances are reduced.
The structure of the phosphorlycholine (PC) binding antibody McPC603 has also 
been determined in the absence and presence of the interaction with PC (Segal et 
al., 1974). A comparison of these structures found no evidence for a 
conformational change having occured within the domains or at the VL:VH domain 
interface on PC binding. PC is a small molecule and it is, therefore, possible 
that the degree of any conformational change that occurs on antigen binding may 
reflect the size of the epitope involved i.e. a conformational change is more 
likely when a large number of contacts are made.
Comparisons of the Fab crystal structures complexed to antigen with those 
determined in the absence of antigen have found no evidence for an antigen-induced 
conformational change having occured in the C-domains (CHI and CL). Conformational 
change in C-domains of the Fab of D 1.3 in the complexed state was not reported 
(Bhat et al., 1990). Studies o f the interactions of Fc-gamma-receptors, and 
complement with IgG have shown that the ability of these molecules to bind IgG 
after antigen binding results from an increased affinity for antibody in the 
aggregated state (Burton, 1985).
1.7 Three-dimensional Molecular Models of Antigen Binding Sites.
The high degree of structural homology between V-domains has enabled molecular 
models of antigen binding sites to be constructed by replacing the hypervariable 
loops in a known crystal structure with loops of modelled conformation. Strong 
conservation of residues at the VL:VH domain interface (Novotny and Haber, 1985; 
Chothia et al., 1985) enables FRs from V-domains to be used in combinations other 
than those found in the Ig crystal structures. In some cases, the accuracy of the 
model has been tested by applying the methods to loops of known conformation and 
comparing the results with the crystal structure.
Methods used to model loop conformations have used three approaches: two
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general approaches; the knowledge-based approach and the ab initio approach and a 
third, the combined algorithm, which combines the two general approaches.
1.7.1 The Knowledge-based Approach.
The knowledge-based approach constructs models using main chain conformations 
of loops present in Ig crystal structures (Padlan et al., 1976; Mainhart et al., 
1984; de la Paz et al., 1986; Chothia et al., 1986; Smith-Gill et al., 1987; 
Padlan and Kabat, 1988; Chothia and Lesk, 1987; Chothia et al., 1989). The 
sequence o f the loop is converted to that o f the loop being modelled by side 
chain replacement and the modelled structure subjected to energy minimisation.
Main chain conformations have been selected on the basis of length and maximum 
sequence homology to loops in the crystal structures (Padlan et al., 1976; 
Mainhart et al., 1984; de la Paz et al., 1986; Smith-Gill et al., 1987). In cases 
where a loop of the same length could not be found, the main chain conformation 
has been modelled by making manual deletions or insertions using a loop of similar 
length. The model o f Gloop-2 constructed by de la Paz et al., (1986) has 
subsequently been compared with the crystal structure (Martin et al., 1989) and 
overall reasonable agreement in conformations was obtained; however, loops 
constructed by making deletions or insertions gave poorer results. Better results 
have been obtained when the emphasis for selecting the main chain conformation is 
placed on length, and identifictaion of 'key' amino acids that are responsible for 
determining the main chain conformation of the loop (Chothia and Lesk, 1987; 
Chothia et al., 1989). This approach is therefore limited to loops which are the 
same length and include identical amino acids at the 'key* interacting residues as 
a loop in the database of antibody crystal structures i.e. those predicted to 
belong to a defined canonical form. The limitations o f this approach are 
exemplified by CDR-H3. The genetic mechanisms that operate to maximise the length 
and sequence variation of CDR-H3 (section 1.9) have resulted in loops with 
different main chain conformations in each o f the crystal structures and 'key' 
interacting residues have not been identified. Failure to define canonical forms 
for CDR-H3 has prevented accurate models of this loop from being made using the 
knowledge-based approach.
A slightly different approach has been used to construct models of anti-a-(l-6) 
dextran monoclonal antibodies W3219 and 19.1.2 (Padlan and Kabat, 1988). In these 
models, the main chain conformation o f certain loops were selected from 
different parts of loops found in the crystal structures. These models have not 
been tested directly as the crystal structures of the antibodies modelled have not
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been determined. However, the results o f the modelling are consistent with 
information obtained from binding studies o f the antibodies with alpha-(l-6) 
dextran. W3219 binds the terminal non-reducing end of the molecule, whereas 19.1.2 
binds several internal glucose units. The model of W3219 describes a cavity, 
consistent with end-binding. The model of 19.1.2 forms a relatively flat surface 
with a shallow groove, consistent with side-binding.
1.7.2 The ab initio Approach.
The ab initio approach constructs all the theoretical loop conformations 
compatible with the rest of the structure and selects a final conformation on the 
basis of criteria such as potential energy and solvent accessible surface area 
(Stanford and Wu, 1981; Fine et al., 1986; Bruccoleri et al., 1989). This approach 
has been used to reconstruct loops deleted from Ig crystal structures McPC603 and 
HyHEL-5 (Bruccoleri et al., 1989). For each loop modelled, one of the lowest 
energy conformations generated was in good agreement with the crystal structure; 
however, the lowest energy conformation was not always the closest to the crystal 
structure and in a true modelling situation, the most accurately modelled 
conformation would not have been selected.
1.7.3 The Combined Algorithm.
The combined algorithm approach selects the main chain conformation for the 
base of the loop being modelled from all the structural information (Ig and non- 
Ig) contained within the Brookhaven Protein Databank (Martin et al., 1989; Martin, 
1990). The main chain conformation is selected from a much larger sample of loop 
conformations and, therefore, overcomes the limitations of the small number of Ig 
crystal structures upon which the knowledge-based approach is based. Database 
loops are selected from the Brookhaven Protein Databank (Bernstein et ai., 1977) 
using at set of defined distance constraints derived from an analysis o f known 
antibody structures (Martin et al., 1989). The middle section o f the selected 
loops are then deleted and reconstructed using a conformational search program.
This method has been tested directly by modelling antibody combining sites of 
known structure and has given accurate reproducible results for all six CDRs, 
including those for which a canonical form has not been described.
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1.8 Applications of Antibodies in Biological Sciences.
The high degree of specificity of antibody-antigen interactions, and the advent 
of hybridoma technology (Kohler and Milstein, 1975) have been expolited to produce 
monoclonal antibodies (Mabs) that are specific for defined antigens. Mabs have 
found a wide variety o f applications, including the identification and 
quantitation of specific molecules in complex mixtures, the purification of mole­
cules and cells, as probes to explore the structural-functional relationship of 
proteins, and as 'magic bullets' to kill tumours.
The production of human Mabs is limited by the potential for immunisation and 
the lack of suitable myelomas for fusion with human B-cells (Gordon, 1988). In the 
absence of human Mabs with therapeutic potential, rodent Mabs have been used to 
image and kill tumours (Levey and Miller, 1983). The use of rodent antibodies is 
compounded by a host anti-globulin immune response that abrogate their therapeutic 
effects. These problems have led to the construction and expression of functional 
recombinant antibodies with human isotype characteristics and rodent antigen 
binding sites (1.8.1).
1.8.1 Genetically Engineered Antibodies.
Ig domains are encoded by separate genomic exons (sections 1.10.1 and 1.10.2), 
which has enabled chimaeric antibodies, with rodent V-domains and human C-domains, 
to be constructed by exon shuffling (Morrison, et al., 1984; Bonlianne et al., 
1984; Neuberger et al., 1985). Such antibodies have potential as therapeutic 
agents and have the advantage over rodent antibodies that they should minimise an 
anti-globulin immune response. In addition, they enable the biological effector 
functions of the antibody to be selected; however, rodent V-domains retain the 
potential to act as immunogens (Riechmann et al., 1988). This limitation has 
prompted the construction of 'humanised' antibodies with reshaped V-domains (Jones 
et al., 1986; Verhoeyen et al., 1988; Riechman et al., 1988). 'Humanised' 
antibodies include reshaped V-domains, formed by human FRs and rodent CDRs from 
monoclonal antibodies of known specificity that are joined to human C-domains. 
Such antibodies have been demonstrated to retain the antigen binding specificity 
and biological effector functions o f the parent antibodies and should reduce 
further host anti-globulin responses.
Antibodies as therapeutic agents are limited by their size, for example, 
penetration of solid tumours may not be possible and tumour immaging is 
complicated by high non-specific binding to non-tumour cells via Fc-receptors
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(Wahl et al., 1983; Harwood et ah,1985). Attempts to overcome these problems have 
led to the expression o f Ig fragments (Fabs and Fvs) that retain the antigen 
binding specificity of the antibody from which they are derived (Better et al., 
1988; Bird et al., 1988; Skerra and Pluckthun, 1988). Treatment of cancers may be 
improved by the use of such fragments as Fabs diffuse into tumours more rapidly 
than whole Igs (Larson, 1985; Buchegger et al., 1983). The genomic exons that 
encode Fab and Fv fragments have been engineered and expressed in E.coli and may 
be engineered further to deliver toxic molecules to specific cancer cells. For 
example, the Fv fragment o f an antibody that specifically binds cell surface 
receptors for interleukin-2 (IL-2) has been expressed as a single chain which 
includes the pseudomonas exotoxin (Chaudhary et al., 1989) and is selectively 
toxic for cells expressing IL-2 receptors.
The VH-domain of the anti-lysozyme monoclonal antibody D1.3, binds lysozyme 
with only a 10 fold reduced affinity, compared to D1.3 (Ward et al., 1989). This 
observation has led to the selection of VH-domains with specific antigen binding 
activity from mouse spleen cDNA expression libraries of diverse VH-genes (Ward 
et al., 1989). Single, antigen binding VH-domains, because of their small size, 
should penetrate solid tumours more readily and, therefore, represent the smallest 
antigen binding fragment that may be used to deliver toxic molecules to specific 
sites; however, the absence of the VL-domain may led to high non-specific 
interactions between the hydrophobic region of the VH-domain that is nor mally 
buried at the VL:VH interface and hydrophobic molecules. It is envisaged that this 
problem may be overcome by changing the nature of the amino acids at these 
residues (Ward et al., 1989) and in addition, through CDR grafting and genetically 
engineered increased affinity, rodent VH-domains o f defined antigen binding 
specificity with therapeutic importance may be improved.
Selection o f antigen binding domains with defined specificity, from libraries
which represent the diversity of V-domains, enables a much larger proportion of
0
the germline encoded V-gene repertoire to be screeira for antigen binding than the 
more conventional methods of hybridoma technology. Direct selection for antigen 
binding may circumvent the problems associated with immunisation protocols for the 
production of human monoclonal antibodies and enable antibodies against molecules 
that may be difficult to isolate or identify (such as transition states for the 
production of catalytic antibodies) to be identified (Huse et al., 1989; Sastry et 
al., 1989).
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1.9 The Generation of Antibody Diversity: The Molecular Basis.
The mammalian immune system has the capacity to produce a virtually unlimited 
number o f unique antibody molecules, each with a different antigen binding 
specificity, which is determined by the conformation of the CDRs (Amit et al., 
1986; Colman et al., 1987; Sheriff et al., 1987; Padlan et al., 1989). Diversity 
of antigen binding sites is achieved by DNA rearrangments that create new CDR 
conformations (CDR-H3 and CDR-L3) and utilize germline encoded conformations (CDRs 
LI, L2, HI and H2) in different combinations (Tonegawa, 1983).
Antibody V-domains are encoded by separate genomic exons (V-exons). V-exons 
are formed from segments that are separated in the germline DNA and recombine 
during B-cell development (Reviewed in Tonegawa, 1983; Blackwell and Alt, 1989). 
V-exons that encode VL-domains are formed from two segments, a variable (VL) 
segment, and a joining (JL) segment (Bernard et al., 1978; Max et al., 1979; 
Sakano et al., 1979). VL and JL-segments exists in multiple copies in the genome 
(usually 100s of V segments and a few J segments) and each copy has a unique 
sequence. VL-JL joining occurs in seemingly unrestricted combinations and forms 
the coding sequence for CDR-L3. Combinational assortment of any VL segment with 
any JL segment therefore results in amino acid heterogeneity at CDR-L3. VL seg­
ments encode the majority of VL-domains, including CDR-L1 and CDR-L2. Length and 
sequence heterogeneity of CDRs LI and L2 therefore results from the large number 
of V segments in the mammalian genome. Heavy chain V-domains are similarly 
encoded by different germline DNA segments; however, in addition to VH and JH 
segments, D-segments (D, diversity) contribute to the formation of CDR-H3 (Early 
et al., 1980; Sakano et al., 1981) to further increase diversity.
DNA rearrangments therefore produce a large number of unique VL and VH domains 
which may pair in apparently unrestricted combinations to form a antibody 
molecules with distinct antigen binding specificities. Additional mechanisms, 
such as junctional site diversity (section 1.10) and somatic hypermutation 
(section 1.11), are superimposed on the DNA rearrangments to maximise combining 
site diversity.
Studies of Ig DNA rearrangments have focused on murine systems; however, the 
mechanisms that operate to produce antibody diversity in other mammalian species 
are believed to be analogous to those o f the mouse as the organisation o f their 
germline and rearranged Ig DNA are similar.
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1.10 Junctional Site Diversity.
The joining o f V-segments is imprecise, which contributes to the length and 
sequence heterogeneity of CDRs H3 and L3, thereby increasing the number of 
conformations available to these loops above that which would be generated by 
combinational assortment of germline sequences alone (Tonegawa, 1983).
The codon formed at the site o f joining of a VL-segment to a JL-segment 
(Residue 96) may be formed by nucleotides derived exclusively from a VL segment, 
or from combinations of nucleotides from both VL and JL (i.e. one from VL and two 
from JL, or two from VL and one fron JL). In addition, the V-kappa - J-kappa 
recombination site in the light chain of a mouse monoclonal antibody (HyHEL-5) has 
been formed by the deletion of the nucleotides that code for residue-96 (Hartman 
et al., 1988).
Nucleotides, that cannot be explained by the joining of germline sequences have 
been observed at the sites of VH-D and D-JH joining(Alt and Baltimore, 1982). 
The extra nucleotides are believed to be added by terminal deoxynucleotidyl 
transferase (TdT) which catalyses the addition of nucleotides to DNA chains in the 
5 '-to -3 ’ direction in the absence of template DNA (Alt and Baltimore, 1982; 
Kurosawa and Tonegawa, 1982). Evidence for the involvement of TdT comes from its 
activity profile in the stages of B-cell developement and the type of nucleotides 
added. In developing B-cells, TdT is known to be active at the time of heavy chain 
DNA rearrangment (Desiderio et al., 1984), whereas TdT activity can no longer be 
detected when the light chain DNA is undergoing rearrangment, The activity of the 
enzyme is consistent with a lack of additional nucleotides at VL-JL joining sites. 
The additional nucleotides added at VH-D and D-JH joins are frequently guanine 
and cytosine which is consistent with the known preference o f TdT for these 
nucleotides.
In addition, at the heavy chain locus (and to a lesser extent at the light 
chain locus), nucleotides may be deleted from the joining ends (Tonegawa, 1983). 
Nucleotide deletions are believed to be generated by exonuclease activity that 
removes nucleotides during the recombination event (Tonegawa, 1983; Alt et al.,
1987).
1.11 Somatic Hypermutation.
V-domains generated by the rearrangements described above are limited to the 
sequences, and therefore conformations, o f .CDRs LI, L2, HI, and H2 that are
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encoded by the germline V-segment repertoire; however, the sequences (and 
conformations) of these loops (and CDRs L3 and H3) are further diversified by a 
hypermutation mechanism that operates on the coding nucleotides of V-domains 
(Bothwell et al., 1982;Allen et al., 1987; Malipiero et al., 1987; Manser et al., 
1987; Siekevitz et al., 1987).
Antibodies with higher affinity are produced as an immune response develops 
from the primary to secondary phase. Extensive sequence analysis of germline and 
rearranged V-exons, of hybridomas made at various stages of an immune response to 
a defined antigen, has demonstrated that the observed increase in antibody 
affinity results from a V-specific, antigen-induced hypermutation mechanism that 
becomes effective during the late primary response (Allen et al., 1987; Malipiero 
et al., 1987; Manser et al., 1987; Siekevitz et al., 1987). Point mutations are 
the predominant type observed, with the occasional deletion or insertion. These 
observations have led to the proposal that the primary role of the hypermutation 
mechanism is to increase the affinity of secondary response antibodies, so that 
memory B-cells are better able to respond on a subsequent antigen challenge 
(Siekevitz et al., 1987); however, mutations also contribute to the overall 
antibody repertoire as antibodies carrying somatic mutations that have lost 
antigen-binding specificity have been observed (Siekevitz et al., 1987).
1.12 Organisation of Ig Germline DNA.
Ig chains are encoded by 3 independant gene families: heavy chain genes, kappa 
light chain genes, and lambda light chain genes, with each family located on a 
separate chromosome (Honjo, 1983).
1.12.1 The Heavy Chain Locus.
In germline DNA, the Ig heavy chain coding sequence is organised into 4 
distinct regions, VH-segments, D-segments, JH-segments and the constant region (C- 
region) genes (Figure 3).
The C-region genes are clustered on the chromosome over approximately 200 kb 
(Scimizu et al., 1982) and in the mouse they are found in the order 5 '- mu, delta, 
gamma-3, gamma-1, gamma-2b, gamma-2a, epsilon and alpha -3'(Gough and Cory, 1986). 
In man, the order of heavy chain isotypes is similar with the mu-chain as the most 
5' isotype (Flanagan and Rabbitts, 1982; Migone et al., 1984), followed by the 
delta-chain. The coding sequence for the C-regions of each heavy chain isotype are 
divided between exons, and each exon codes for a single domain. The hinge region
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is also encoded by a separate exon. The exon arrangement of Ig heavy chains, as 
represented by the mu-chain, is schematically shown in Figure 3.
The JH-segments (6 in man and 4 in the mouse) are located 5-10 kb upstream of 
the Cm-gene. In the mouse, the VH-segments lie approximately 100 kb further 
upstream of the JH-segments. The D-segments number approximately 30 in man 
(Ichihara et al., 1988) and 12 in mouse (Kurosawa and Tonegawa, 1982) and are 
located in the intervening region between VH and JH-segments (Figure 3). In the 
mouse, the D segments have been divided into three families based on nucleotide 
sequence homology (Kurosawa et al., 1981; Wood and Tonegawa, 1983; Kabat et al.,
1987).
The number of VH-segments in the mammalian genome varies greatly between 
species, with estimates of up to 2000 being made for some strains of mice (Livant 
et al., 1986). Each V-segment includes the coding sequence for a leader sequence 
(or signal peptide) which is divided between two exons (Figure 3). The signal 
peptide is cleved from the chains as part of post-translational modifications.
1.12.2 The Light Chain Locus.
In mammalian species, the C-domain of the light chain isotypes are encoded by a 
single exon. In man and mouse, the organisation of the kappa locus is essentially 
the same: the J-segments (4 in the mouse and 5 in man) are located a few kb 
upstream of a single C-kappa exon. Multiple V-segments (100s) are located further 
upstream (Figure 4).
The organisation of the lambda light chain locus is different to that o f the 
kappa locus and varies between man and mouse. In the mouse, there are only two V- 
segments (V-lambda-1 and V-lambda-2), each followed downstream by two J-C units 
(Figure 4; Blomberg and Tonegawa, 1982; Elliot et ai., 1982; Miller et al., 1982; 
Seising et al., 1982) and each V-segment predominantly rearranges with the J- 
segments o f the J-C units located downstream. In man, there are multiple V- 
segments (Tsujimoto and Croce, 1984; Anderson et al., 1985) and several C-coding 
exons, corresponding to at least six different isotypes (Hieter et al., 1981).
1.13 Transcription of Ig Genes.
A transcriptional promoter is located 5' of each germline V-segment (Parslow et 
al., 1984; Ballard and Bothwell, 1986). The promoter drives transcription of 
rearranged Ig genes, whereas germline V-segments are usually transcriptionally
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Figure 4. Organisation of the murine Ig light chain  
loci and VL-gene assem bly.
Lam bda light chain
a) Germline configuration
L2 L2 V 2  J 2  C 2  J 4  C 4
- c m — i— »■— □ — i i— □ — i ......... ~~f
L1 L1 V I  J 3  C 3  J1 C1
- o - n z z i — if— □ — i-------------1— □ — c z :
b) Rearranged configuration
11 L1 V1 J1 ci
- c m  n — c   i—
(V1 joined to J1)
Kappa light chain
a) Germline configuration
L1 L1 V1 Ln Ln Vn J1 J2  J3  J4
b) Rearranged configuration
L1 L1 V1 L2 L2 V 2  J3 J4
■cm  h - n - n ~ - c
(V2 joined to J3)
The organisation of the kappa and lam bda light chain loci differ. 
VL-exons are form ed from two segm ents that a re  separated in 
germ line D N A  and com bine during B cel! developm ent.
VL-exon assem bly results in transcription of a  com plete  
light chain gene.
Stages of VL-exon assem bly.
a) G erm line configuration
b) Rearranged eg. V1 joined to J1 (lam bda locus)
L= leader sequence Th e  coding region of the leader sequence  
is divided betw een two exons.
J = joining segm ent V  = variable segm ent C = constant region
Boxes indicate coding region, lines indicate non-coding region 
H i-  indicates distance and relative transcriptional orientation  
are unknown
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silent (Mather and Perry, 1981; Wang and Calame, 1985) . The activity of the 
promoter is regulated by B-cell specific transcriptional enhancer elements (Queen 
and Baltimore, 1983). DNA rearrangements reposition the rearranged V-segment 
promoter within the functional range of the enhancers which activates 
transcription of the rearranged gene.
The first Ig enhancer discovered was in the major intron of the mouse heavy 
chain locus (Figure 3. Banerji et al., 1983; Gilles et al., 1983; Neuberger,
1983). Subsequently an homologous enhancer was discovered in the human heavy chain 
locus (Rabbitts et al., 1983), and at the mouse kappa light chain locus (Pichard 
and Schaffner, 1984; Queen and Stafford, 1984). More recently, a second B-cell 
specific Ig enhancer has been identified 3* to the murine C-kappa gene (Meyere and 
Neuberger, 1989), and 25 kb downstream of the rat C-alpha gene (Petterson et al., 
1990). The second enhancer is stronger than the intronic enhancer and its 
discovery explains the previous observation that transcription o f heavy chain 
genes that are formed by aberrant class switching (section 1.18) which results in 
the deletion of the intronic enhancer, are actively transcribed. This implied that 
the intronic enhancer may only be required for initiation of transcription, but 
not for its maintainence.
1.14 Aberrant Rearrangements.
The synthesis of functional heavy and light chains require the V and J-segments 
(and therefore the C-region) be joined in the same translational reading frame. As 
previously stated (section 1.10), the joining of V to J (and D) is imprecise which 
allows for greater diversity of antigen binding sites. However, imprecise joining 
may also result in non-functionally rearranged genes in which the V and J-segments 
are joined in different translational reading frames. Such non-functionally 
rearranged genes may be faithfully transcribed into full length mRNA, but yield 
truncated, non-functional Ig chains (Altenburger et al., 1980; Max et al., 1980; 
Wallfield and Storb, 1981 ).
1.15 DNA Rearrangements: Allelic and Isotypic Exclusion.
V-exon assembly is an ordered process and results in the expression of a single ' 
allele at the heavy and light chain loci (allelic exclusion) and expression o f 
only one light chain isotype (isotype exclusion; Reviewed by Blackwell and Alt,
1989). Assembly occurs during B-cell development and prior to antigen 
stimulation. Each B-cell is therefore precommitted to the production of 
homogeneous antibody, with identical antigen binding sites, before antigen
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challenge.
Control o f Ig DNA rearrangements have been studied in murine pre-B-cells 
transformed by Abelson murine leukaemia virus (A-MuLV. Alt et al., 1986). 
Transfection with A-MuLV immortalizes immature B-cells at early stages of 
development and transformants continue to rearrange their Ig DNA when cultivated 
in cell culture. Studies using these cell lines, and more recently transgenic 
mice, have demonstrated that allelic exclusion occurs at the level o f V-gene 
assembly.
VH-exon assembly normally preceeds that of the light chain, and kappa DNA 
normally rearranges before that o f lambda. The first rearrangement observed 
involves the joining of a D-segment to a JH segment to form a D-JH complex (Maki 
et al., 1980; Perry et al., 1981). D-JH complexes are usually formed on both 
chromosomes, and one such complex may then undergo further rearrangement with a 
VH-segment to form the complete coding sequence for a VH-domain (VH-D-JH; Figure 
3). Secondary D to JH rearrangements, which replace the pre-existing D-JH complex 
by joining an upstream D to a downstream JH, have also been observed (Reth et 
al., 1986).
Rearrangements that result in expression o f functional membrane mu-chains 
(section 1.20) signal the cessation of further VH-DJH rearrangements (Alt et al., 
1986), and onset of rearrangements at the kappa light chain loci (Alt et al., 
1987; Reth et al., 1987). The role of mu-chains in heavy chain allelic exclusion 
has been demonstrated using transgenic mice and A-MuLV transformants. Transgenic 
mice, in which a rearranged mu-gene has been introduced, fail to assemble 
endogenous heavy chain V-exons (Rusconi and Kohler, 1985: Weaver et al., 1985). 
A-MuLV transformed cell lines, in which Ig DNA rearrangements have not been 
initiated, have been prevented from rearranging their endogenous heavy chain Ig 
DNA by the expression of a transfected, functionally rearranged m-chain (Alt et 
al., 1986). Reth et al., (1987) have studied the influence o f the membrane and 
secretory forms of functionally rearranged mu-chains on rearrangements at the 
kappa locus in null pre-B cells. Activation of the kappa locus followed expression 
of the membrane-bound form, but not that of the secretory form.
D-segments have transcriptional promoters located 5' to the coding sequence 
(Alt et al., 1987) and D-JH-Cmu RNA transcripts have been identified (Reth and 
Alt, 1984). Transcription from heavy and light chain C-region genes have also been 
observed (Alt et al., 1982; Lennon et al., 1985; Nelson et al., 1985). The 
possibility of a regulatory role for such incomplete transcripts in V-exon assem­
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bly, and allelic and isotypic exclusion has been suggested (Alt et al., 1987).
The majority of kappa light chain producing B-cells have their lambda light 
chain DNA in the germline configuration, whereas lambda light chain producers 
often have non-functionally rearranged kappa light chain DNA (More et al., 1985; 
Siminovitch, 1985; Alt et al,, 1987), which suggests that the lambda light chain 
locus only rearranges if kappa light chain rearrangements are unsuccessful. A- 
MuLV transformed pre-B cells, that rearrange light chain genes in culture, 
rearrange the kappa locus, either exclusively or at a higher frequency than the 
lambda locus (Alt et al., 1987). These observations have been interpreted to imply 
that productive kappa light chain rearrangements result in allelic and isotypic 
exclusion with respect to the light chain loci. Non-productive kappa 
rearrangements allow the lambda loci to undergo rearrangement. However, in the 
case of the light chain loci, simple sequential rearrangement of kappa and lambda 
chains cannot account for the ability of hybridomas constructed from transgenic 
mice, with an introduced rearranged kappa gene, to produce both kappa and lambda 
light chains (Storb, 1987). Such hybridomas were also found to have their 
endogenous kappa DNA in a rearranged configuration. In addition, secondary 
recombinations, that correct non-productive rearrangements between V-kappa and JL- 
kappa segments have been observed in A-MuLV transformants (Feddersen et al.,
1990).
1.16 Mechanism of Variable-exon Assembly.
Germline V and D-segments are flanked, immediately 3' by a conserved heptamer 
and a conserved nonamer, that are separated by approximately 12 nucleotides 
(Early et al., 1980; Sakano et al., 1980; Tonegawa, 1983). Similarly, all germline 
D and J-segments are flanked, 5' by the identical heptamer and nonomer sequences, 
separated by a spacer of approximately 23 nucleotides (Figure 5). The involvement 
of these sequences in Ig DNA rearrangements has been demonstrated as they are 
sufficient to cause recombination o f genetically engineered recombination 
substrates that are devoid of all other Ig DNA (Blackwell and Alt, 1984; Akira et 
al., 1988 ).
The heptamer and nonamer that flank segments that normally combine (i.e. VH and 
D, D and JH, and VL and JL) are complementary inversions with the potential to 
form a stem loop structure (Figure 6). The length of the spacers between the 
heptamer and nonamer undergoing recombination restricts joining to sequences with 
spacers o f different length (12/23 base pair rule), possibly via the secondary 
structure o f the stem loop. This mechanism is believed to prevent VH joining
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Figure 5. H eptam er-nonam er and 12 /23 -b p  spacer rule
Lam bda light chain
Kappa light chain
H eavy chain
V ,D  and J-segm ents are  flanked by a  conserved heptam er and nonam er 
as indicated in the figure.
The size of the spacer betw een the heptam er and the nonam er restricts 
recombination to segm ents with spacers of different length
V  = variable segm ent 7  = heptam er (C A C A G T G )
J = joining segm ent 9 = nonam er (A C A A A A A C C )
D = diversity segm ent 12 /23  = spacer
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Figure 6. Proposed secondary structure of V-exon  
segm ent recombination substrates.
Secondary structure proposed to act as a  substrate for D N A  rearrangem ents  
involving V H , D , JH  V L and JL- segm ents.
T h e  heptam ers and nonam ers have the potential to com plem entary base  
pair to form a  stem  structure.
A stem  structure m ay be form ed on both stranda of the D N A  double  
helix.
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directly to JH; however, indirect mechanisms that result in VH to JH and D to D 
joining have been proposed. The imprecise nature of VH to D-JH joining may result 
in the complete removal of the D sequence (Desiderio et al., 1984). D segments, 
which have their normal heptamer-nonamer arrangement replaced by that which is 
normally found adjacent to VH segments have been identified (Morzycka-Wroblewska 
et al., 1988). Such novel D segment flanking regions are generated by unusual VH 
to D rearrangements and if this type of rearrangement were to occur between a D 
and a JH segment the direct joining of a VH to a JH segment could theortically 
occur. Human D-gene segments with irregular spacer have been identified which 
could permit certain D-D recombinations (Ichihara et al., 1988). Both of the 
above types of recombination could act as additional mechanisms for the generation 
of antibody diversity.
The rearrangement mechanism may involve either the deletion or inversion of 
the intervening DNA between the joined sequences. Blackwell and Alt (1984) 
demonstrated that D-JH joining occured by DNA deletion in pre-B cells cells. 
Circular DNA molecules containing D and JH-segments have subsequently been 
identified, which are consistent with a deletion event (Fujimoto and Yamagishi, 
1987; Okazaki et al., 1987; Abe and Shiku, 1989; Blackwell and Alt, 1989; Toda et 
al., 1989). The reciprocal products (heptamers joined back to back) of an 
endogenous inversion event within the kappa locus has also been identified (Lewis 
et al., 1982; Lewis et al., 1984), which is consistent with an inversion event and 
suggested that the rearrangements at the heavy and light chain loci may operate by 
different mechanisms. On the basis of these observationa, it has been proposed 
that a single mechanism could account for either outcome (inversion or deletion), 
depending on the orientation of the segments being joined (Reviewed in Blackwell 
and Alt, 1989). Deletion is proposed to occur when the segments undergoing rear­
rangement are in the same transcriptional orientation on the chromosome, whereas 
inversion occurs if the segments are in opposite transcriptional orientations and 
results in the products of the inversion ( VL-JL and fused heptamers) remaining on 
the chromosome.
1.17 The Accessibility Model.
The rearrangement process may be regulated by controlling the access o f a 
single recombinase to the segments undergoing rearrangement (The 'accessibility 
model', Yancopoulous and Alt, 1985). In the 'accessibility model' recombination is 
proposed to be controlled by the configuration o f the DNA undergoing 
rearrangement, rather than by a specific recombinase expressed at the time of 
rearrangement. Rearrangement of heavy chain DNA is preceded by transcription of
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heavy chain gene segments. Germline VH-segments, in addition to that undergoing 
rearrangment, are transcribed and probably translated into V-proteins (Yancopoulos 
and Alt, 1985). D-segments have their own upstream promoters and D-JH-mu 
transcripts, and their translation products, are also produced at the time of the 
rearrangement (Reth and Alt, 1984). In the accessibility model, transcription of 
these segments is proposed to result from an 'opening up' of chromatin structure 
rather than resulting as a consequence of the rearrangement process.
In the accessibility model, the intronic enhancer is proposed to modulate 
access o f the recombinase to germline sequences (Blackwell and Alt, 1989) by 
'opening up' chromatin structure. This hypothesis is supported by various lines of 
evidence. Kappa light chain V-gene assembly can be induced in pre-B cell lines by 
bacterial lipopolysaccharide (LPS) (Blackwell and Alt, 1989), which activates the 
kappa transcriptional enhancer (Nelson et al., 1985). Cells that have undergone 
aberrant class switching (section 1.18) that results in the loss o f the intronic 
heavy chain enhancer are still able to actively transcribe their rearranged Ig 
heavy chain gene. This implies that the intronic enhancer is not required for 
transcription. The discovery of a second Ig enhancer at both the heavy and light 
chain loci has added support to a minor role of the intronic enhancer in 
transcription.
Direct evidence to support 'the accessibility model' has been supplied by the 
ability of A-MuLV transformed cells (with endogenous rearranged heavy chain DNA) 
to rearrange kappa light chain DNA, but not exogenous heavy chain gene segments 
(Blackwell et al., 1984; Yancopoulos and Alt, 1985; Alt et al., 1986).
1.18 Heavy Chain Class Switching.
B-cells initially produce IgM. Antigen binding may select a mature B-cell in a 
primary immune response in which they clonally expand, switch heavy chain isotype 
to produce antibody o f a different class (Davies et al., 1980), and terminally 
differentiate into antibody secreting plasma cells. Class switching is achieved 
through independant DNA rearrangements that bring the coding sequence of the C- 
region of a new heavy chain isotype close to the rearranged VH-exon and therefore 
allows B-cells to produce antibody with retained antigen binding specificity, but 
with different biological effector functions. The S-region o f the mu-chain is 
located downstream of the Ig intronic enhancer (Figure 7) and the enhancer is 
therefore retained on the chromosome after class switching.
Heavy chain exchange is mediated through switch (S) regions located 5' of the
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C-region coding sequence of each isotype, except for delta-chains (Figure 7. 
Davies et al., 1980; Kataoka et al., 1980; Kataoka et al., 1981 Nikaido et al., 
1982; Shimizu et al., 1984 ). The molecular details of the switch mechanism are 
unknown; however, S-regions resemble Chi sequences (bacterial recombination 
sequences) and mediate recombination in E.coli (Kataoka et al., 1983) which 
suggests that S-regions may act as substrates for a general recombination 
mechanism; however, switch recombination substrates recombine at a higher 
frequency in B-cells than in non-B-cells (Ott et al., 1987) which implies that a 
B-cell specific mechanism may effect recombination.
Recently, circular DNA products of a class switching event have been identified 
to include a mu-gene, thereby indicating that heavy chain exchange occurs through 
looping out and deletion (Schwedler et al., 1990). This mechanism is supported by 
the inability to detect mu-chain sequences using the polymerase chain reaction in 
cells that have switched heavy chain isotype to IgG2b on both alleles (Jack et 
al., 1988).
Class switching appears to be a regulated process as specific Ig classes/sub­
classes are produced by mature B-cells in response to stimulation with LPS and 
specific lymphokines (Blackwell and Alt, 1989). It is not known if lymphokines 
operate at the level o f directing specific class switching or select clones 
synthesizing antibody classes/sub-classes after a random switching event.
1.19 Simultaneous Expression of IgM and IgD.
All B-cells initially produce IgM. In addition, a proportion of unstimulated B- 
cells simultaneously produce IgM and IgD. The IgM isotype is the first heavy chain 
C-region coding sequence downstream of the rearranged VH-exon (Figure 3 and 
section 1.12.1) and explains why IgM is the first antibody class expressed by all 
B-cells. The position of the delta-chain C-region coding sequence, immediately 3' 
of the mu-chain coding sequence allows for the simultaneous production of IgM and 
IgD. Transcription of the rearranged mu-chain may continue through the coding 
sequence for the delta-chain to produce a primary transcript including the rear­
ranged VH-exon and the coding sequence of both the C-mu and C-delta genes. The 
heavy chains of IgM and IgD are produced by differential processing of the common 
primary transcript (More et al., 1981; Tucker, 1985; Figure 8). IgD and IgM 
produced by the same cell, therefore, uses identical VH-exon and share identical 
antigen binding specificity.
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1.20 Membrane and Secretory Ig.
Each heavy chain isotype may be produced in two forms: a membrane-bound form 
and a secretory form. The membrane-bound form includes a C-terminal hydrophobic 
transmembrane tail which anchors the molecule in the plasma membrane (Hombach et 
al., 1990). Secretory forms have a hydrophilic tail in place of the transmembrane 
region. The different forms of heavy chain are produced, like the heavy chains of 
IgM and IgD, by differential splicing of a common precursor RNA transcript (Figure 
9). The transmembrane amino acids are encoded by two membrane (M) exons. To 
produce the membrane form the M-exons are spliced to the coding sequence of the C- 
terminal domain. The splice acceptor site is located within the coding sequence of 
the C-terminal domain and splicing to this site removes the coding sequence of the 
hydrophilic tail and adds that of the transmembrane amino acids (Rogers and Wall,
1984).
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1.21 Research objectives.
Antibody specificity has been exploited in agriculture to immunomodulate the 
oestrous cycle of domestic ruminants such as sheep and cattle (Land et al., 1982; 
Wise and Schanbacher, 1983; Price et al., 1987; Sreenan et al., 1987). 
Testosterone is a key hormone in the ruminant oestrous cycle having a negative 
feedback effect on the secretion of gonadatrophin hormones and has therefore been 
chosen as a means of immunoregulation in cattle (Webb et al., 1984; Morris et al.,
1988). In order to obtain consistent regulation o f the oestrous cycle, high 
affinity allogenic antibodies o f uniform and constant characteristics are 
required. This need has led to the development of heterohybridomas secreting 
bovine and ovine monoclonal antibodies specific for the gonadal steroid hormones 
(Groves et al., 1987a; Groves et al., 1987b; Groves at al., 1988a: Groves et al., 
1988b).
The bovine anti-testosterone (IgGl) monoclonal antibody secreted by a mouse x 
bovine heterohybridoma (BMT.4A) produced for the above studies has a relatively 
high affinity (binding dissociation constant (Kd) of 2.5 x 10-11 M (Groves et al, 
1987a); however, the affinity of this antibody is only 1-2 orders of magnitude 
higher than that of receptors for steroid hormones (Schilling and Liao, 1984; 
Chang et al., 1988). Therefore, in order to improve the immunoneutralising 
properties of the bovine monoclonal antibody secreted by BMT.4A, it was considered 
necessary to increase its affinity for testosterone by at least another order of 
magnitude.
The affinity of the anti-testosterone monoclonal antibody is already relatively 
high; however, an ovine monoclonal antibody with even greater affinity for 
testosterone (Kd = 7.63 x 10“ 12 M) has been produced (Groves et al., 1987b), which 
demonstrates that anti-testosterone antibodies with higher affinity than that of 
the bovine antibody may be obtained. In addition, ovine polyclonal antisera, 
raised against oestradiol and fluorescein isothiocyanate with avidities of Kd = 
10“ 14 have also been produced (B.A.Morris, personal communication) which suggests 
that rumminant antibodies with affinities in the 10-15 range are possible.
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A bovine anti-testosterone monoclonal antibody with higher affinity than that 
of the antibody secreted by BMT.4A may be achieved in two ways.
1). The production of more heterohybridomas and selection of a clone(s) secreting 
higher affinity antibody.
2). Engineering the affinity of the current antibody.
The second route may be more speculative, but should provide molecular 
information on bovine IgG and has reinvent implications for the design of high 
affinity antibodies. It was therefore proposed to investigate the affinity of the 
bovine antibody secreted by BMT.4A for testosterone and on the basis of the 
information obtained attempt to increase its affinity.
Investigating the nature of the interactions between the bovine antibody and
testosterone and the design of a higher affinity antibody would best be aided by a
crystal structure o f the antibody-testosterone complex; however, this structure
has not been determined. In the absence of such precise structural information it
was proposed to identify residues crtitical for the antibody's specificity and
affinity by the introduction of specific amino acid substitutions into the CDRs.
To aid identification o f the residues most likely to make contact with
testosterone (i.e. form the antibody paratope) it was proposed to construct a
three-dimensional molecular model o f the antigen binding site o f the bovine
antibody. Before the model could be used to aid the rationale design of a higher
affinity antibody it was considered necessary to obtain a measure of its accuracy.
It was therefore proposed to test the major findings of the model and predictions
of the likely interactions between the antibody and testosterone by site-directed 
umtagenesis.
v
Amino acid substitutions are more easily introduced at the nucleotide level. 
Therefore, as a first step to achieve the above objectives, cDNAs that encode for 
the heavy and light chain of the antibody secreted by BMT.4A were to be cloned and 
sequenced. Testosterone binding by the antibody encoded by the cDNAs was to be 
verified by expression o f the cDNAs in mammalian cells and demonstrating 
testosterone binding using an ELISA specific for bovine anti-testosterone IgG. The 
effects o f specific amino acid substitutions on the affinity o f the antibody for 
testosterone were to be quantitated by calculating the Kd of the wild-type and 
mutated antibodies.
45
1.22 The Molecular History of the Heterohybridoma (BMT.4A).
It is relevant when cloning Ig cDNA from a heterohybridoma (or hybridoma) to 
consider its cellular history, so as to determine the number of Ig mRNA species 
that may present and, therefore, represented in cDNA libraries constructed from 
such cell lines.
The bovine x mouse heterohybridoma (BMT.4A. Groves et al., 1987a) resulted from 
two cellular fusions, both involving bovine peripheral blood mononuclear cells, 
isolated from a steer immunised with a testosterone-3-carboxymethyloxime-ovalbumin 
conjugate. The first fusion utilised the mouse myeloma NSl/l-Ag4-l as the fusion 
partner and resulted in a cell line (BMT-2) that secreted bovine IgGl that bound 
testosterone. After 30 days in culture, BMT-2 stoped secreting antibody and non­
secreting hypoxanthine- aminopterin-thymidine sensitive BMT-2 cells were used as 
a heteromyeloma fusion partner in a second cellular fusion (Groves et al., 1987a).
NSl/l-Ag4-l is a non-secreting variant of the mouse plasmacytoma P3K (Kohler et 
al., 1976). P3K secretes an IgGl(kappa) antibody, MOPC21 (Potter., 1972; 
Horibata., 1970). The failure of NSl/l-Ag-4-1 to secrete antibody is due to the 
loss of synthesis of functional MOPC21 heavy chains. The intracellular heavy chain 
content of a number of non-secreting variants of P3K, including NSl/l-Ag4-l, has 
been examined (Cowan et al., 1976). Immu^recipitates, prepared using anti-MOPC21 
antisera, were found to include a protein that upon enzymatic digestion yielded 
peptide fragments characteristic of the MOPC21 heavy chain. This implies that a 
mRNA species that translates into an Ig heavy chain fragment may be present in 
cell lines that are derived from NSl/l-Ag4-l and may, therefore, be represented in 
the heterohybridoma cDNA library.
N Sl/l-A g4-l synthesizes, but fails to secrete, MOPC21 kappa light chain. In 
addition, two non-functionally rearranged kappa light chain genes are also 
present, one of which is transcriptionally active and produces full-length kappa 
mRNA (Walfield et al., 1981). cDNA libraries constructed from BMT.4A mRNA would, 
therefore, be expected to contain cDNAs derived from two murine kappa light chain 
genes, one functional and the other non-functional.
Bovine antibodies have lambda light chains (Butler, 1983). Investigations into 
the nature of the lambda light chain loci of P3K variants have not been 
undertaken; however, virtually all kappa light chain producing myelomas and 
hybridomas studied have their lambda light chain DNA in the germline configuration 
and it is, therefore, unlikely that N Sl/l-A g-1 will contain lambda light chain
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mRNA transcripts.
The cause of the loss of antibody secretion by BMT-2 has not been investigated 
and could conceivably have arisen from loss of a bovine chromosome(s) carrying 
either the heavy chain or the light chain gene, or both. It is therefore 
interesting to speculate that BMT.4A may contain more than one functionally 
rearranged gene for either a bovine heavy chain, or a bovine light chain.
In addition, the cellular fusions have the potential o f introducing non- 
functionally rearranged bovine Ig genes into BMT.4A. Several types o f non­
functional rearrangments yield full length, fully processed mRNAs that fail to 
translate into functional protein (section 1.14). Any such transcripts present in 
BMT.4A would also be expected to he represented in cDNA libraries derived from 
this cell line.
In conclusion, a variety o f Ig mRNA species may be represented in cDNA 
libraries constructed from BMT.4A (Table 2). Therefore, it is important to 
consider both the species from which the cDNAs are derived and their 
functional/non-functional status when cloning cDNAs for the bovine anti­
testosterone monoclonal antibody.
Table 2. Known and potential Ig mRNA snecices of BMT.4A.
Cellular origin of mRNA
NSl/l-Ag4-l bovine lymphocyte
Heavy chain
Functional gene 
Non-functional gene ?
+
?
Light chain
Kappa
Functional gene 
Non-functional gene 
Lambda 
Functional gene 
Non-functional gene
+
+
?
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CHAPTER 2. 
MATERIALS AND METHODS.
CHAPTER 2. MATERIALS and METHODS.
PART A. MATERIALS.
2.1 Reagent and kit suppliers.
Aldridge Chemical Company, (Dorset).
3,31,5,5 '-Tetramethylbenzidine.
Amersham International pic, (Amersham, Buckinghamshire).
Hybond-N™ Nylon membranes; cDNA synthesis system;Rabbit reticulocyte lysate 
translation system; Hybond mAP™ messenger affinity paper; Radioactive 
nucleotides; cDNA cloning system Lambda-gtlO; In vitro mutagenesis system;
Multiprime DNA labelling system.
Applied BioSystems, (Warrington).
All solvents and reagents for oligonucleotide synthesis.
BDH Chemicals, (Eastleigh, Hampshire).
DMSO; All laboratory chemicals, unless otherwise stated.
Boehringer Corporation Ltd., (BCL) (Lewis, East Sussex).
Calf Intestinal Alkaline phosphatase (CIAP); ATP; IPTG; X-gal; Lysozyme.
Cambridge Bioscience, (Cambridge).
Sequenase™ kit.
Dakopatts, (High Wycombe).
Rabbit anti-bovine IgG horse radish peroxidase conjugate.
Difco Laboratories, (East Molesey, Surrey).
Bacterial culture media.
Dynatech, (Billingshurst, Sussex).
PVC microtitration plates.
Flow Laboratories, (Irvine, Scotland).
Dulbecco's Modified Eagles Medium.
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Fuji Photo Film Co.,Ltd, (Japan).
RX X-ray film.
Genetic Research Instruments, (Dunmow, Essex).
Saran-Wrap™.
Gibco-BRL, (Uxbridge, Middlesex).
Restriction endonucleases; T4 DNA Ligase; Klenow polymerase; Acrylamide; Foramide; 
Ribonuclease; DNA and RNA electrophoresis markers; Ultra-pure agarose; 
DH5a-maximum efficiency competent cells.
Schleicher and Schuell, (Kingston-Upon-Thames, Surrey).
NA45 DEAE membrane.
Sigma Chemicals Co. Ltd., (Poole, Dorset).
Ampicillin; Ultra-pure Caesium chloride (optical grade);Chloroquine; 8-hydroxy 
quinoline; Trizma base; EDTA; Polyethylene glycol (Mw 6000); Urea; Bovine serum 
albumin ( Fraction V). Deoxyribonucleic acid from herring testis (type XIV).
Stratech Scientific Ltd., (London).
Geneclean™ Kit.
Whatmann Labsales Ltd., (Maidstone, Kent).
DE52 cellulose; Whatman 3MM™ filter paper.
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2.2 Mammalian cells, Bacteria, Bacteriophage and Plasmids
(i) Mammalian cell lines
Cell line 
NSl/l-Ag4-l 
B/MT-2 
B/MT.4A
COS-1
Mouse myeloma (Cowan et al., 1976).
Murine x bovine heteromyeloma (Groves et al., 1987a). 
Murine x bovine hetrohybridoma (Groves et al., 1987a). 
Secretes bovine IgGl anti-testosterone monoclonal 
antibody.
African Green Monkey kidney cells, transformed
with a replication deficient SV40 genome (Gluzman, 1981).
(ii) Bacterial strains
E.coli
DH5o:
NM514
TGI
JM109
supE44 lacU169(08OlacZ M15)hsdR17recAl 
endAlgyrA96thi-lrelAl Hanahan, (1983) 
(hfl+)
supEhsd 5thi (lac-proAB)F' [traD36proAB + 
lacIqlacZ M15] Gibson, (1984) 
recA 1 supE44end AlhsdR17gyrA96rel A lthi 
(lac-proAB)Yanish-Perron et al., (1985)
(iii) Bacteriophage
M13mpl8
M13mpl9
lambda-gtlO
(Yanisch-Perron et al., 1985) 
(Yanisch-Perron et al., 1985) 
(Hyunh et al., 1985)
(iv) Plasmids 
pUC13
pEE6.hcmv.gpt 
pEE6.hcmv.gpt.HC 
nF.Rfi. h cmv. rmt.. T ,0
(Yanisch-Perron et al, 1985) 
(This thesis)
(This thesis)
(This thesis)
2.3 Culture Media
Media and solutions were sterilised by autoclaving at 121°C (15 p.s.i) for 15 minutes or by 
filtration through a 0.2/im FlowPore D filter.
50
(i) Animal cell media
Mammalian cells were grown in Dulbeco's Modified Eagle's Media (DMEM) 
supplemented with heat-inactivated Foetal Calf Serum (10% v/v), glutamine (20mM) and 
buffered with sodium hydrogen carbonate (0.2% v/v). Animal cells used in this study were 
cultured in the above media in an atmosphere of 5% C02, 95% air at 37°C, except where 
otherwise stated.
(ii) SM Buffer
NaCi 5.8g
MgS04.7H20  2.0g
1M Tris.HCI pH7.5 5.0ml
2% (w/v) Gelatin 5.0ml
water to 1000ml 
Autoclaved
(iii) Luria-Bertani (LB) medium (agar).
Bacto tryptone lOg
Bacto yeast extract 5g
NaCl 5g
water to 1000ml
pH to 7.5 with 5M sodium hydroxide.
LB agar contained 15g/litre of Bacto agar.
Autoclaved
(iv) 50x salts
MgS04.7H20 lOg
Citric acid lOOg
K2HP04 500g
NaNH4(HP04).4H20  175g
water to 1000ml.
Autoclaved
(v) Minimal medium
Bacto agar 7.5g
Glucose 1,0g
water to 500ml.
Autoclaved
10ml of 50x salts was added after autoclaving.
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(vi) 2x TY medium (agar).
Bacto tryptone 16g
Bacto yeast extract lOg
NaCl 5g
water to 1000ml.
2x TY agar contained 15g/litre of Bacto agar. 
Autoclaved
(vii) H-Top agar
(viii) Top agar
Bacto tryptone lOg
NaC 18g
Agar 8g
water to 1000ml.
Autoclaved
Bacto tryptone l.Og
Bacto yeast extract 0.5g
NaCl 0.5g
MgSO4.7H20 25g
Agarose 1.0g
water to 100ml.
Autoclaved
2.4 General Buffers and Solutions 
(i) TE Buffer
Tris lOmM
EDTA ImM
pH 8.0 with HC1.
Autoclaved
(iii) STE
NaCl lOOmM
Tris lOmM
EDTA ImM
pH 7.5 with HC1 
Autoclaved
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(iv) Sodium acetate
3M Na acetate
pH 5.2 with glacial acetic acid. 
Autoclaved
(v) Ammonium acetate
7.5 M solution 
Filter sterilised
(vi) Phenol/chloroform
Phenol:chloroform was prepared as a 1:1 (v:v) mixture, saturated with 1M 
Tris.HCl (pH 8.0) and stored in the presence of the antioxidant 8-hydroxyquinoline (0.1% 
w/v).
(vii) DE52-celIulose in LB
Several volumes of 0.05M HC1 were slowly stired into approximately lOOg of 
DE52-cellulose until the pH was below 4.5. Concentrated NaOH was then added until the 
pH reached 7.5. The resin was washed several times in LB media by sedimentation and 
decanting the excess liquid. A final slurry was prepared in excess LB medium and stored at 
4°C in the presence of 0.1 % sodium azide.
(viii) PEG/Salt/SM
20% Polyethylene glycol (PEG 6000).
2.0M NaCl in SM buffer
(ix) PEG/S alt
20% Polyethylene glycol (PEG 6000).
2.5M NaCl
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2.5 Enzyme Buffers
(i) lOx Kinase buffer
Tris-HCl (pH 7.5) 700mM
MgCl2 lOOmM
KC1 ImM
DTT 50mM
Spermidine ImM
EDTA ImM
gamma-32p-ATP 0.5mM
(ii) lOx Calf intestinal alkaline phosphatase buffer
Tris.HCl (pH 8.0)
MgCl2 
ZnCl2
(iii) lOx restriction endonuclease buffer 
DNA restriction endonuclease buffers were either supplied with the enzyme and used 
according to the manufacturer's instructions or prepared as filter sterilized lOx solutions.
10 x Stock solitions.
lOx Medium salt buffer.
NaC
Tris.HCl pH 7.5 
MgCl2 
DTT
150mM
lOmM
lOmM
ImM
500mM
lOmM
ImM
lOx High salt buffer
NaCl lOOmM
Tris.HCl pH7.5 50mM
MgCi2 lOmM
DTT ImM
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2.6 Solutions for Transformation of Escherichia.coli
(i) SOC
Bacto tryptone 2% (w/v)
Bacto yeast extract 0.5% (w/v)
NaCl lOmM
KC1 2.5mM
MgCl2 20mM
MgS04 20mM
Glucose 20mM
pH 7.0
SOC was prepared in the absence of the magnesiun salts and glucose and sterilised by 
autoclaving. Filter sterilized magnesium salts and glucose were added prior to use.
(ii) TSS (Transformation and Storage Solution)
PEG (3500) 10% (w/v)
DMSO 5.0% (v:v)
MgCl2 20 inM
MgS04 20 mM
Prepared in LB media and the pH adjusted to 6.5
2.7 Solutions for Agarose-gel Electrophoresis.
2.7.1 DNA Electrophoresis.
(i) lx TAE (Tris-acetate)
Tris-acetate 40mM
EDTA ImM
pH to 8.0 with glacial acetic acid.
(ii) lx TBE (Tris-borate)
Tris-borate 89mM
Boric acid 89mM
EDTA 2mM
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(iii) DNA loading buffer, (6x).
Bromophenol blue 
Xylene cyanol 
Sucrose
0.25% (w/v) 
0.25% (w/v) 
40% (w/v)
2.7.2 RNA Elect rophesis.
(i) lOx Gel-running buffer 
MOPS
Sodium acetate 
EDTA
400mM
lOOmM
lOmM
(ii) RNA loading buffer 
Glycerol 
EDTA
Bromophenol blue 
Xylene cyanol
50% (v/v) 
ImM
0.4% (w/v) 
0.4% (w/v)
2.8 Solutions for Polyacrylamide-gel Electrophoresis.
(i) 2x SDS-PAGE loading dyes 
Tris-HCl (pH 6.8) 
SDS 
Glycerol
2-mercaptoethanol 
Bromophenol blue
60mM
2% (w/v)
20% (v/v)
5% (v/v) 
0.001% (w/v)
(ii) lOx running buffer.
Tris
Glycine
SDS
0.5M 
0.55 M 
1.0% (w/v)
(iii) 30% acrylamide
Prepared as a 29.2% acrylamide, 0.8% 
N,N'-methylene-bis-acrylamide solution.
56
2.9 Solutions for DNA and RNA Hybridisations
(i) Denaturing solution
NaCl 1.5M
NaOH 0.5M
(ii) Neutralising solution
NaCl 1.5M
Tris.HCi pH 7.0 1.0M
(iii) 20x SSC
NaCl 3.0M
Tri-sodium citrate 0.3M
pH 7.0 
Autoclaved.
(iv) Phosphate buffer (0.2M) pH 6.5
Na2HP04 18.75 ml, 0.2M
NaH2P04 31.25 ml, 0.2M
Water 50ml
(v) 50x Denhardt's solution
Ficoll 5g
Polyvinylpyrrolidone 5g
Bovine serum albumin (Fraction V) 5g
water to 500 ml
(vi) Prehybridisation/hybridisation solutions:
DNA hybridisations:
SSC 6x
SDS 0.1% (w/v)
Denhardt's solution 5x
EDTA 5mM
Phosphate buffer (pH 6.5) 25mM
Denatured Herring testis DNA 20ug/ml
Hybridisations with genomic DNA were performed in the presence of dextran sulphate 
(10% w/v).
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RNA hybridisations 
Deionised formamide 
SSC
Denhardt's solution 
Phosphate buffer (pH 6.5) 
Denatured Herring testis DNA
50% (v/v)
5x
5x
25mM
20/ig/ml
2.10 Solutions for RNA Extractions
(i) Lysis buffer
Tris.HCl pH 7.5
NaCl
MgCl2
Cycloheximide 
Nonidet P40, (NP40)
Vanadyl ribonucleoside complex
0.2M
0.14M
2.0mM
lOug/ml
0.5% (v/v)
20mM
Lysis buffer was prepared as a sterile solution by autoclaving in the absence of 
cycloheximide, N-P40 and the vanadyl ribonucleoside complexes and stored at -20°C. 
Cycloheximide, NP-40 and the vanadyl ribonucleoside complexes were added prior to use.
(ii) TSE.
Tris.HCl pH 8.5
EDTA
SDS
lOmM
5mM
0.5% (w/v)
(iii) Phenol/chloroform (1:1, v/v) 
See section 2.4 (iv).
(iv) Denaturing solution.
Guanidinium thiocyanate 
Sodium citrate, pH 7.5 
Sarcosyl
2-mercaptoethanol
4.0M 
25mM 
0.5% (v/v) 
0.1M
(v) Phenol saturated with water.
(vi) 2M sodium acetate pH 4.0.
(vii) Chloroform:isoamyl alcohol (49:l,v:v).
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2.11 Solutions for Plasmid Extraction from Bacteria
(i) Solution I.
Glucose 
EDTA pH 8.0 
Tris.HCl pH 8.0
50mM
lOmM
25mM
(ii) Solution II. 
NaOH 
SDS
0.2M
1.0% (w/v)
(iii) Solution III.
Potassium acetate
(3M potassium 5M acetate)
Prepared as follows:
60ml 5M potassium acetate
11.5 ml glacial acetic acid
28.5 ml water
(iii) Sucrose solution.
Sucrose 25% (w/v)
Tris.HCl pH 8.0 0.05M
(v) Brij-Doc solution.
Brij 58
Sodium deoxycholate 
In lx TE pH 8.0
(vi) Isopropanol saturated with Caesium chloride (CsCl)
CsCl (lOg) dissolved in STE (10ml). Isopropanol (100ml) was added and 
the mixture allowed to settle overnight.
2.12 Solutions for Genomic DNA Extractions
PEG 6000, 20% (w/v) in TE pH 8.0
1% (w/v) 
0.4% (w.v)
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(i) Coating buffer
Sodium carbonate 0.015M
Sodium bicarbonate 0.035M
pH 9.6
(ii) Phosphate-buffered saline (PBS)
NaCl
Na2HP04.12H20  
KC1
khpo4
water to 1000ml
(iii) PBS/Gelatine/Tween (PBS/G/T)
Gelatin 
Tween-20 
Disolved in PBS
2.13 ELISA Solutions
(iv) Substrate buffer (1 litre)
Citric acid 
Na2HP04
(v) Tetramethylbenzidine (TMB) substrate
lml of TMB (lOOmg) in DMSO (10ml) made up to 100ml with substrate buffer containing 
0.045% ofH 20 2.
2.14 Radioimmunoassay Solutions
(i) Phosphate buffer (Assay buffer)
Phosphate buffer 40mM
(ii) Dextran-coated charcoal
Charcoal (2.5g) was stired into 100ml of phosphate buffer for 15 minutes. Dextran T.70 
(250mg) was added and stirring continued for a further 30 minutes. The charcoal was 
removed by centrifugation (2500 x g, lOmins). The supernatant and fines were removed 
and the charcoal resuspended in 100ml of phosphate buffer and stored at 4°C.
5.1g
7.3g
0.5% (w/v) 
0.5% (v/v)
8.0g
2.9g
0.2g
0.2g
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2.15 Solutions for COS-1 Cell Transfections
(i) Transfection cocktail
DNA (500ng) in 200/ri DEAE dextran (0.05% w/v) in sterile PBS.
(ii) Transfection media
DMEM (section 2.3 (i)) supplemented with DMSO (10% v/v) or chloroquine 
(80/iM, filter sterilized)
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PART B. METHODS
2.16 Ethanol Precipitation of Nucleic Add.
DNA was precipitated using one of the following methods.
Method A.
Addition of 0.1 volume of 3M sodium acetate pH5.2 followed by 2.0
volumes of ethanol.
Method B.
As for method A, except that an equal volume of isopropanol (2-propanol)
was substituted for ethanol.
Method C.
Ammonium acetate was added to a final concentration of 2.5M (0.5 volume of 7.5 
M ammonium acetate) followed by the addition of 2.5-3.0 volumes of ethanol.
After the addition of ethanol (or isopropanol) the solutions were mixed and cooled 
on ice for 30 minutes or for longer time periods at -20°C. Precipitated DNA was collected 
by centrifugation (10000 x g, 5-30 mins). The DNA pellet was washed in 70% (v/v) 
ethanol and dried in vacuo prior to resuspending in TE. After isopropanol precipitation 
DNA was reprecipitated using ethanol.
The following methods were used to precipitate RNA.
Cytoplasmic RNA fractions were precipitated by the addition of 2.5 volumes of 
ethanol. Messenger RNA fractions were precipitated by the addition of 2.5 volumes of 
ethanol in the presence of 0.3M sodium acetate (pH 5.2). Precipitates were cooled to -70°C 
overnight and recovered by centrifugation as described for DNA.
2.17 Extraction of Solutions of Nucleic Acid with Phenol-chloroform
Phenol-chloroform extractions were performed using an equal volume of 
phenol/chloroform (section 2.4(v)). Phenol-chloroform was added to nucleic acid solutions 
and emulsified by mixing. The aqueous and organic phases were separated by 
centrifugation (2500 x g, 10 mins) and the aqueous phase transferred to a fresh tube. The 
extraction procedure was repeated until the interface between the phases became clear. A 
final extraction was performed using an equal volume of chloroform.
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2.18 Quantitation of Nucleic Add in Aqueous Solution.
The concentration and purity of nucleic acid in aqueous solutions was estimated by 
measuring the u.v. absorbance of the solution over the wavelength range of 220-300nm.
Pure solutions of DNA and RNA have an absorbance peak at 260nm, and a 
260nm/280nm ratio of 2.0 and 1.8 respectively (Sambrook et al., 1989). The 
concentration of nucleic acid was calculated using an absorbance value of 1 at 260nm to be 
equivalent to 50/ig/ml for double stranded DNA and 40/tg/ml for single stranded nucleic 
acid. When estimating the concentration of oligonucleotides made using an Applied 
Biosystems DNAsynthesizer (section 2.40), a concentration of 33/ig/ml was used to 
calculate DNA concentration in accordance with the manufacturer's recomendations.
2.19 Agarose-gel Electrophoresis
2.19.1 DNA Electrophoresis.
In general, gels were run at 100 volts for a time dependant on the gel dimensions 
and the agarose concentration. Gels were cast and run in lx TAE (section 2.7.1) with 
samples loaded in 1 x loading solution. After electrophoresis, gels were stained with ethidi- 
um bromide (0.5/ig/ml) for 20-30 minutes and DNA bands visualized under u.v. light.
2.19.2 RNA Electrophoresis.
Electrophoresis of RNA was carried out under denaturing conditions. The gel 
(1.5%) was prepared by dissolving the agarose (1.5g) in 72 ml of sterile water and allowing 
the molten agarose to cool to 55°C. Electrophoresis buffer (10ml of lOx) and 
formaldehyde (18ml) were then added to the cooled agarose, the solutions mixed by 
swirling and the gel immediately poured.
RNA samples (l-20^g in 4.5^1) were adjusted to lx with respect to the 
electrophoresis buffer and denatured by the addition of formamide (3.5 /aI) and 
formaldehyde (10/ri) and heated to 55°C for 15 minutes. RNA loading dyes (2/fl) were 
added to the samples prior to electrophoresis. Gels were run at 100 V until the xylene 
cyanol had migrated 8cm. Gels were stained in ethidium bromide (5/xg/ml) prepared in 
sterile water at 4°C for 3-5 minutes, and subsequently destained in sterile water at 4°C for 
4-12 hours.
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2.20 Purification of DNA Fragments from Agarose-gels
Standard DNA agarose gel-electrophoresis was performed and the gel stained with 
ethidium bromide (section 2.19). The fragments) of interest were recovered from agarose 
gels by one of two methods depending on the intended use of the DNA. DNA to be used as 
a radiolabelled probe was purified using the Geneclean™ method, whereas DNA to be used 
in ligations was purified using adsorbtion on to DEAE membrane.
2.20.1 Geneclean™ Method.
The method is based on that of Vogelstein and Gillespie (1979) and was carried out 
according to the manufacturer's instructions.
2.20.2 DEAE Membrane Method.
The gel was stained in ethidium bromide in lx electrophoresis buffer. The 
fragment(s) of interest were visualised under u.v light and incisions made in front of and 
behind the DNA band. Strips of DEAE membrane were inserted into the incisions and 
electrophoresis continued until the DNA adsorbed on to the membrane. DNA was eluted 
from the membrane by incubation at 70°C for 2 hours in an arginine solution (50mM, 1M 
NaCl). Ethidium bromide was removed by mixing with an equal volume of isoamyl alcohol 
saturated with water and allowing the phases to settle. The upper alcohol phase was 
discarded and DNA recovered from the lower aqueous phase by ethanol precipitation 
(section 2.16, method A).
2.21 Extraction and Purification of Plasmid DNA
2.21.1 Alkaline Lysis Method; Small Scale Preparations.
Small scale preparations were prepared using a method based on that of Bimboim 
and Doly (1979). Overnight cultures (1.5ml) of bacteria, grown in LB broth containing an 
appropriate antibiotic, were collected by centrifugation and resuspended in 150 /d of ice- 
cold solution I (section 2.11 (i)). The cells were incubated at room temperature for 5 
minutes, then lysed and chromosomal DNA denatured by the addition of 300/d of freshly 
prepared solution II (section 2.11 (ii)). After 5 minutes on ice, the denatured DNA was 
precipitated by the addition of 225/d of ice-cold solution III (section 2.11 (iii)). After a 
further 5 minutes on ice, the denatured chromosomal DNA was pelleted by centrifugation 
(10000 x g, 5-10 mins) leaving the plasmid DNA in the supernatant. The supernatant was 
transferred to a fresh tube and extracted with phenol/chloroform (section 2.17). The 
aqueous phase was then transferred to a fresh tube and plasmid DNA precipitated from
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solution with two volumes of ethanol (section 2.16).
2.21.2 Cleared Lysate Method; Large Scale Preparations.
An exponentially growing bacterial culture (in the presence of an appropriate 
antibiotic) was diluted 1:200 into 200ml of prewarmed (37°C) LB broth containing an 
appropriate antibiotic. This culture was grown overnight at 37°C with vigourous shaking. 
The cells were harvested by centrifugation (3000 x g, 10 mins) and resuspended in 3.5ml of 
ice-cold sucrose solution (section 2.11 (iv)). Lysozyme (0.5ml 20mg/ml in 0.25M EDTA 
pH 8.0) was added and the cells placed on ice. After 10 minutes, ice-cold EDTA (0.25M 
pH 8.0, 3.5ml) was added, the solutions mixed and returned to ice for a further 5 minutes. 
Brij-Doc solution (5ml. Section 2.11 (v)) was added, the solutions mixed by pipetting up 
and down 3-4 times and then returned to ice for a further 30 minutes. Cell debris and most 
of the chromosomal DNA were removed by centrifugation (15000 x g, 4°C, 45 mins). The 
supernatant was removed and solid CsCl (0.95g/ ml) and ethidium bromide (150ul,1.5% 
v/v) added and the lysate transferred to a Beckman Quick Seal polyallomer ultracen­
trifugation tube. Plasmid DNA was isolated by centrifugation (45000 rpm, 18°C , 48 
hours, 10ml gradient) or 16-24 hours (5ml gradient) in a Beckman L8 ultracentrifuge. The 
plasmid band was visualized under u.v. light (300nm) and recovered by puncturing the tube 
with a 19G disposable needle and drawing into a 1ml syringe. Ethidium bromide was 
removed from solution by several extractions with isopropanol saturated with caesium 
chloride (section 2.11 (vi)). Plasmid DNA was precipitated using an equal volume of 
isopropanol in the presence of 0.3M sodium acetate after diluting the plasmid solution 1:1 
with sterile water. Precipitated DNA was recovered by centrifugation (10000 x g, 15 mins) 
and resuspended in 200/xl of sterile water. The DNA was then reprecipitated with ethanol in 
the presence of sodium acetate (section 2.16, method A ). The DNA was resuspended in 
sterile water and stored at -20°C.
2.22 Restriction Enzyme Digests
Restriction enzymes were obtained from BRL and digests performed according to 
the manufacturer's instructions.
Small scale analysis was performed using approximately lju.g of DNA and 1-5 units 
of enzyme in a volume of 10-20/il. When anlysing small DNA fragments RNase (0.1 
mg/ml) was included in the digestion buffer.
Digestion of genomic DNA was performed in the presence of spermidine (4mM) 
and BSA, in a volume of 100-500ju,l with 50 units of enzyme. The digestion products were 
ethanol precipitated (section 2.16, method A) prior to electrophoresis.
65
2.22.1 Radiolabelling Digested DNA using Klenow Fragment.
Reactions performed using Klenow fragment usually followed restriction 
endonuclease digestion and were carried out at 37°C without adjustment of the buffer 
conditions. Enzyme and lO^Ci of an appropiate radiolabelled (35S or 32P) dNTP were 
added directly to the digestion products.
pBR322 Hinfl fragments were end-labelled in the presence of 2mM dNTPs.
2.23 Dephosphorylation of DNA.
Dephosphorylation of vector molecules was performed using calf intestinal alkaline 
phosphatase (CIAP) and usually followed restriction digest of vector DNA. After digestion, 
the restriction enzyme was inactivated by heating to 70°C for 10 minutes and the digestion 
products precipitated with ammonium acetate (section 2.16). The DNA pellet was 
resuspended in CIAP buffer (section 2.5) and the phosphatase reaction performed at 37°C 
for 1 hour with 1 Unit of enzyme per nmol of 5' ends. CIAP was inactivated by 
phenol/chloroform extraction (2.17). The dephosphorylated vector was then recovered by 
ethanol precipitation (section 2,16, method A).
2.24 DNA Ligations
DNA ligations were performed using T4 DNA ligase according to the 
manufacturer's instructions. Generally, ligations were carried out using lOOng of a 
dephosphorylated vector at a insert:vector molar ends ratio of 2:1. Cohesive end ligations 
were incubated at 14°C and blunt end ligations at 9°C overnight.
Ligation products were either diluted or added directly to competent cells for 
transformation (section 2.25).
2.25 Transformation of Escherichia coll
2.25.1 One Step PEG Method.
E.coli were transformed using the method of Chung et al., (1989), which allows for 
the preparation and storage of competent cells.
Preparation of Competent Cells.
An overnight culture of bacteria was diluted 1:50 in prewarmed LB media and
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grown with vigourous shaking, at 37°C until the OD (optical density) of the culture at 600 
irni reached 0.3-0.4. The cells were cooled on ice prior to centrifugation (1000 x g, 4°C 
10 mins) in a precooled rotor. The cell were resuspended in 0.1 volume of ice-cold 
transformation and storage solution (TSS. Section 2.6 (ii)).
For long term storage, the cells were immediately frozen in a dry ice/IMS bath and 
stored at -70°C. Frozen cells were thawed on ice and used immediately for transformation.
Transformation procedure.
Plasmid DNA (l-10ng) was added to 0.1ml of competent cells and incubated on ice 
for 20-30 minutes. The cells were grown, with gentle shaking (225rpm), at 37°C for 1 hour 
in 900/d of TSS suplemented with 20mM glucose. Dilutions of the transformation mix 
were spread over LB agar plates containing an appropiate antibiotic (usually ampicillin, 
100/tg/ml) and when required IPTG (O.lmM) and X-gal (20/ig/ml). The plates were 
incubated at 37°C overnight. When using an M13 vector, the transformed cells were plated 
directly in an overlay lawn of exponentially growing JM109 including IPTG (O.lmM) and 
X-gal (20/tg/ml) on 2x TY agar plates. Overlays were prepared in 3ml of molten H-top 
media (section 2.3 (x)) and immediately poured on to prewarmed agar plates.
2.25.2 Transformation of DH5a.
DH5a cells were obtained from BRL already competent for transformation and 
were used according to the manufacturer's recomendations.
2.26 Extraction and Purification of Genomic DNA from 
Mammalian Cells.
Genomic DNA extractions were performed on diploid mammalian cells grown in 
cell culture using the method of Longmire et al., (1987). A modified form of this method 
was used to extract genomic DNA from mammalian tissue. Approximately 106 cells (or lg 
of tissue) were used per extraction. Cells grown in culture were trypsinized from the flask 
where appropriate and collected by centrifugation (1000 x g, 5mins), washed free of culture 
media in sterile PBS and resuspended in 5ml of TE (pH 8.0). Tissue samples were 
homogenised directly in 5ml of TE and centrifuged (1000 x g, 30 s) to remove tissue 
debris. Cells (including homogenised tissue) were lysed by the addition of SDS (0.1 % 
w/v), and protein digested at 37°C with proteinase K (100/ig/ml) for 8-12 hours. The DNA 
was dialysed and concentrated using an Schuell and Schell UH 020/25 microdialysis 
apparatus. Dialysis was performed at room temperature against four 60 minute changes of 
PEG 8000 (20% w:v, TE pH 8.0), followed by 2 x 15 minute changes of TE (pH8.0). The
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solution outside the dialysis bag was gently stirred during dialysis.
When DNA and RNA were extracted from the same cells, cell lysis was performed 
as for cytoplasmic RNA extractions (2.27.1), and the nuclei pellet resuspended in TE (5ml 
pH 8.0) prior to the addition of SDS and protinase K.
2.27 RNA Extractions.
Glassware and plastic ware were pretreated overnight with DEPC (0.1% v/v), 
rinsed in 100% ethanol, and autoclaved prior to use.
2.27.1 Cytoplasmic RNA Extractions from Culture Cells.
Cytoplasmic RNA was extracted from mammalian cells grown in culture using the 
method of Preston, (1977), modified by Sanders and Wilson (1984).
Monolayer cells were removed from culture flasks with trypsin and washed free of 
culture media in sterile PBS. Suspension cells were washed in PBS. Cell were lysed by 
resuspending in 5.0ml of ice cold lysis buffer (section 2.10 (i)). The nuclei were removed 
by immediate centrifugation (2500 x g, 4°C ,3 mins) in a precooled rotor. The supernatent 
was transferred to a sterile 40ml polyallomer Oakridge tube containing TSE (5ml, section 
2.10 (ii)), sterile water (10ml) and phenol/chloroform (15ml, section 2.4 (v)). The solutions 
were emulsified by inversion and incubated at room temperature for 10 minutes with 
continuous mixing. The aqueous and organic phases were separated by centrifugation (2500 
x g, 10 mins). The aqueous phase was re-extracted with an equal volume of 
phenol/chloroform (section 2.17) until all traces of vanadyl ions were removed from the 
aqueous phase. A final extraction was performed using an equal volume of chloroform. 
RNA was precipitated with 2.5 volumes of 100% ethanol (section 2.16), except that the 
RNA was resuspended in sterile water and stored at -70°C.
2.27.2 RNA Extraction from Mammalian Tissue
RNA was extracted from mammalian tissues using a method based on that of 
Chomczynski et al., (1987).
Fresh bovine liver was diced on ice and immediately frozen in liquid nitrogen. 
Frozen liver (lg) was thawed in denaturing solution (10ml, section 2.10), and homogenised 
at 4°C. The homogenate was transferred to a sterile 40ml polyallomer Oakridge tube and 
sodium acetate (1ml 2M pH 4.0), phenol saturated with water (10ml), and chloroform/iso­
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amyl alcohol (49:1, v:v, 2ml) added sequentially. The mixture was emulsified by vigorous 
shaking and placed on ice for 15 minutes. The aqueous and organic phases were separated 
by centrifugation (10000 x g, 4°C, 25 mins) and the aqueous phase transferred to a fresh, 
sterile tube. RNA was precipitated from the aqueous phase with an equal volume of 
isopropanol at -20°C for 1 hour. The precipitated RNA was collected by centrifugation, 
resuspended in water and reprecipitated using 2.5 volumes of ethanol in the presence of 
0.3M Na acetate (section 2.16).
2.28 Isolation of Messenger RNA (mRNA).
Messenger RNA (mRNA) was isolated from cytoplasmic RNA using messenger 
affinity paper (Hybond mAP™). The paper was cut into small strips and washed in 0.5M 
NaCl (10ml). The RNA solution (lmg/450/d in sterile water) was heated at 65°C for 3-5 
minutes and placed on ice. RNAguard (20 units) was added to the RNA and the solution 
adjusted to 0.5M NaCl in a volume of 500/ri. The paper was immersed in the RNA solution 
and shaken at room temperature for 20-25 minutes. The paper was removed and washed 
twice in 0.5M NaCl (10ml), once in 70% ethanol and air dried on a sterile plastic petri 
dish. mRNA was eluted from the paper by immersion in sterile water (700/tl) and 
incubation at 70°C for 5 minutes. mRNA was precipitated with 2.5 volumes of ethanol in 
the presence of 0.3M sodium acetate at -70°C overnight. The mRNA was recovered by 
centrifugation (10000 x g, 4°C, 30 mins) dried jn vaccuo. resuspended in sterile water at 
lug/ul, and stored at -70°C.
2.29 In vitro Translation of mRNA.
RNA fractions were translated in the presence of [35S]-methionine (5mCi/ml, 
specific activity 800Ci/mmol) using a rabbit reticulocyte translation system. The translation 
products were separated through an SDS-polyacrylamide gel (10% acrylamide) and the gel 
treated as described in section 2.30.
2.30 SDS-Polyacrylamide-gel Electrophoresis.
A 10% resolving gel (40ml) was prepared from stock solutions as follows,
water 15.8ml
30% acrylamide mix 13.3ml
1.5 M Tris (pH 8.8) 10.0ml
10% SDS 0.4ml
10 % Ammonium persulphate 0. 4ml
TEMED 0.016ml
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Ammonium persulphate and TEMED were added immediately before the gel was 
cast. The resolving gel was allowed to set for 45 minutes under a overlay of butanol 
saturated with water. After the gel had set, the overlay was poured off and the gel surface 
washed with 1M Tris (pH 6.8 ).
A stacking gel (10ml) was also prepared from stock solutions as follows,
water 6.8ml
30% acrylamide mix 1.7ml
1.0 M Tris (pH 6.8) 1.25ml
10% SDS 0.1ml
10 % Ammonium persulphate 0.1 ml
TEMED 0.01ml
The stacking gel was poured directly on to the resolving gel and the comb inserted 
into the gel solution. After the stacking gel had set the comb was removed under buffer and 
the wells washed with electrophoresis buffer.
The samples were mixed with an aqual volume of 2x gel loading dyes (section 2.8 
(i)) and boiled for 2 minutes before loading into the bottom of the wells. The gel was run in 
lx running buffer. Initially, the gel was electrophoresed at 100 V until the dye had reached 
the resolving gel at which point the voltage was increased to 200 V. After electrophoresis, 
protein was fixed in the gel by precipitation in 30% methanol; 10% acetic acid for 1 hour. 
After fixing, the gel was immersed in ENHANCE solution for 1 hour before drying the gel 
and autoradiography.
2.31 Transfer of Nucleic Acid onto Nylon Membrane.
All hybridisation performed during these studies used Hybond-N™ nylon 
membrane.
2.31.1 Southern Transfer of DNA.
Southern transfer was performed according to the method of Southern, (1975) as 
described in Sambrook et al., (1989).
DNA-agarose gel electrophoresis (2.19) was followed by soaking the gel in several 
gel volumes of denaturing solution (45 mins, section 2.9 (i)), neutralising solution (30 mins, 
section 2.9 (ii)) and rinsing the gel in 2x SSC. Blotting was carried out with 20x SSC for 
12-16. After blotting the nylon was air-dried and the DNA fixed to the nylon by either
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baking at 80°C for 2 hours or by u.v cross linking. Cross linking was performed by 
wrapping the nylon in Sarran wrap and placing it DNA side down, in contact with a u.v 
transluminator (405nm) for 3-5 minutes.
2.31.2 Northern Transfer of RNA.
RNA samples were electrophoresed through a 1.5% agarose formaldehyde 
denaturing gel (2.19), the gel rinsed in 2x SSC and blotted as described for DNA.
23 1 3  Colony/Plaque Lifts.
Replica filters of colonies on a plate were prepared by direct contact with the plate 
surface. The initial replica remained in contact for 30 seconds and subsequent replicas for 
an additional 30 seconds. The membrane was then placed, colony side uppermost, on to an 
LB-agar plate, containing ampicillin (100/ig/ml), and the plate incubated at 37°C until 
colonies of 0.5-1.0 mm in diameter were visible. The membrane was then placed 
sequentially, colony side uppermost, on to 3-MM paper soaked in SDS (0.1%, w/v, 30 s), 
denaturing solution (5mins), neutralising solution (5mins), and 2x SSC (3mins). The 
membrane was air-dried and the DNA fixed to the nylon by u.v cross linking (section 
2.31).
Replica filters of plaques were prepared as for colonies except that incubation on 
ampicillin plates and the SDS steps were omitted.
2.32 DNA Hybridisations
Hybridisations (and prehybridisations) were carried out in a sealed Hybaid™ bag in 
a shaking water bath at 65°C. Prehybridisations were performed in hybridisation solution 
(section 2.9 (vi)) at 65°C for 1 hour. After prehybridisation, denatured probe DNA (section 
2.34) was added directly to the hybridisation solution and hybridisation carried out under 
identical conditions, for 16-24 hours. After hybridisation, the nylon was washed in SSC, in 
the presence 0.1% SDS, with the concentration of SSC and the washing temperature 
depending on the specificity of the probe DNA for its target. In the text, low stringency 
refers to 6x SSC at 55°C, medium stringency refers to 3x SSC to lx SSC at 55°C, and 
high stringency to 0. lx SSC at 65°C. After washing, the membrane was wrapped in Saran- 
wrap™ and autoradiographed with Fuji-X-ray film in the presence of an intensifing screen 
at -70°C..
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2.33 RNA Hybridisations
RNA hybridisations were performed at 45°C in the presence of 50% formamide 
(section 2.9) as described above for DNA.
2.34 Preparation of 32P labelled DNA Probes.
Radiolabelling of DNA probes was carried out using an Amersham Multiprime 
DNA labelling system, based on the method of Feinberg and Vogelstein (1983). Probe 
DNA was isolated from agarose gels using Geneclean™ (section 2.20). The amount of 
DNA used per labelling reaction was estimated by visual inspection after gel electrophoresis 
and ethidium bromide staining. Single stranded template was prepared by boiling the probe 
DNA for 2-3 minutes followed by rapid cooling on ice.
A standard reaction, using [a-32P] dCTP with a specific activity of 3000Ci/mmol, 
results in probes with an average length of 200 nucleotides with a specific activity of 1.8 x 
109 dpm/jtig.
2.35 Preparation of Bacteriophage Stocks.
2.35.1 Lambda-gtlO.
A single plaque was picked from an LB agar plate into sterile SM buffer using a 
sterile glass pasteur pipette. Phage were stored, over chloroform, at 4°C.
2.35.2 M13mpl8.
Exponentially growing JM109 were innoculated with phage picked from a plaque 
using a sterile toothpick and the culture grown, with vigorous shaking, at 37°C for 12-24 
hours. A phage stock was prepared from this culture by removing the cells by sucessive 
centrifugations (10000 x g, 5 mins). The supematent, containing viable phage particles, was 
transferred to a fresh sterile tube and stored at 4°C.
2.36 Purification of Lambda-gtlO DNA.
2.36.1 Small Scale Liquid Culture Method.
Phage stock (100;d) was added to 0.5 ml of freshly prepared plating cells (NM514, 
section 2.37) and placed at 37°C for 15 minutes. LB media (5ml supplemented with 5mM
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CaCl2) was added and the culture grown at 37°C, with vigorous shaking, until the cells 
lysed. Chloroform (10/xl) was added to the cell lysate and shaking continued for a further 5 
minutes. The lysate was centrifuged (3000 x g, 10 mins) and the supernatant (4ml) 
transferred to a fresh tube. An equal volume of PEG 6000 (20% w/v in 2M NaCl in SM) 
was added to the lysate, the solutions mixed by inversion and placed on ice for 1 hour. A 
phage pellet was collected by centrifugation (3000 x g, 20 mins) and resuspended in LB 
media (750/d). An equal volume of DE52 resin (section 2.4) was added to the phage and 
the solutions mixed by inversion. The resin was removed by sucessive centrifugation 
(10000 x g, 5 mins). Proteinase K (100/xg/ml) and SDS (0.1%) were added to the 
supernatant (750ul), and incubated at room temperature for 5 minutes. Potassium acetate 
(130/d of 3M) was added and the phage incubated at 88°C for 20 minutes followed by 
centrifugation (10000 x g, 10 mins). The supernatant (750/d) was transferred to a fresh tube 
and phage DNA precipitated using an equal volume of cold (-70 °C) isopropanol (section 
2.16).
2.36.2 Large Scale Preparations.
Five small scale lysates prepared as above were pooled in a volume of 20ml, an 
equal volume of PEG 6000 (20% w/v, in 2M NaCl in SM) added, the solutions mixed and 
placed on ice for 60 minutes. A phage pellet was collected by centrifugation (6000 x g, 
4°C, 20 mins) and resuspended in SM (3ml). DNase (5/ig/ml) and RNase (100/tg/ml) were 
added and the phage incubated at 37°C for 60 minutes. EDTA (20 mM pH 8.0) was added 
and the phage kept at room tempersture for 3-5 minutes. Proteinase K (100/ig/ml) and SDS 
(0.5%) were added and the solution incubated at 68°C for 30 minutes. The solution was 
extracted with phenol/chloroform ( section 2.19) and DNA precipitated in the presence of 
2.5M ammonium acetate (method C, section 2.16).
2.37 Preparation of Phage Plating Cells (NM514).
An individual colony was picked from a freshly grown LB agar plate and used to 
innoculate LB media (10ml supplemented with 0.4% maltose). The culture was grown 
overnight at 37°C. The overnight culture (1ml) was used to further innoculate prewarmed 
LB media (50ml supplemented with 0.4% maltose) and this culture grown at 37°C until 
the OD (optical density) at 600nm, reached 0.5. The culture was transferred to a precooled 
sterile tube and cooled on ice for 5 minutes prior to collecting the cells by centrifugation 
(3000 x g, 4°C, 5 mins). The cells were resuspended in ice-cold MgS04 (15ml, lOmM) 
and placed on ice.
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2.38 Construction of the cDNA Libaries
2.38.1 cDNA Synthesis.
cDNA synthesis was carried out using an Amersham cDNA synthesis system 
according to the manufacturer’s instructions. The system is based on the method of Gubler 
and Hoffman, (1983) and results in double stranded cDNA molecules with EcoRl linkers at 
each end.
2.38.2 Ligation of cDNA into Cloning Vectors.
Double stranded cDNA was ligated into EcoRl digested cloning vectors (lambda- 
gt-10 arms or pUC13) as described in section 2.24.
2.38.3 In vitro Packaging of Recombinant Lambda-gtlO.
Recombinant lambda-gtlO were packaged into viable phage particles using an 
Amersham lambda-gtlO in vitro packaging system according to the manufacturer's 
instructions.
2.38.4 Transformation of DH5a with the pUC13/cDNA 
Ligation Products.
The pUC13/cDNA ligation was diluted 1:5 with TE (pH 8.0) and used to transform 
E.coli host DH5a (section 2.25.3) to ampicillin resistance.
2.38.5 Titration of Lambda-gtlO Recombinants.
The library phage stock was plated on a lawn of NM514. Phage dilutions (10“2, 
10-3 , 10-4 in 100/il) were mixed with freshly prepared plating cells (NM514, section 
2.37) and the cells placed at 37 °C for 15 minutes. Molten top-agarose (4ml) was added to 
the cells, the mixture poured over LB agar plates (90mm dish) and the plates incubated 
overnight at 37°C.
2.38.6 Preparation of Lambda-gtlO Library Plates.
The lambda-gtlO library was plated on LB agar plates (20cm x 20cm) using a large 
scale method (xlO) of that used to titrate the library (section 2.38.5).
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2.39 DNA Sequencing
DNA sequencing was carried out on 1-2 ug of template DNA using a Cambridge 
BioScience Sequenase™ kit. The kit is based on the dideoxy chain termination method of 
Sanger et al., (1977) and includes all the buffers, solutions and enzyme required to catalyse 
the addition of deoxynucleotides (and their derivatives) to the 3' ends of a DNA chain.
2.39.1 Preparation of Single Stranded Template DNA
2.39.1.1 M13 Template DNA.
Single stranded, recombinant M13 template DNA was prepared from phage stocks 
(section 2.35.2). Phage stock (5/d) was used to innoculate mid-log phase JM109 (1.5ml) 
and the culture grown, with vigorous shaking, at 37°C for 6-7 hours. Cells were removed 
by sucessive centrifugations (10000 x g, 5 mins). PEG 6000 (250/d, 20% w/v, 2.5M 
NaCl) was added to the supernatant (1ml), the solutions mixed and placed on ice for 15 
minutes. A phage pellet was collected by centrifugation (1000 x g, 10 mins, 4°C) and 
resuspended in TE (100/d, pH 8.0). The solution was extracted with phenol/chloroform 
(section 2.17.) and phage DNA precipitated with ethanol in a dry ice/IMS bath for 15 
minutes ( method A, section 2.16 ). The DNA was resuspended in TE (100/d,pH 8.0), 
proteinase K (0.5mg/ml) added and the solution incubated at room temperature for 30 
minutes. Phenol/chloroform extraction and ethanol precipitation were repeated with the 
DNA pellet resuspended in TE (20/d, pH 8.0). The amount of single stranded DNA 
prepared was estimated by ethidium bromide staining after agarose gel electrophoresis (sec­
tion 2.19).
2.39.1.2 pUC Template DNA.
Double stranded, recombinant plasmid DNA (1-2/tg of caesium chloride density 
gradient DNA, section 2.21) was denatured and prepared for sequencing using the method 
of Zang et ah, (1988) with the following modification. Denatured DNA was rapidly cooled 
in an IMS/dry ice bath for 10 minutes after the neutralising step.
2.39.1.4 Preparation of DNA Sequencing-gel and Electrophoresis Conditions.
Acrylamide gels (4%) were polymerised using a molar ratio of acrylamide to N,N'- 
methylenebisacrylamide of 19:1, in 8.3M urea, lOOmM Tris-borate (pH 8.3) and 2mM 
EDTA. The gel was cast between glass plates (31cm x 38.5cm x 0.4mm) previously 
coated with either dimethyl dichlorosilane (repellant) or gamma-methacryloxypropyl- 
trimethoxy silane (adhesive). The gel was pre-electrophoresed for 15-30 minutes and run at
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75W constant power in lx TBE electrophoresis buffer. After electrophoresis, the DNA was 
fixed in the gel by immersion in 10% methanol, 10% acetic acid for 20 minutes then 
rinsed throughly under running water for 5 minutes to remove the urea, before drying in a 
hot air oven at 80°C for 1 hour. The gel was then placed in direct contact with Fuji-RX
film in an X-ray cassette and kept in the dark for 16-48 hours.
2.40 Oligonucleotide Synthesis.
Oligonucleotides, used for DNA sequencing, site-directed mutagenesis and for 
cDNA synthesis were made on a Applied Biosystems DNA synthesizer according to the 
manufacturer's instructions.
2.41 Site-directed Mutagenesis
Site-directed mutagenesis was carried out using an Amersham oligonucleotide-directed in 
vitro mutagenesis system. The system is based on the method of Eckstein and Nakamaye, 
and Eckstein, (1986 and Sayers et al, (1988) and supplies all the enzymes and buffers 
required for the synthesis of closed circular homoduplexed mutant molecules. The system 
uses a primer carrying the desired mutation(s) to initiate a DNA synthesis reaction from a 
single site on a single stranded M13 template. The primers carrying the mutations were 
synthesised using a Cambridge BioScience DNA synthesizer (section 2.40). The primers 
were phosphorylated using T4 polynucleotide kinase (section 2.5) prior to use at a ratio of 
primer to template of 2:1 (approximately 1.6 pmol of primer DNA per jig of template for 
5ug of template DNA; this was calculated to be 20 and 22ng for primer 14 and 15 
respectively). Recombinant single stranded M13mpl8 DNA, including the cDNA that 
coded for the bovine heavy chain of the anti-testosterone antibody served as the template
DNA and was prepared as described in section 2.39.1.
2.41.1 Transformation and Plating of the Mutant Recombinant Phage.
E.coli strain TGI was transformed with the homoduplexed mutant M13 DNA using the 
one step PEG method (section 2.25.1) and the transformed cells plated on a lawn of mid­
log phase TGI cells using the method described for JM109 transformed with M l3 DNA 
(section 2.25.2).
2.41.2 Analysis of Mutant Progeny.
Molecules earring the introduced mutation(s) were identified by DNA sequencing through 
the target region. Isolated plaques were picked from the lawn of TGI cells and phage 
stocks prepared as described in section 2.35.2. Single stranded template DNA was prepared
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as in section 2.39.1,1 and sequenced using primer complementary to a region in the CHI 
domain of bovine IgGl heavy chains as described in section 2.39.
2.42 DEAE-Dextran Mediated Transfection of COS-1 Cells.
COS-1 cells were obtained from Celltech Ltd and cultured in DMEM (section 2.3 (i)). 
Exogenous DNA was introduced into COS-1 cells using a DEAE dextran transfection 
method (Lopata et al., 1984). Subconfiuent monolayers of cells were prepared for 
transfection by seeding at 7.5 x 105 cells/35mm well 12-16 hours prior to transfection. For 
each transfection the DNA (500ng, CsCl gradient purified, section 2 21.2) was prepared as 
individual transfection cocktails (section 2.15).
At 12-16 hours post seeding, culture medium was aspirated and the cells washed in warm 
(37°C) sterile PBS. The transfection cocktail was evenly applied over the cell monolayer 
surface and the cells returned to 37°C, with occasional gentle shaking to prevent drying. 
After 30 minutes, DMEM (2ml) additionally supplemented with 80uM chloroquine 
(section 2,3) was added to the cells, and incubation continued at 37°C for a further 2.5 
hours. The medium was aspirated and replaced with DMEM (1ml), additionally supple­
mented with 10% DMSO (section 2.3 (i)). After 2.5 minutes, the DMSO medium was 
aspirated and replaced with 3ml of fresh, warmed (37°C) DMEM and the cells returned to 
37°C. After 24 hours, the medium was replaced with 3ml of fresh pre-warmed DMEM and 
incubation at 37°C continued for a further 48 hours.
2.43 Enzyme-linked Immunosorbent Assay (ELISA)
Transfected COS-1 cell supernatents were screened for the presence of bovine anti­
testosterone IgG using an ELISA (Groves et al., 1987a).
Flat-bottomed, flexible, PVC microtitration plates were coated with a testosterone- 
3CMO-chicken gammaglobulin conjugate (prepared in coating buffer at 0.5/tg/ml) at 
200/d/well. Coating was performed overnight at 4°C in a humidified container. The plates 
were then washed three times in PBS/G/T using a Titretek microplate washer 120 (Flow 
laboratories) and rapped dry. Dilutions of culture media from transfected COS-1 cells 
(200/d), including media from control transfections, were applied to the plates in duplicate 
wells. Additional controls of a dilution series of a known ammount of the bovine anti­
testosterone monoclonal antibody secreted from B/MT.4A, and chicken gammaglobulin in 
PBS/G/T were included on each plate. The plates were then incubated at 37°C for 2 hours 
in a humidified container, then washed as above in PBS/G/T. Specific binding was detected 
using an horse radish peroxidase-labelled rabbit anti-bovine IgG conjugate. The rabbit 
antibody conjugate (200/d) was added to each well and the plates returned to 37°C. After 2
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hours the plates were washed in PBS/G/T, then incubated with TMB substrate (150/d/well) 
in the dark at 37°C for 30 minutes. The enzyme reaction was stoped by the addition of 
2.5M sulphuric acid (50/d/well) and the optical density of the wells read at 450nm using a 
Dynatech MR 590 microELISA plate reader.
The labelled rabbit antibody was obtained from Dakopatts and further purified before use 
by passage down a Sephadex G200 column in PBS and 1% thiomersol. The conjugate was 
obtained in this form from Dr D.J.Groves and used at the optimum dilution of 1:1500 
made in PBS/G/T (D.J.Groves, personal communication).
2.44 Radioimmunoassay (RIA)
The equilibrium binding association constant (Ka) of the wild-type antibody, secreted by 
BMT.4A and by transfected COS-1 cells, and the mutated antibodies (Chapter 6) were 
measured using a competetive radioimmunoassay (Groves et al., 1987a) with the data being 
analysed by the method of Muller, (1980).
Preparation of antibody dilution curves.
An antibody dilution curve of the percentage bound of a fixed amount of titrated 
testosterone against antibody dilution was derived, in order to determine the antibody 
dilution that bound 50% of the added label as required by the Muller analysis.
Triplicate dilutions of cell media were made in 40mM phosphate buffer (pH 7.4, section
2.14) and were allowed to come to equilibrium, at 4°C overnight with a fixed amount of 
labelled testosterone (Chapter 7). The antibody and label were mixed in a volume of 300/d 
made up as follows: 100/d of tritiated testosterone, 100/d of diluted antibody, 100/d of 
40mM phosphate buffer. At equilibrium, antibody-bound and free testosterone were 
separated using a dextran-coated charcoal suspension prepared in phosphate buffer (section
2.14). Cold charcoal suspension (lml, 4°C) was added to each tube, the solutions mixed by 
vortexing and returned to 4°C. After 30 minutes, the charcoal was removed by 
centrifugation (2000 x g, 4°C, 15 mins) and the supernatant (0.5ml) containing the 
antibody-bound testosterone transfered to a scintillation vial containing scintillation fluid 
(4.5ml, "Optiphase safe"). The amount of antibody-bound radioactivity in the 0.5 ml 
sample was measured by liquid scintillation counting using a LKB 1217 RACKBETA II 
scintillation counter.
The amount of labelled testosterone used in each experiment was calculated as the mean 
value of 4 counts of tubes prepared in the absence of charcoal (1ml of 40mM phosphate 
buffer was substituted for the charcoal). The amount of testosterone (pmol) was calculated
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from the mean using the equation,
T x 2.6
2222
81
Where, T = Mean of counts (dpm) in the absence of charcoal
2222 = Conversion factor to convert dpm to nCi.
2.6 = Dilution factor to convert dpm to dpm/tube.
81 = The specific activity of the labelled testosterone
(nCi/pmol)
Non-specific binding of label was calculated from the mean of 4 counts in tubes prepared 
in the absence of antibody (the volume of the assay was adjusted using 40mM phosphate 
buffer).
Preparation of the Standard curve.
A standard curve was derived using the same amount of labelled-testosterone and the 
antibody dilution that bound 50% of the added testosterone in the presence of increasing 
amounts of competing unlabelled testosterone (0.0078-10.0 pmol/tube).
2.44.1 Muller Analysis.
The Muller analysis was used to calculate antibody affinity (Ka) from the molar labelled 
testosterone concentration, the amount of antibody-bound testosterone in the absence of 
unlabelled testosterone and the molar unlabelled testosterone concentration resulting in 50% 
inhibition of antibody binding to label.
The concentration of unlabelled testosterone, at 50% inhibition of antibody binding to 
label was determined from a plot of the percentage bound of the added labelled-testosterone 
against unlabelled testosterone concentration.
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The above values are used in the following equation to calculate K.
Ka = _________________________________  M/1
( M  - |T t]) «l-1.5b) + (0.5b2))
Where,
Ko = The binding association constant
[It] = The molar concentration of unlabelled testosterone that gives 50%
inhibition of antibody binding.
[Tt] = The molar concentration of labelled testosterone,
b = The percentage binding of the available labelled testosterone in the
absence of unlabelled testosterone.
Kd was calculated from the relationship
1
Kd = ---------
Ka
2.45 Modelling the Antigen Binding Site of the Bovine Anti-testosterone Monoclonal 
Antibody.
A 3-D molecular model of the antigen-binding site of the bovine anti-testosterone 
monoclonal antibody secreted BMT.4A was constructed using the methods of de la Paz et 
al., (1986), Chothia and Lesk, (1987), Chothia et al., (1989) and Martin et al., (1989).
The model was visualised using an Evans and Sutherland ESV Workstation.
2.45.1 The Framework Regions.
The model was constructed using the framework regions (FR) taken from the VL and 
VH-domains of the crystal structures KOL (Marquart et al., 1980) and D1.3 (Amit et al.,
1986) respectively. The atomic co-ordinates of these structures were obtained from the 
Brookhaven Protein Databank (Bernstein et al., 1977). The above domains were paired to 
form a Fv module by optimally superimposing the main chain atoms of the heavy chain 
framework regions (FR1, FR2, and FR3) of KOL and D1.3, and the appropriate domains 
deleted.
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2.45.2 Modelling the Complementarity Determining Regions (CDR).
With the exception of CDR-H2, the CDRs were modelled according to the Kabat 
definition (Kabat et al., 1987). The 7 C-terminal residues of CDR-H2, as defined by Kabat, 
were not modelled as these residues occupy positions in Ig crystal structures that are unlike­
ly to be available for contacts with antigen (Martin et al., 1989).
2.45.2.1 Modelling CDR Ll-3, HI and H2.
CDRs predicted to share the same, or similar main chain conformation to a loop of 
known structure were modelled using the methods of de la Paz et al., (1986), Chothia and 
Lesk, (1987) and Chothia et al., (1989). Loops were modelled by side chain replacement 
using the selected loop conformation as a template. Side chain replacementswere made 
using the maximun overlap procedure (MOP) using the REPLACE and REFI (Hermans and 
McQueen, 1974) options of the molecular graphis program FRODO (Jones, 1978). MOP 
attempts to place as many atoms as possible of the replacement side chain in positions 
occupied by atoms of the parent structure. In cases where atoms cannot occupy the exact 
same position, or when additional atoms need to be acco&odated, atoms are positioned 
using the REFI local minimisation procedure.
2.45.2.2 Modelling CDR-H3.
CDR-H3 was modelled using the methods of Martin et al., (1989) and Martin, (1990). 
Structural information (Ig and non-Ig) contained within a processed form of the Brookhaven 
Protein Databank was searched using a set of defined distance constraints derived from an 
analysis of known antibody structures (Martin et al., 1989). The search was used to identify 
loops that are the same length and considered to share a similar main chain conformation 
over defined regions as CDR-H3 of the bovine antibody.
Loops identified by the above database search were extracted from the Protein Databank 
and overlapped individually onto the "take off points" of CDR-H3 of the VL-KOL:VH- 
D1.3 Fv (section 2.45.1). CDR-H3 was then deleted and the loops processed to make the 
final selection for the model.
Processing the loops.
The sequence of each loop processed was corrected using the program RESEQUENCE 
(Martin et al., 1989). Explicit hydrogens were added and the loops subjected to the 
conformational search program CONGEN (Bruccoleri and Karplus, 1988). CONGEN 
rebuilds the main chain of a defined 5 residue section (the middle 5 residues) and positions
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all of the side chains. The middle three residues of the section rebuilt were joined using the 
Go-Scheraga chain closure algorithm (Go and Scheraga, 1970). The generated 
conformations were screened using the solvent-modified GROMOS potential (Aqvist et al., 
1985) to rank the loops in order of their potential energies (Martin et al., 1989). Analysis 
of the ranking procedure, using loops of known structure, has shown that the loop with the 
lowest root mean square deviation from the known structure is found within the lowest 5 
energy conformations (Martin, 1990). Therefore only the lowest 5 energy conformations 
were further analysed to make the final selection.
The lowest 5 energy conformations were analysed using a structurally determining 
residue filter algorithm (Martin., 1990). This procedure compares the <f> and)6 angles of the 
lowest 5 energy conformations with their values in the loops selected by the database 
search. The sequence of the loop being modelled is compared with the sequence of each 
loop identified by the database search and for positions where identical amino acids are 
found, the 4> and?J torsion angles are recorded. The </> and^ angles of the lowest 5 energy 
modelled conformations are measured against the recorded values and given a score of 1/9, 
where 0 is the angular mismatch between the two values and is less than a cutoff (+/-15 ). 
The score is then multiplied by a confidence factor of 100%. For positions where the 
identical amino acid is not found, the above procedure is performed using the most similiar 
amino acid, identified using a Dayhoff mutation matrix (Barker and Dayhoff, 1972). The 
confidence factor is decreased in 5% increments for each step that has to be made down the 
Dayhoff matrix. A second scoring scheme assigns a value of 1 to residues with $ and+ 
angles that lie within the cutoff angles of any database conformation. The scoring schemes 
therefore allow for each of the conformations to be evaluated in terms of both a total score 
and a score distribution across the loop. In situations where more than one conformation is 
given identical scores by the first scoring scheme, the conformation with the better 
distribution across the loop is selected.
The complete model was energy minimised using the full GROMOS potential ]n vacuo.
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ISOLATION OF BOVINE IMMUNOGLOBULIN cDNA.
CHAPTER 3.
CHAPTER 3.
ISOLATION OF BOVINE IMMUNOGLOBULIN cDNA.
3.1 Introduction.
Bovine Ig heavy and light chain cDNAs were isolated from libraries constructed 
using mRNA prepared from a mouse x bovine heterohybridoma (BMT.4A) that secretes 
bovine anti-testosterone (IgGl) monoclonal antibody (Groves et al., 1987a).
3.2 Hybridisation Studies.
Specific DNA probes for bovine Ig C-gamma-1 heavy and light chains were 
unavailable on initiation of these studies; however, the relatively high degree of 
sequence homology of mammalian Ig genes suggested that interspecies hybridisation 
may be used to detect Ig DNA in a species for which specific probes cannot be 
used. Therefore, in the absence of bovine probes, murine Ig probes were selected 
for screening BMT.4A cDNA libraries. Hybridisation studies were, therefore, 
undertaken to investigate the possibility of using murine Ig probes to detect 
their bovine counterparts.
After initiation of the light chain hybridisation studies, a bovine lambda 
light chain cDNA (Ivanov et al., 1987) was made available and this clone was 
susequently used to screen the library in place of the murine probe.
3.2.1 Heavy Chain Hybridisation Studies.
A murine C-gamma-1 heavy chain probe was selected to aid the identification of 
C-gamma cDNAs of NSl/l-Ag4-l origin that may be present in BMT.4A cDNA libraries 
(section 1.22). The rationale used was that, at relatively low stringency, all C- 
gamma heavy chain cDNAs (murine and bovine) represented in a BMT.4A cDNA library 
would hybridise, whereas only cDNAs of murine origin would strongly hybridise at 
high stringency.
BMT.4A secretes bovine IgGl and, therefore, contains at least one bovine C- 
gamma-1 heavy chain gene. Hybridisation with the bovine gene was to be identified 
by comparing the hybridisation pattern of BMT.4A DNA with that of the mouse 
myeloma fusion partner (N Sl/l-A g4-l) used in its construction. Additional 
hybridisation with BMT.4A DNA would most likely result from hybridisation with the 
bovine C-gamma heavy chain gene. NSl/l-Ag4-l DNA was, therefore, included in these 
studies to represent the murine Ig background present in BMT.4A. DNA from the
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second fusion partner (BMT-2) was also included to investigate the possibility of 
there being bovine C-gamma heavy chain gene(s) present in this cell line (section 
1.22 ). Bovine liver DNA was also included as a control.
Genomic DNA (10/ig) from NSl/l-Ag4-l, BMT-2, BMT.4A and bovine liver were 
digested with EcoRl or Hind III. The digestion products were separated by agarose 
gel electrophoresis, transferred to nylon membrane and hybridised with the murine 
C-gamma-1 probe. Hybridisation was analysed by washing the membrane at different 
levels of stringency, i.e. medium stringency (3x SSC, 0.1% SDS at 55°C or lx SSC, 
0.1% SDS at 55°C), and at high stringency (O.lx SSC, 0.1% SDS at 65°C). Figures 10 
and 11 show the hybridisation patterns obtained with EcoRl (Fig. 10) and Hind III 
(Fig. 11) with the washing conditions indicated on the figures.
The results obtained with both enzymes were essentially the same. The 
hybridisation pattern obtained with NSl/l-Ag4-l DNA (lane 1) appears to remain 
unaltered in both BMT-2 (lane 2) and BMT.4A DNA (lane 3). Additional hybridisation 
with BMT.4A DNA was detected at medium stringency, at approximately 4.5 kb (EcoRl. 
Figure 10a) and 7.5 kb (Hind III. Figure 11a). Under identical conditions, 
specific hybridisation is also detectable with bovine liver DNA (lane 4), At 
high stringency, (Figures 10b and lib ), the extra band seen with BMT.4A DNA 
remains clearly visible, whereas hybridisation with bovine liver DNA is virtually 
removed completely.
3.2.2 Light Chain Hybridisation Studies.
Bovine antibodies have lambda light chains (Butler, 1983) and a murine lambda 
light chain probe was selected for screening. Bovine liver genomic DNA (10ng) was 
digested with Bam HI, EcoRl, Hind III or Bgl II and hybridized with the murine 
lambda light chain probe (Figure 12). Specific hybridisation is visible in all 
lanes after washing at medium stringency (lx SSC). Hybridisation was completely 
removed after washing at high stringency.
3.2.3 Discussion.
Hybridisation, additional to that observed with the fusion partner DNAs 
(NSl/l-Ag4-l and BMT-2), was detected in BMT.4A DNA under identical conditions to 
those resulting in specific hybridisation with bovine liver DNA (Figures 10a and 
11a). This suggested that the murine probe would be suitable for screening the 
library; however, the intensitiy of the hybridisation signals suggested that the 
extra band seen in BMT.4A may be of murine origin. At medium stringency, the
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Figure 10 a  
H eavy chain hybridisation studies using EcoRl. 
Medium  stringency (3x S S C ).
1 2  3 4
4.5
M
Kb
•  23
a 9.6
•  6.4
. 4.6
2.3
2.0
Genomic DNA (5-1 Opg) from NS1/1-Ag4-1 (lane 1), BMT-2 (lane 2), 
BMT.4A (lane 3) and bovine liver (lane 4) were digested with EcoRl 
and hybridised with a murine Ig C-gamma-1 heavy chain probe.
Hybridisatiom, additional to the murine background (lane 1) is 
visible with BMT.4A DNA (lane 3) at 4.5 kb 
M = DNA size markers in kilobase pairs (Kb)
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Figure 10 b 
H eavy chain hybridisation studies using EcoRl. 
High stringency (0.1 x S S C ).
1 2 3 4 M
Kb_
23
9.6 
6.4
4.6
2.3
2.0
Genomic DNA (5-1 Opg) from NS1/1-Ag4-1 (lane 1), BMT-2 (lane 2 ) ,  
BMT.4A (lane 3) and bovine liver (lane 4) were digested with EcoRl 
and hybridised with a murine Ig C-gamma-1 heavy chain probe.
Hybridisation, additional to the murine background (lane 1) remains 
visible with with BMT.4A DNA at 4.5 kb, whereas virtually all 
hybridisation with bovine liver DNA is removed.
M = DNA size markers in kilobase pairs (Kb)
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Figure 11 a
H eavy chain hybridisation studies using Hind III. 
Medium stringency (1x S S C )
1 2 3 4 M kb
Genomic DNA (5-10 |jg) from NS1/1-Ag-4 (lane 1), BMT-2 (lane 2), 
BMT.4A (lane 3) and bovine liver (lane 4) were digested with Hind III 
and hybridised with a murine Ig C-gamma-1 heavy chain probe.
The filter was washed at 1 x SSC.
Hybridisation, additional to the murine background (lane 1) is 
is visible with BMT.4A DNA at 7.5 kb.
M = DNA size markers in kilobase pairs (kb).
Figure 11 b
H eavy chain hybridisation studies using Hind III. 
High stringency (0.1 x S S C )
1 2 3 4 M kb
Genomic DNA (5-10 jjg) from NS1/1-Ag-4 (lane 1), BMT-2 (lane 2), 
BMT.4A (lane 3) and bovine liver (lane 4) were digested with Hind III 
and hybridised with a murine Ig C-gamma-1 heavy chain probe.
The filter was washed at 0.1 x SSC.
Hybridisation, additional to the murine background (lane 1) remains 
visible with BMT.4A DNA at 7.5 kb, whereas virtually all hybridisation 
with bovine liver DNA is removed (lane 4).
M = DNA size markers in kilobase pairs (kb).
Figure 12 Light chain hybridisation studies.
M 1 2 3 4
2.3 •—
2.0 —
Bovine liver genomic DNA (5-10 pg) was digested with Bam HI (lane 1) 
EcoRl (lane 2), Hind III (lane 3) and Bgl II (lane 4) and hybridised with 
a murine Ig C-lambda light chain probe and the filter subsequently 
washed at medium stringency (1x SSC)
Bands of hybridisation were detected in each lane.
M = DNA size markers in kilobase pairs
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intensitiy of the hybridisation signal of the extra band seen with BMT.4A DNA and 
the major hybridising band in bovine liver DNA appear similar; however, at high 
stringency, the extra band seen with BMT.4A DNA remains clearly visible, whereas 
virtually all hybridisation with bovine liver DNA is removed.
Southern hybridisation, using target DNA as above and a cDNA probe that codes 
for part of a bovine C-gamma-1 heavy chain that was isolated on initial screening 
of the library (Figure 17, see section 3.3.4), confirmed the murine origin of the 
extra band seen with BMT.4A DNA. The extra hybridising band detected at 4.5 kb 
with the mouse probe (Figure 10, lane 3) was not detected subsequently with the 
bovine probe, under identical conditions to those that resulted in specific 
hybridisation with bovine liver DNA. Failure to detect hybridisation with the 
known C-gamma-1 gene of BMT.4A most likely results from insufficient target DNA 
since initial karyotyping studies have indicated that BMT.4A contains aproximately 
two murine genomes and only a few bovine chromosomes (D.J.Groves personal 
communication). The large murine chromosome number effectively reduces the bovine 
target DNA in BMT.4A to half that expected.
The hybridisation pattern obtained with NSl/l-Ag4-l and BMT-2 DNA are identical 
(Figures 10 and 11) which implies that the latter cell line does not contain 
bovine Ig heavy chain genes; however, failure to detect hybridisation with the 
known bovine C-gamma-1 gene of BMT.4A prevented this conclusion from being made.
Nevertheless, the initial conclusion made from the above studies was that the 
murine C-gamma-1 heavy chain and lambda light chain probes would be suitable for 
screening the library. In addition, the results suggested that differential 
washing of library replica filters could be used to aid the identification of any 
murine C-gamma chain cDNAs present in the library as hybridisation with bovine 
liver DNA was completely removed at high stringency (Figures 10b and lib).
3.3 Messenger RNA Purification and in vitro Translation.
Cytoplasmic RNA was extracted from BMT.4A using a vanadyl method (section
2.27.1). Messenger RNA (mRNA) was isolated using Hybond-map™ affinity paper 
(section 2.28). Prior to cDNA synthesis, the integrity of the mRNA was verified by 
In vitro translation to high molecular weight proteins. mRNA (lOOpg) was 
translated in the presence of 3 5S-methionine using a rabbit reticulocyte 
translation system (section 2.29). Total cytoplasmic RNA (lOng) and a control 
reaction in the absence of exogenous RNA, were translated in parallel. The
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The integrity of the mRNA used to construct the cDNA libraries 
was verified by translation to high molecular weight proteins.
Lane 1, size markers.
Lane 2, negative control (i.e. no added RNA).
Lane 3, mRNA from BMT.4A
Lane 4, cytoplasmic RNA from BMT.4A
Figure 13. In vitro translation studies.
k  i lo d a  I to n s
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translation products were separated through a 10% polyacrylamide gel and 
autoradiographed (section 2.30).
Figure 13 shows the results of this analysis. Cytoplasmic RNA and the purified 
mRNA fraction were able to direct translation of high molecular weight proteins 
(lanes 3 and 4), whereas the system control (no exogenous RNA, lane 2) failed to 
do so. The mRNA preparation analysed in the figure was that used to constructed 
the cDNA libraries.
3.4 Construction and Screening of the cDNA Libraries.
Two cDNA libraries were constructed. Library 1 was constructed in lambda-gtlO 
and used oligo-dT as a primer to intiate first strand synthesis. Library 2 was 
constructed in pUC13 and used a primer complementary to a region in the CHI 
domain of bovine C-gamma-1 heavy chains.
3.4.1 cDNA Cloning in Lambda-gtlO.
A cDNA library of 1.6 x 105 recombinant phage was constructed in lambda-gtlO 
and screened with a bovine lambda light chain cDNA probe (Ivanov et al., 1987) and 
a murine C-gamma-1 heavy chain probe using the methods described in section 2.39. 
After isolating a bovine heavy chain cDNA on initial screening, the remainder of 
the library was screened with a probe derived from its N-terminus.
3.4.1.1 Monitoring cDNA Synthesis.
The quality of the cDNA synthesized was determined, prior to its ligation with 
lambda-gtlO arms. After second strand synthesis, 0.01 volumes of the 
radiolabelled double stranded cDNA (section 2.39.1) was analysed through a 1.4% 
Tris-acetate agarose gel. The gel was stained in ethidium bromide and photographed 
under u.v. light to obtain a permanent record of the DNA size markers. The cDNA 
was then fixed in the gel by immersion in 7% trichloroacetic acid, the gel dried, 
wrapped in Sarran wrap and autoradiographed for 16 hours. Figure 14 shows the 
size distribution of the double stranded cDNA synthesised to be up to 4.0 kb.
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Figure 14. S ize distribution of cD N A  used to construct 
Library 1.
Radiolabelled double-stranded cDNA used to construct Library 1 
was separated by agarose-gel electrophesis and exposed 
to X-ray film (see text for details).
The size distribution of the cDNA ranged from approximately
4.0 kb to less than 0.5 kb.
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3.4.1.2 Screening the Lambda-gtlO Library for bovine Light Chain cDNA.
Library replica filters were hybridised with a radiolabelled bovine lambda 
light chain cDNA (section 2.31.3) and subsequently washed at high stringency (0.1 
x SSC, 0.1 % SDS at 65°C). Putative positive clones were further analysed by 
Southern hybridisation using both a mouse kappa and a bovine lambda light chain 
probe to ensure that kappa light chain cDNA of NSl/l-Ag4-l origin (section 1.22) 
had not been cloned by cross hybridisation. This analysis also allowed for the 
clones with the largest inserts to be selected for DNA sequencing. Phage DNA, 
purified from positive clones, was digested with EcoRl and the digestion products 
evenly divided between two agarose gels. An equal amount of mouse kappa and bovine 
lambda light chain DNA were included on each gel as controls. After 
electrophoresis, the DNA was blotted onto nylon filters and the filters hybridised 
with either a mouse C-kappa or a bovine C-lambda probe. The filters were then 
washed under identical conditions at high stringency (0.1 x SSC 0.1% SDS at 65°C). 
Figures 15a and 15b shows the results of this analysis. The filter in Figure 15a 
was hybridised with the bovine probe and, as can be seen, all the inserts and the 
bovine control resulted in strong hybridisation, whereas hybridisation with the 
mouse kappa DNA could not be detected. The filter in figure 15b was hybridised 
with the mouse kappa probe and hybridisation could only be detected with the mouse 
kappa control. This analysis demonstrated that the conditions used to screen the 
library detected only bovine lambda light chain cDNAs.
Positive clones with the largest inserts were selected for sequencing and one 
such clone (clone 182) was found to contain full length bovine Ig lambda light 
chain cDNA. The sequence of clone 182 cDNA is presented and discussed in Chapter
4.
3.4.1.3 Screening the Lambda-gtlO Library for bovine Heavy Chain cDNA.
The strategy employed to identify bovine heavy chain cDNA was designed to 
reduce the possibility of isolating Ig clones of murine origin. Library replica 
filters were screened with a mouse C-gamma-1 heavy chain probe and washed at 
different levels of stringency. At medium stringency (3 x SSC, 0.1% SDS at 55°C), 
both bovine and murine clones would be expected to result in specific 
hybridisation (section 3.2.3, Figures 10a and 11a), whereas under high stringency 
conditions (0.1 x SSC, 0.1% SDS at 65°C), only Ig DNA of murine origin would be 
expected to give a strong positive signal (Figures 10b and l ib ) . Initial 
screening, using this strategy, identified several putative bovine clones. One 
such clone (clone 8) gave a good signal at medium stringency (3x SSC, 0.1% SDS at
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55°C), the strength of which significantly decreased at increased stringency (0.5 
x SSC, 0.1% SDS at 55°C, Figure 16a). The reduction in the signal intensity seen 
on the library replica filters was reproduced upon differential washing of filters 
prepared for plaque purififation (Figure 16b).
The length of the cDNAs in putative bovine clones were estimated by analysis of 
the EcoRl digested products of isolated phage DNA by Southern hybridisation with 
the mouse C-gamma-1 probe. Of several putative bovine clones identified on the 
initial screening, clone 8 had the largest insert and was selected for use as a 
DNA probe on Southern and Northern blot analyses to confirm its bovine origin.
Southern blot analysis.
Figure 17 shows the results of the Southern blot analysis. The murine C-gamma-1 
probe was removed from the filter shown in Figure 10b (section 3.2.1) and the 
filter reprobed with clone 8 insert cDNA. As can be seen in Figure 17, bands of 
specific hybridisation with bovine liver DNA were detected and the bands occur at 
corresponding positions in lane 4 Figure 10b which suggested that the cDNA of 
clone 8 coded for an Ig heavy chain; however, the additional hybridisation seen 
with BMT.4A DNA using the mouse C-gamma-1 probe (Figure 10b, lane 3) was not 
detected, which confirmed that the extra hybridising band seen with BMT.4A DNA, 
when using the mouse probe, results from hybridisation with DNA of murine origin.
Northern blot analysis.
The insert cDNA of clone 8 was also used as a probe on Northern blot analysis 
(Figure 18a and 18b) using RNA (lOug) from NSl/l-Ag4-l, BMT-2, BMT.4A and bovine 
liver. Prior to hybridisation with the insert cDNA of clone 8, the filter was 
hybridized with the mouse C-gamma-1 probe and washed at medium stringency (3 x 
SSC, 0.1% SDS, 55°C. Figure 18a). Minimal hybridisation was detected with NS1/1- 
Ag4-1 and BMT-2 (lanes 1 and 2), slightly increased hybridisation with BMT.4A 
(lanes 3-8), and as expected, hybridisation was not detected with bovine liver RNA 
(lane 9). After washing at high stringency, virtually all the hybridisation seen 
at 3x SSC was removed. The residual probe was removed from the filter and the 
filter reprobed with the cDNA from clone 8 and the filter subsequently washed at 
high stringency (Figure 18b). As can be seen, hybridisation was not detected with 
RNA from NSl/l-Ag4-l (lane 1), BMT-2 (lane 2) and bovine liver (lane 9), whereas 
strong hybridisation is seen with BMT.4A RNA (lanes 3-8). This indicated that 
the cDNA insert of clone 8 is of bovine origin and results from a gene that is 
transcriptionally active in plasma cells, but inactive in liver cells. In
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Bovine C-lambda probe (0.1 x SSC)
lanes 1 2 3 4 5 6 7 8 9 10 11 12 13 14
MK BL
Figure 15a. Hybridisation of putative bovine light chain
clones with the bovine probe.
15 16 17 18 19 20 21 22 23 24 25 26 27 28
MK BL
Recombinant phage DNA was digested with EcoRl, to release 
the cDNA insert and hybridised with the bovine lambda light chain 
probe used to screen the Library.
Hybridisation was detected in all lanes except for the murine 
C-kappa control (MK).
Lanes 1 and 15 = MK (mouse kappa control DNA)
Lanes 14 and 28 = BL (bovine lambda control DNA) 
lanes 2-13 and 16-23 = DNA from recombinant clones 
identified on screening the library
N.B. The DNA in lanes 2,16 and 21 gives 2 hybridising bands 
after EcoRl digestion.
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Figure 15b. Hybridisation of putative bovine light chain
clones with the murine probe.
Murine C-kappa probe (0.1 x SSC)
lanes 1 2 3 4 5 6 7 8 9 10 11 12 13 14
MK BL
15 16 17 18 19 20 21 22 23 24 25 26 27 28
MK BL
Recombinant phage DNA was digested with EcoRl, to release 
the cDNA insert and hybridised with the murine kappa light chain 
probe. Hybridisation was on ly detected with the murine 
C-kappa control (MK).
Lanes 1 and 15 = MK (mouse kappa control DNA)
Lanes 14 and 28 = BL (bovine lambda control DNA) 
lanes 2-13 and 16-23 = DNA from recombinant clones 
identified on screening the library
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Figure 16. Putative bovine heavy chain clones.
Fig. 16A Hybridisation of the murine C-gamma-1 probe with a library replica filter.
Medium stringency High stringency
3 x SSC 0.5 x SSC
Fig. 16B Hybridisation with the murine C-gamma-1 probe on plaque purification.
Medium stringency High stringency
3 x SSC 0.1 x SSC
*■ * fM  m0
»
%
Figure 16A shows hybridisation of the murine C-gamma-1 probe 
to putative bovine heavy chain clones on the library replica 
filters. Increasing the stringency reduces hybridisation.
Figure 16B shows the same clone as shown above at the first 
stage of plaque purification. The reduction in the hybridisation 
signal is more dramatic.
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Figure 17. Hybridisation of clone 8 cDNA to bovine
and murine DNA.
High stringency (0.1 x S S C )
1 2 3 4 M kb
The residual probe was removed from the blot shown in Figure 10 
and the filter rehybridised with the insert cDNA of clone 8.
The filter was then washed at 0.1 x SSC, 0.1%SDS at 65 C.
The additional band seen with BMT.4A using the mouse C-gamma-1 
probe (Fig. 10 lane 3) does not hybridise with this probe.
Lane 1 = NS1/1-Ag4-1. Lane 2 = BMT-2 lane 3 = BMT.4A 
Lane 4 = Bovine liver.
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Figure 18A. Hybridisation of bovine and murine R N A  with 
the murine C -gam m a-1 heavy chain probe. 
Medium stringency (3x S S C )
1 2 3 4 5  6 7 8 9
l-8kb Hi
Minimal hybridisation was detected in lane 1 (NS1/1-Ag4-1) and 
lane 2 (BMT-2), and hybridisation in lane 9 (bovine liver) 
could not be detected.
Hybridisation with BMT.4A RNA (lanes 3-8) was detected.
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High stringency (0.1 x S S C )
1 2 3 4 5  6 7 8 9
Figure 18B. Hybridisation of bovine and murine RNA with
clone 8 insert cDNA.
1 - 8 kb
Hybridisation with the murine RNA (Lane 1, NS1/1-Ag4-1.
Lane 2, BMT-2) and bovine liver RNA (Lane 4) was not detected. 
BMT.4A RNA (Lanes 3-8) gave strong hybridisation.
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addition, fully processed mRNA trancripts for mammalian C-gamma heavy chains are 
approximately 1.8 kb, which coincides with the size of the RNA resulting in the 
hybridisation signal. These results strongly suggested that the insert of clone 8 
codes for part of a bovine immunoglobulin heavy chain and this insert was 
therefore selected for DNA sequencing.
The sequence of clone 8 cDNA subsequently identified it as coding for part of a 
bovine C-gamma-1 heavy chain (Chapter 4). The remainder of the lambda-gtlO library 
was, therefore, screened using a N-terminal EcoRI-AccI fragment of clone 8 cDNA 
and the filters washed at high stringency. Six additional bovine Ig heavy chain 
clones were identified using this probe, but none were found to contain full- 
length cDNA (Chapter 4). A second cDNA library was, therefore, constructed to 
obtain the missing coding sequence for the N-terminus of the heavy chain.
3.4.2 cDNA Cloning in pUC13.
A second cDNA library was constructed in pUC13 using an oligonucleotide primer 
complementary to a region in the CHI domain of the bovine heavy chain cDNA 
(obtained from the sequence of clone 8 cDNA) to initiate first strand synthesis, 
Dilutions of the library stock were plated on LB agar plates containing 
ampicillin, IPTG and X-gal (section 2.39.4) and the number of recombinant plasmids 
estimated to be 1.2 x 10 3 . The library was screened using a bovine heavy chain 
probe derived from the N-terminus of the insert cDNA of clone 8 (EcoRI-AccI 
fragment).
The size of a cDNA molecule that codes for the region of an Ig heavy chain, 
between the mid-region of the CHI domain and the ATG translation start site would 
normally be approximately 500-550 bp. After first strand synthesis, the length of 
the cDNA synthesized, and the specificity of the priming reaction, were analysed 
by high resolution electrophoresis (section 2.41.1.3) through a 4% acrylamide, 8M 
urea sequencing gel. Denatured radiolabelled pBR322, Hinfl fragments were used as 
size markers (section 2.23.1).
Figure 19 shows the results of this analysis and that several bands of labelled 
cDNA are present. This pattern may have resulted from premature termination of 
first strand synthesis resulting in multiple bands of similar size or from relaxed 
priming of a specific set of abundant molecules. Alternatively, it may indicate 
that the mRNA template had degraded and was, therefore, of poor quality; however, 
single stranded cDNA bands at approximately 500-550 bases are visible and the cDNA 
preparation shown in Figure 19 was used for library construction.
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Figure 19. First strand cD N A  used to construct Library 2.
345 ----
Radiolabelled first strand cDNA was separated through a DNA
sequencing gel and autoradiographed (see text for details).
Denatured, radiolabelled Hinfl pBR322 fragments were used as
size markers as indicated on the left of the Figure.
Several bands of cDNA are visible including bands at 550 
nucleotides.
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3.4.2.I Screening the pUC13 Library.
Several positive clones were identified using the EcoRI-AccI N-terminal 
fragment of clone 8 cDNA as a probe. The insert size of positive clones was 
analysed by EcoRl digestion and agarose-gel electrophoresis. The largest cDNA
molecules were selected for DNA sequencing and one cDNA was found to code for the
\
missing N-terminus of the heavy chain (Chapter 4).
3.5 Discussion.
The double cellular fusion protocol that led to the construction of BMT.4A had 
the potential to introduce non-functionally rearranged bovine Ig heavy and light 
chain genes from two bovine lymphocytes (section 1.22). In addition, the 
possibility that there are two functionally rearranged bovine heavy chain genes, 
or two functionally rearranged bovine light chain genes present in BMT.4A was 
considered.
Northern analysis, using a bovine C-gamma-1 cDNA probe (Figure 18b), failed to 
detect specific hybridisation with BMT-2 RNA under identical conditions to those 
that resulted in strong hybridisation with BMT.4A RNA. This indicated that bovine 
C-gamma-1 mRNAs present in BMT.4A were derived from a gene(s) introduced by the 
second cellular fusion. This observation, taken together with the small number of 
bovine chromosomes identified in BMT.4A, suggested that the bovine heavy chain 
cDNA clones isolated from the library were likely to be derived from a 
functionally rearranged gene and, therefore, code for the heavy chain of the anti­
testosterone monoclonal antibody. The functional state of the isolated heavy chain 
cDNAs was subsequently confirmed by sequencing through the sites of VH-D and D-JH 
recombination and by expression of the cDNAs (in association with the light chain) 
and the demonstration of testosterone binding by the resultant antibody.
Hybridisation studies, using putative bovine lambda light chain clones and the 
bovine light chain probe, indentified two hybridisation patterns after EcoRl 
digestion (Figure 15a lanes 2, 16 and 21). The different patterns could result 
from two mRNA species, one of which gives rise to cDNA molecules with an internal 
EcoRl site. The mRNA transcript that gives rise to such a molecule would be 
unusually large (approximately 1.9 kb, Figure 15a lane 2) and could result from 
transcription initiating from the promoter of the V-segment immediately 5 ’ to the 
functionally rearranged lambda light chain gene of BMT.4A (section 1.7). It was 
expected that DNA sequence analysis and expression of the light chains encoded by 
the two types of cDNA molecules would indicate which of the cDNAs, if any, are
104
non-functional. However, the possibility of there being two functionally 
rearranged light chain genes in BMT.4A remained and if this was the case, then it 
cannot be assumed that both light chains, when associated with the bovine heavy 
chain, would result in an antibody that can bind testosterone.
Northern blot analysis, using the mouse C-gamma-1 probe (Figure 18a), found no 
evidence for Ig heavy chain mRNA transcripts in NSl/l-Ag4-l. Similarly, washing 
the library replica filters at high stringency, after hybridisation with the 
murine C-gamma-1 heavy chain probe, failed to identify any strongly hybridizing 
plaques. These observations indicate that there is no practical problem of cross 
hybridisation with murine Ig heavy chain cDNA when cloning from a heterohybridoma 
(or hybridoma) which used NSl/l-Ag4-l as the myeloma fusion partner.
The Southern hybridisation results obtained with the mouse lambda light chain 
probe and bovine liver DNA as the target (Figure 12), indicated that this probe 
would probably be suitable for screening the library. In addition, the 
hybridisation pattern suggested that there are at least 2 C-region lambda light 
chains genes in the bovine genome, as none of the enzymes used in this analysis 
cut within the coding sequence of the C-domain of the isolated bovine lambda light 
chain cDNA (Chapter 4).
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NUCLEOTIDE AND DERIVED PROTEIN SEQUENCES OF 
THE BOVINE Ig cDNAs.
CHAPTER 4.
CHAPTER 4.
NUCLEOTIDE AND DERIVED PROTEIN SEQUENCE OF THE BOVINE Ig cDNAs.
4.1 Introduction.
The nucleotide and derived protein sequence of the bovine heavy and light chain
cDNAs are shown in Figure 20 (heavy chain) and Figure 21 (light chain). The
proteins encoded by the cDNAs were identified as Ig chains by sequence homology
with Igs of other mammalian species (see below). The conserved cysteine residues
b o n d
that form an intrachain disulphide in all Ig domains (V and C-domains) are present 
in the domains of the bovine antibody which suggests that the overall domain 
structure, characteristic of the Ig fold, will be conserved in bovine Igs
The coding sequence for the heavy chain, including that for the signal 
peptide, was isolated on overlapping fragments (Figure 22). The complete coding 
sequence for the light chain was isolated as a single cDNA molecule (Figure 23). 
The nucleotide sequence, for both chains, indicated that the V and C-region had 
been joined in the same translational reading frame and that the cDNAs were, 
therefore, derived from functionally rearranged genes.
The light chain cDNA includes two in-frame ATG translation initiation codons 
that are separated by six nucleotides. The second ATG is more likely to initiate 
translation, as the flanking nucleotides are in complete agreement with the 
optimal site for initiation by eukaryote ribosomes (Kozak, 1986). Both the heavy 
and light chain cDNA have a potential polyadenylation signal in the 3' non-coding 
region (Wickens and Stephenson, 1984; Wickens, 1990).
4.2 Sequencing Strategy.
DNA sequencing was performed using both single-stranded M l3 templates (section
2.39.1.1) and the double stranded sequencing method described in section 2.39.1.2.
The strategy employed to determine the nucleotide sequence of the heavy and 
light chains is schematically represented in Figure 22 (heavy chain) and Figure 23 
(light chain). The complete nucleotide sequence was determined for both strands of 
the heavy chain cDNAs 8 and 75 and the light chain cDNA, 182. In addition, the 
complete nucleotide sequence for one strand of the small fragment of light chain 
cDNA 104 (104s. Clone 104 includes a cDNA insert with an internal EcRI site) and 
partial sequence data for one strand of 2 additional light chain (198 and 236) and
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Figure 20. Nucleotide and derived protein sequence of cDNA 8.75 (The bovine C-gamma-1 heavy chain).
1 CTGACTCTCATCTGCTCCAAGATGAACCCACTGTGGACCCTCCTCTTTGTGCTGTCAGCCCCCATAGGGGTCCTGTCCCAGGTGCAGCTG
M N P L W T L L F V L S A P I G V L S Q V Q L  
Signal -10 -1 FR1
91 CGGGAGTCGGGCCCCAGCCTGGTGAAGCCCTCACAGACCCTCTCCCTCACGTGCACGGTGTCTGGATTCTCATTGAGCAGCTATGCTCTA 
5 R E S G P S L V K P  S Q T L S L T C T V S G F S L S S Y A L
CDR-H1
181 ACCTGGGTCCGCCAGGCTCCAGGGAAGGCGCTGGAGTGGGTTGGTGGTATAACCAGTGGTGGAACCACATACTATAATCCAGCCCTGAAA
35 T W V R Q A P G K A L E W V G G I T S G G T T Y Y N P A L K
FR2 CDR-H2
271 TCCCGGCTCAGCATCACCAAGGAGAACTCCAAGAGCCAAGTCTCTCTGTCAGTGAGCAGCGTGACACCTGAGGACACAGCCACATACTAC
65 S R L S I T K E N S K S Q V S L S V S S V T P E D T A T Y Y
FR3 82 A B C 83
361 TGTGCAAGAAGTACTTATGGTGAGGTTGGTGATGGTGCCATCGCCGATGCCTGGGGCCAAGGACTCCTGGTCACCGTCTCCTCAGCCTCC
92 C A R S T Y G E V G D G A I A D A W G Q G L L V T V S S A S
CDR-H3 100 A B C D E F 101 FR4 113 CHI
451 ACCACAGCCCCGAAAGTCTACCCTCTGAGTTCTTGCTGCGGGGACAAGTCCAGCTCCACCGTGACCCTGGGCTGCCTGGTCTCCAGCTAC 
120 T T A P K V Y P L S S C C G D K S S S T V T L G C L V S S Y
541 ATGCCCGAGCCGGTGACCGTGACCTGGAACTCGGGTGCCCTGAAGAGCGGCGTGCACACCTTCCCGGCTGTCCTTCAGTCCTCCGGGCTG 
150 M P E P V T V T W N S G A L K S G V H T F P A V L Q S S G L
651 TACTCTCTCAGCAGCATGGTGACCGTGCCCGGCAGCACCTCAGGACAGACCTTCACCTGCAACGTAGCCCACCCGGCCAGCAGCACCAAG 
180 Y S L S S M V T V P G S T S G Q T F T C N V A H P A S S T K
721 GTGGACAAGGCTGTTGATCCCACATGCAAACCATCACCCTGTGACTGTTGCCCACCCCCTGAGCTCCCCGGAGGACCCTCTGTCTTCATC 
211 V D K A V D P T C K P S P C D C C P P P E L P G G P S V F I
215 Hinge 227 CH2 234 238
811 TTCCCACCGAAACCCAAGGACACCCTCACAATCTCGGGAACGCCCGAGGTCACGTGTGTGGTGGTGGACGTGGGCCACGATGACCCCGAG 
243 F P P K P K D T  L T I S G T P E V T C V V V D V G H D D P E
901 GTGAAGTTCTCCTGGTTCGTGGACGACGTGGAGGTAAACACAGCCACGACGAAGCCGAGAGAGGAGCAGTTCAACAGCACCTACCGCGTG 
273 V K F S W F V D D V E V N T A T T K P R E E Q F N S T Y R V
991 GTCAGCGCCCTGCGCATCCAGCACCAGGACTGGACTGGAGGAAAGGAGTTCAAGTGCAAGGTCCACAACGAAGGCCTCCCGGCCCCCATC 
303 V S A L R I Q H Q D W T G G K E F K C K V H N E G L F A P I
1081 GTGAGGACCATCTCCAGGACCAAAGGGCCGGCCCGGGAGCCGCAGGTGTATGTCCTGGCCCCACCCCAGGAAGAGCTCAGCAAAAGCACG 
333 V R T I S R T K G P A R E P Q V Y V L A P ; P Q E E L S K S T
340 CH3
1171 GTCAGCCTCACCTGCATGGTCACCAGCTTCTACCCAGACTACATCGCCGTGGAGTGGCAGAGAAACGGGCAGCCTGAGTCGGAGGACAAG 
363 V S L T C M V T S F Y P D Y I A V E W Q R N G Q P E S E D K
88 89
1261 TACGGCACGACCCCGCCCCAGCTGGACGCCGACAGCTCCTACTTCCTGTACAGCAAGCTCAGGGTGGACAGGAACAGCTGGCAGGAAGGA 
391 Y G T T P P Q L D A D S S Y F L Y S K L R V D R N S W Q E G
\ 0 1
1351 GACACCTACACGTGTGTGGTGATGCACGAGGCCCTGCACAATCACTACACGCAGAAGTCCACCTCTAAGTCTGCGGGTAAATGAGCCTCA 
421 D T Y T C V V M H E A L H N H Y T Q K S T S K S A G K
1441 CGXCCCTGCACCAGCAAGCCCTCACCCAGCCCACCCTCCCCGGGCTCCAGGTCCAGCCAGGACGCCCTAGCCCCTCCCTGTGTGCATTCC
1531 TCCTGGGCCGCCGTGAATAAAGCACCCAGGCCGCCCTGGGACCCTGCAAAA
Figure 20 (and 21).
The V-domains and the CL-domain are numbered according to Kabat et 
al., (1987). The CH-domains are numbered according to Edelman et 
al., (1967).
(VH, 1-113; CHI, 118-215; Hinge, 216-227; CH2, 230-340; CH3, 341- 
347; VL, 1-107; CL, 108-215).
Nucleotides and protein residues are numbered in the columes (far 
left) and under the N-terminal residues of each domain and at»sites 
where deletions have been introduced to maximise sequence homology 
with Ig of other species.
A consensus polyadenylation signal AATAAA (underlined) is present 
in the 3 ’ non-coding region of both the heavy and light chain 
CDNAs.
FR - Framework region. CDR = Complementarity determining region. 
CL = Constant domain of the light chain.
CHI, CH2 and CH3 = Constant domains of the heavy chain.
Hinge = Hinge region. Signal = Signal peptide.
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Figure 21. Nucleotide and derived protein sequence of cDNA 182 (The bovine light chain)
1 CAGACAGCAGGACGCCCTGACCATGTCCACCATGGTCTGGTCCCCTCTGCTGCTCACCCTGGTCGCTCTGTGCACAGGATCCTGGGCCCA
M S T M V W S  P L L L T L V A L C T G S W A Q  
-19 -1 FRl
91 GGCTGTGCTGGGGCAGCCGTCCTCCGTGTCCGGGTCCCTGGGCCAGAGGGTCTCCATCACCTGCTCTGGAAGCAGCAGCAACATCGGTAC
2 A V L G Q P S S V S G S L G Q R V S 1 T C . S G S S S N I G T
10 12 CDR-Ll 27 A B 28
181 ATATGGTGTAGAGTGGTACCAACAGGTCCCAGGATCGGGCCTCAGAACCATCATCTATGGTAGTAACAGTCGACCCTCGGGGGTCCCCGA
31 Y G V E W Y Q Q V P G S G L R T I I Y G S N S R P S G V P D
FRl CDR-L2 FR3
271 CCGATTCTCCGGCTCCAAGTCTGGCAACACAGCCACCCTGACCATCAGCTCACTCCAGGCTGAGGACGAGGCAGATTATTTCTGTGCAGC
61 R F S G S K S G N T A T L T I S S L Q A E D E A D Y F C A A
CDR-L3
361 TGGTGACAGCAGTAGCAGAGGTGCTGTTTTCGGCAGCGGGACCACACTGACCGCCCTGGGTCAGCCCAAGTCCCCACCCTCGGTCACCCT
91 G D S S S R G A V F G S G T T L T A L G Q P K S P P S V T L
95 A B 96 FR4 106 A 107 CL
451 GTTCCCGCCCTCCACGGAGGAGCTCAACGGCAACAAGGCCACCCTGGTGTGTCTCATCAGCGACTTCTACCCGGGTAGCGTGACCGTGGT
118 F P P S T E E L N G N K A T L V C L I S D F Y P G S V T V V
541 CTGGAAGGCAGACGGCAGCACCATCACCCGCAACGTGGAGACCACCCGGGCCTCCAAACAGAGCAACAGCAAGTACGCGGCCAGCAGCTA
148 W K A D G S T I T R N V E T T R A S K Q S N S K Y A A S S Y
168 170
631 CCTGAGCCTGACGAGCAGCGACTGGAAATCGAAAGGCAGTTACAGCTGCGAGGTCACGCACGAGGGGAGCACCGTGACGAAGACAGTGAA
179 l s l t s s d w k s k g s y s c e v t h e g s t v t k t v k
200 203
721 gccctcagagtgttcttagggccctggacccccaccctcgggggccctctggcccacaccccctcccccacctctccatggacccctgag
211 P S E C S
811 cccctacccaggtcgcctcacaccaggggcctctcctccctccctgttcctgcttctcctgaataaagaccttctcatttatcaataaaa
For Legend see Figure 20.
109
Figure 22. Heavy chain sequencing strategy
HA4
H75
VH
150
8
L I I I CH1 H CH2 CH3 n
H1 H2 H3 | |
Acc1
Sst1
Sma1 
Sst1
Sma1
Number indicate the clones form which the sequenced cDNA was isolated. 
L = leader sequence.
VH = Variable domain.
Dark boxes = CDRs (H1, H2 and H3).
CH1, CH2 and CH3 = C-region domains 
H = hinge region
Restriction endonuclease sites used for subcloning are showm. 
indicates direction of sequencing
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Figure 23. Light chain sequencing strategy
182
198
236
104S
VL
L I I  ■ ■ I CL
L1 L2 L3
Number indicate the clones from which the sequenced cDNA was isolated. 
Dark boxes = CDRs (L1, L2 and L3)
L = leader sequence 
CL = Constant domain 
VL -  V-domain
 indicates direction of sequencing
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2 additional heavy chain (142 and 150) cDNAs were also determined.
The sequences of the heavy chain cDNAs examined were identical over the common 
regions sequenced, which includes CDR-H3 and the cDNAs are therefore, likely to be 
derived from the same rearranged gene. Similarly, the sequences of the light chain 
cDNAs (including the small hybridising fragment of clone 104, 104s. Chapter 3, 
Figure 15a, lane 2.) are identical over the common regions sequenced. The common 
region of the light chain cDNAs also includes the third CDR (CDR-L3) and the light 
chain cDNAs, including 104, are therefore, also likely to be derived from a common 
gene.
As stated above, the different EcoRl digestion pattern of clone 104 (Chapter 3, 
Figure 15a) may result from DNA transcription inita'ting at the V-lambda segment 
that is immediately 5' to the rearranged gene. Alternatively, the hybridisation 
pattern of clone 104 may result from a relatively frequent rearrangement involving 
the light chain cDNA in lambda-gtlO. The nature of cDNA 104 could be charaterized 
by sequencing the large hybridizing EcoRl fragment of this clone; however, 
sequence data for this fragment was not obtained.
4.3 The Signal Peptides.
4.3.1 Light Chain Signal Peptide.
The light chain signal peptide was predicted to be 19 residues long (-19 to -1) 
by a sequence comparison with the lambda light chain signal peptides of other 
mammalian species (Kabat et al., 1987), The most common amino acids, present in 
the signal peptides of lambda light chains of other species (Kabat et al., 1987), 
are also found at 7 residues (including Met-19) in the predicted bovine signal 
peptide (Tablei). In addition, the second most common amino acids found in the 
signal peptides of lambda light chains are also present at five residues (-15, 
-13, -11, -3 and -1), which includes -1. The predicted signal peptide of the 
bovine light chain is rich in leucines and is characteristically hydrophobic.
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Comparison of the predicted bovine light chain signal peptide with the most 
common amino acids present in the lambda light chain signal peptides of other 
mammalian species.
Table 3.
Residue BOV Most common Residue BOV Most commonLC f Gamino acid amino acid
-19 + Met -9 Val Leu
-18 Val Ala -8 Ala Ala
-17 + Trp -7 + Leu
-16 Ser Leu -6 + Cys
-15 Pro Ser -5 Thr Ser
-14 + Leu -4 + Gly
-13 Leu lie -3 Ser Ala
-12 + Leu -2 Leu lie
-11 Thr Ser -1 Ala Ser
-10 + Leu
BOV LC = predicted signal peptide of the bovine light chain.
+ indicates that the most common amino acid acid is present in the bovine 
sequence.
4.3.2 The Heavy Chain Signal Peptide.
The signal peptide of the bovine heavy chain was also predicted to be 19 
residues long by a sequence comparison with the heavy chain signal peptides of 
other mammalian species (Kabat et al., 1987). At five sites, including -1, the 
most common amino acids present in the signal peptides of other species are also 
present in the bovine heavy chain (Table 4).
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Comparison of the predicted bovine heavy chain signal peptide with the most 
common amino acids in the heavy chain signal peptides of other mammalian species.
Table 4.
Residue BOV Most common Residue BOV Most common
HC h camino acid amino acid
-19 + Met -9 Leu Val
-18 Asn Gly -8 Ser Ala
-17 Pro Trp -7 Ala Thr
-16 Leu Ser -6 Pro Ala
-15 Trp Cys -5 lie Thr
-14 Thr lie -4 + Gly
-13 Leu (F,I,M) -3 + Val
-12 + Leu -2 Leu His
-11 + Phe -1 + Ser
-10 Val Leu
BOV HC = Predicted signal peptide of the bovine heavy chain.
+ indicates that the most common amino acid is present in the bovine sequence.
At residue -13, Phe (F), He (I) and Met (M) occur an equal number of times.
4.4. The Framework Regions.
Regions, characteristic of Ig V-domains, were identified immediately downstream 
of the signal peptides.
The invariant residues, characteristic of the FRs of VH-domains (Kabat et al.,
1987), were present in the derived protein sequence of the heavy chain; however, 
in the VL-domain, an unusual amino acid, glycine, was found in FRl, at residue
5. Kabat et al., (1987) list 965 sequences for which the amino acid at light 
chain residue 5 has been determined and in 928 of those sequences, it is 
threonine. At the remaining 37 sites, 10 different amino acids have been found, 
none of which is glycine.
The conserved quaternary structure of Fv-modules results from strongly 
conserved residues that form the VL:VH domain interface (Novonty and Haber, 1985; 
Chothia et al., 1985). Comparison of the VL:VH interface residues of the bovine
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antibody with those in other Igs (Kabat et al., 1987), show that unusual amino 
acids were also present in the light chain, at two interface residues, (Table 5). 
These were glycine (residues 43) and leucine (residue 44). Kabat et al., (1987) 
list 444 and 446 sequences respectively for which the amino acid at residues 43 
and 44 were known. At both of these sites, 8 different amino acids have been 
identified and only one previous light chain has been reported with leucine at 
residue 44; whereas there have been no previous reports of glycine at residue 43. 
The amino acids at these 
sequencing two independently
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residues in the bovine light chain were verified by 
isolated light chain cDNAs (cDNA 182 and 236).
Table 5. Comparison of FR residues that form the VL:VH interface 
in the bovine antibody and Ig Fv modules.
The data in the was compiled from Novotny and Harber (1985), Chothia et al., 
(1985) and de la Paz et al (1986).
VL-domain.
Bovine
antibody.
Most common 
amino acid.
Number of 
sequences.
Number of 
amino acids.
Occurances. 
A B
Tyr-36 +
Gln-38 +
Gly-43 Ser 444 8 159Ser OGly
Leu-44 Pro 446 8 378Pro lLeu
Thr-46 Leu 446 13 302Leu 12Thr
Phe-87 Tyr 421 4 313Tyr 99Phe
VH-domain.
Bovine
antibody
Most common 
amino acid.
Bovine
antibody
Most common 
amino acid.
Val-37 + Trp-47 +
Gln-39 + Thr-91 +
Lys-43 + Ala-93 +
Leu-45 +
+ indicates that the most common amino acid is also found the bovine antibody. 
Number of sequences, as listed in Kabat et al., (1987).
Number of amino acids, as listed in Kabat et al., (1987).
Occurances:
A = Occurance of the most common amino acid.
B = Occurance of the amino acid found in the bovine antibody.
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The boundaries between the FRs and the CDRs, as defined by Kabat et al., 
(1987), were identified by comparing the derived protein sequence of the heavy and 
light chains with the highly conserved residues present in Ig V-domains of other 
species (Kabat et al,. 1987). Table 6 lists the residues of the CDRs.
Table 6. Residues of the CDRs of the bovine antibody.
4.5 The Complementarity Determining Regions.
CDR Residue number.
LI 13 (residues 24-34, including 27a and 27b).
L2 7 (residues 50-56).
L3 11 (residues 89-97, including 95a and 95b).
HI 5 (residues 31-35).
H2 16 (residues 50-65).
H3 14 (residues 95-102, including lOOa-lOOf).
4.6 The D and J-regions.
Sequences, characteristic of mammalian J-regions were identified between light 
chain residues 98-107, and heavy chain residues 103-113 (Table 7).
The bovine lambda light chain cDNA used to screen the library [Ivanov et al., 
1987 (Chapter 3)] has a non-functional V-segment and signal peptide, both of which 
include in-frame termination codons. This cDNA also includes a JL-region that is 
presumably functional. The JL-region of cDNA 182 and the probe cDNA differ at 4 
residues (102, 104, 105, and 106), indicating that there are at least 2 J-lambda- 
segments in the bovine genome.
CDR-H3 is relatively long (14 residues) and presumably includes amino acids 
encoded by a D-segment; however, no homology with human and murine D-segment 
families (Kabat et al., 1987) could be identified and conclusive evidence for the 
presence of D-segments in bovine antibodies awaits their identification in the 
bovine genome.
Identification of J-region sequences, in both the heavy and light chain (and 
presumably D region), suggests that the organisation of bovine Ig germline V- 
region DNA segments and their assembly into rearranged V-exons will be similar to 
that of other mammalian species (Tonegawa, 1983).
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Table 7. Comparison of the J-regions of the bovine antibody with the invariant J- 
region amino acids of mammalian species.
JH-region.
Invariant residues.
Trp-103 
Gly-104 
Gly-106 
Thr-107 
Thr-110 
Val-111 
Ser-112
JL-region.
Phe-98 
Giy-99 
Gly-101 
Thr-102 
Leu-106a
+ indicates that the identical amino acid is present in the 
bovine J-regions.
4.7 The Heavy Chain C-domains.
The C-region genes of IgG isotypes are divided into 4 distinct exons, each of 
which encodes for a distinct structural domain. The derived protein sequence of 
the heavy chain C-region displayed homology with human, rabbit and murine IgGs 
which allowed for the C-domains of the bovine C-gamma-1 chain to be identified. 
Homology was the observed over the range of 61-70% (Table 8), which is similar 
to that between human and murine IgGs (e.g human IgGl and murine IgGl =64%).
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Bov cDNA.
+
+
+
Leu
+
+
+
+
+
+
+
Table 8. Amino add homology of the C-region of BMT.4A with other mammalian IgGs.
IgG Hi H2 m H4 Mi M2a M2b M3 Rah
Domain
CHI 68 71 69 70 68 68 67 65 67
CH2 75 73 74 74 69 70 68 72 72
CH3 65 65 63 66 52 54 48 57 60
Overall
homolog v 69 69 68 70 63 64 61 65 66
CHI = C-gamma-1 domain, CH2 = C-gamma-2 domain, 
CH3 = C-gamma-3 domain.
HI = human IgGl 
H2 = human IgG2 
H3 = human IgG3 
H4 = human IgG4 
Ml = mouse IgGl 
M2a= mouse IgG2a 
M2b= mouse IgG2b 
M3 = mouse IgG3 
Rab = rabbit IgG
(Ellison et al., 1982)
(Ellison and Hood, 1982) 
(Takahashi et al., 1982)
(Ellison and Hood, 1982)
(Honjo et al., 1979) 
(Yamawaki-Kataoka et al., 1981) 
(Tucker et al., 1979)
(Weis et al., 1984)
(Martens et al., 1984)
The heavy chain was identified as bovine C-gamma-1 by the presence of Thr-437 
which is in agreement with the C-terminal protein sequence of a bovine C-gamma-1 
heavy chain (Milstein and Feinstein, 1968). Bovine C-gamma-2 heavy chains have 
methionine at this position.
The nucleotide and protein sequence of the CH-domains and hinge region are 
identical to those of a recently reported bovine C-gamma-1 germline gene (Symons 
et al., 1989). This sequence was used to identify the boundaries between the C- 
domains and hinge region. The sequence of BMT.4A confirms the predicted splice 
sites of the germline gene.
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4.7,1 The CHl-domains.
The CHI domain includes no unusual features, except for two consecutive 
cysteine residues (residues-131 and 132), a feature found in rabbit gamma and 
human epsilon CHI domains. One cysteine probably forms anintra-chain disulphide 
bond to the upper hinge region, as in rabbit gamma chains (Beale and Feinstein, 
1976), whereas the other probably forms a disulphide bridge to the light chain.
4.7.2 The CII2-domains.
The derived protein sequence of the 16 N-terminal residues of the CH2 domains 
are in complete agreement with the published protein sequence over this region for 
bovine IgGl (Wie et al,, 1978).
The CH2-domain includes the residues (Glu-318, Lys-320 and Lys-322) that form 
the Clq binding site (Duncan and Winter, 1988). This sequence motif is consistent 
with the ability of bovine IgGl to activate complement (Howard and Brownlie, 
1979).
The conserved carbohydrate attachment site (Asp-297) of Igs of other species is 
also present on the CH2 domains (Burton, 1985).
The hinge-CH2 link region includes the sequence 234-Leu-Pro-GIy-Gly-Pro-23 8, 
which is similar to the human monocyte Fc-gamma-RI receptor binding site on human 
IgGl [234-Leu-Leu-Gly-Gly-Pro-238 (Duncan et al., 1988)]. The sequences differ at 
residue-235, a residue identified as being critical for the interaction with human 
Fc-gamma-RI (Duncan et al., 1988). Bovine IgGl can also bind human monocytes, 
although less well than human IgGl (Nash et al., 1990). It is therefore possible 
that the Leu-235 to Pro-235 substitution results in a functional binding site for 
human Fc-gamma-RI, but with reduced affinity; however, bovine IgGl also binds 
human B-cells, which are known not to express Fc-gamma-RI (Anderson and Looney, 
1986; Hogg., 1988). Bovine IgGl could, therefore, bind human monocytes via a 
different Fc-gamma-receptor type. Consistent with this possibility, human B-cells 
and monocytes both express Fc-gamma-RII (Anderson and Looney, 1986).
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4.7.3 The CH3-domains.
The CH3 domains included 2 additional residues (serine and glutamate) when the 
sequence is aligned with CH3 domains of other mammalian IgGs. The sequence 
alignment suggests that the extra residues are inserted between residues 388 and 
389.
4.8 The Hinge Region.
The hinge region of the IgG isotypes are characteristically unique (Kabat et 
al., 1987; Burton, 1985) and include the cysteine residues that make interchain 
disulphide bonds (Matsushima et al., 1978). The hinge region of the bovine heavy 
chains includes 4 cysteine residues, the first of which (Cys-220) will probably 
bind to one of the two adjacent cysteines of the CHI domain (see above). From such 
an arrangement, it would be predicted that the upper hinge region of bovine IgGl 
is 9 residues long and that this isotype is therefore a relatively flexible 
molecule (Oi et al., 1984. Section 1.4.1). This prediction is consistent with the 
ability of bovine IgGl to fix bovine complement (Howard and Brownlie, 1979).
4.9 The Light Chain C-domain.
The derived protein sequence of cDNA-182, between residues 108-215 (Figure 21), 
was identified as an Ig C-lambda domain by sequence homology with lambda light 
chains of other mammalian species. Virtually all the invariant residues present in 
C-lambda-domains of other species (Kabat et al., 1987), which includes the 
sequence motif Ala-Thr-Leu-Val-Cys-Leu that is found around Cys-134 and an 
additional amino acid following the penultimate cysteine residue at position 214 
which occur exclusively in light chains of the lambda isotype, are present in the 
CL-domain of the bovine light chain. The only exceptions are residues 158 and 164. 
These residues are asparagine and alanine in the bovine C-lambda domain, whereas 
glycine and proline are found in all previously reported lambda light chains. The 
presence of these unusual amino acids in bovine C-lambda domains was confirmed by 
the sequence of a second, independantly isolated light chain cDNA (cDNA 104s) and 
by their presence in the bovine lambda light chain cDNA used to screen the 
library. The effects of these changes on the overall fold of the domain are 
unknown, but are expected to be minimal as residue 158 occurs in a loop segment 
linking strands of beta sheets. Substitution of alanine for proline represents a 
conservative change, as the side chains of these amino acids are both small and 
non-polar.
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The nucleotide (including the 3' non-coding region) and derived protein 
sequence of the C-lambda domain are in complete agreement with those of the 
bovine lambda light chain cDNA used to screen the library (Ivanov et al., 1987; 
Ivanov et al., 1988).
4.10 Identification of Potential Binding Sites for the Bovine
Mammary Epithelial Fc-gamma Receptor on Bovine IgGl.
4.10.1 Selective Transport of Bovine IgGl into Colostrum.
The selective transport of IgGl from blood plasma into colostrum is a property 
unique to ruminants (Micusan and Borduas, 1976; Butler, 1983). The transport 
mechanism is unknown, but involves the appearance of Fc-gamma-1 specific receptors 
on mammary epithelial cells, in the period leading up to parturition (Kremler et 
al., 1975; Sasaki et al., 1977). Specificity for IgGl may result from either 
unique structural features on IgGl or from steric hindrance of a common receptor 
binding site in less flexible isotypes. This situation is known to be the case for 
the Clq binding site on human IgG4. The CH2 domains of human IgG4 include Clq 
binding sites that are inactive in the intact molecule, but when the Fab arms are 
removed, the Fc region is able to fix complement (section 1.5.1). The upper hinge 
region of bovine IgG2 (Symons et al., 1989) is longer than that of bovine IgGl, 
which suggests that bovine IgG2, like bovine IgGl, should be a flexible molecule 
(Oi et al., 1984). This prediction is consistent with the ability of both bovine 
IgGl and IgG2 to fix comparable amounts of homologous complement (Howard and 
Brownlie, 1979). This above observation suggests that the specific transport of 
IgGl in cattle is more likely to result from structural differences between bovine 
IgGl and IgG2, rather than from Fab obstruction of a common binding site on the 
latter isotype.
The case for a structural difference resulting in the selective transport of 
bovine IgGl is supported by the ability of human IgG4 to act as a ligand for the 
human monocyte Fc-gamma-RI receptor, despite the Clq binding site on this isotype 
being obstructed by the Fab arms. The human Fc-gamma-RI and Clq binding site are 
both located on the CH2 domains (Duncan et al., 1988; Duncan and Winter, 1988), 
which implies that CH2 interaction with proteins, such as Fc receptors, that are 
significantly smaller than Clq, may not be similarly obstructed. In addition, Fc 
receptors form a group of related proteins that are members of the immunoglobulin 
superfamily (Williams and Barclay, 1988), based on predicted structural homology 
of their extracellular domains (Hogg, 1988). It is, therefore, likely that the
122
IgGl receptor on bovine mammary epithelial cells will also share structural 
homology with other Fc receptors and may therefore, like human Fc-gamma-RI, be 
able to bind the CH2 domains of inflexible IgG isotypes.
4.10.2 Potential Binding Sites.
Alignment of the predicted protein sequence of the bovine C-gamma-1 heavy chain 
encoded by cDNA 8 with that of the C-gamma-2 heavy chain (Symons et al., 1989) may 
therefore indicate residues occupied by different amino acids, which have the 
potential to be exploited in a selective transport mechanism. Residues involved in 
transport would presumably need to be located on the surface of the protein, in 
positions accessible for interactions with the receptor. The high degree of 
structural homology of Ig domains allows the positions of residues within a domain 
of unknown structure to be estimated from their positions in a domain of known 
structure. Inspection of the crystal structure of the CH-domains of KOL 
(Matsushima et al., 1978) shows that in the case of at all residues where amino 
acid differences are found, the side chains are exposed to solvent, on the protein 
surface.
The ability of bovine IgGl to bind bovine mammary epithelial cells is a 
property shared by IgGs of heterologous mammalian species (Kemler et al., 1975). 
Human IgGl, human IgG3, and rabbit IgG were found to be as effective as bovine 
IgGl at inhibiting the binding of labelled bovine IgGl to bovine mammary 
epithelial cells. Under the same conditions, bovine IgG2, human IgG2 and human 
IgG4 were unable to inhibit binding. The simplest explanation to account for these 
observations is that a common binding site for the bovine mammary Fc-gamma-1 
receptor exists on those IgGs that inhibit binding, but is absent on those IgGs 
that fail to inhibit binding. The above sequence comparison of bovine C-gamma-1 
and C-gamma-2 heavy chains was therefore extended to include the sequence and 
binding specificities of human and rabbit IgGs.
Table 9 lists the C-region residues where different amino acids are found in 
bovine C-gamma-1 and C-gamma-2 heavy chains and also includes the amino acids 
present at these residues in rabbit and human IgGs. Residues with the potential to 
be exploited by the transport mechanism were identified as those with identical 
amino acids in those IgGs that inhibit binding of bovine IgGl to bovine mammary 
epithelial cells (i.e. bovine IgGl, rabbit IgG, and human IgGl and IgG3), with 
different amino acids present in the IgGs that fail to inhibit binding (i.e.
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bovine IgG2, and human Ig2 nd IgG4). This comparison also considered the 
possibility that heterologous IgGs bind bovine mammary epithelial cells with 
different affinities. Amino acid differences between those IgGs that inhibit the 
binding of bovine IgGl to bovine mammary epithelial cells were therefore 
permitted, provided that none of the amino acids found in these IgGs were present 
in bovine IgG2, human IgG2 or human IgG4.
The above comparison was applied directly to the CH-domains and failed to 
identify any residues where the amino acid pattern correlates with the inhibition 
pattern observed by Kremler (1975).
The possibility that binding sites exist on human IgG2 and human IgG4, on the 
upper region (towards the V-domains) of the CH2 domains, which are obstructed by 
the Fab arms, cannot be ruled out. This possibility was considered in a further 
comparison, applied to the CH2 domains, that excluded the above isotypes. Seven 
residues (254, 265, 270, 325, 329, 331 and 335. Table 9) were identified where the 
identical amino acid is found in those IgGs that inhibit binding of bovine IgGl, 
and with a different amino acid in bovine IgG2. In addition, residues 324 and 339 
could participate in formation of the binding site, provided that amino acid 
substitutions are tolerated at these resdues (Table 9).
A binding site on the CHI domains may, presumably, be similarly obstructed by 
the Fc region in inflexible isotypes. Therefore, the above modified comparison was 
also applied to the CH 1-domains. This comparison identified residue 140 as having 
the potential to be exploited in the selective transport mechanism (Table £). In 
addition, residue 191 may also be involved, provided that either glycine (bovine 
IgGl) or serine (rabbit IgG, human IgGl and IgG2) are permitted.
Major differences were found in the hinge-CH2 link region of bovine IgGl and 
IgG2. This region is an attractive site for receptor binding as it is known to be 
accessible for interactions with other proteins, such as proteases and the human 
monocyte Fc-gamma-1 receptor (Duncan et al., 1988). Both bovine IgG2 and human 
IgG2 include a deletion in this region (Table 9), which may account for the 
inability of these isotypes to bind bovine mammary epithelial cells (Kremler et 
al., 1975), The most revealing comparison is that between those IgGs that inhibit 
binding and human IgG4. Residue 234 is the only residue of the hinge-CH2 link 
region that has an amino acid unique to human IgG4 (e.g the sequence of human 
IgGl and human IgG4 are identical except for residue 234). In human IgG4, residue 
234 is phenylalanine, whereas it is leucine in all of the other sequences. This 
comparison, therefore, suggests that Leu-234 may be a residue critical for binding 
of bovine IgGl to bovine mammary epithelial cells. A single amino acid
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Table 9. Comparison of residue differences between 
bovine C-gamma-1 and C-gamma-2 heavy chains and 
those of heterologous human and rabbit IgGs.
CH1 -Domain
CD o CM toCO o> CD CD
B1 T G T -
H1 T S S T
H3 T S S T
RA T S S -
H2 T S N T
H4 T S S T
B2 G A S T
Ch2-domain
Hinge-CH2 link region
CD<MCM
TO­COCM
B1 C P P 
Hi C P A 
H3 C P A 
RAC P P
CV C\y to SP CD 2T £?
f p  t Q 5 p t ^ ( S Q D f & C D < N ( \ l C \ ! < \ l £ O O o £ 0  CV Cty C \j c \ j  C \j c \ j  C \j co co co cb co co
B1 T S D D K N T R H N E P P T T
H1 M S D D K H K T S N K P P T A
H3 M S D D Q H K T S N K P P T T
RAM S D D Q R R P H N K P P T A
H2 M S D D Q H K T S N K P P T T
H4 M S D D Q H K T S N K P S T A
B2 M T N N Q H R P N t  K S S I  S
coCOCM
P E L P G G P
P E L L G G P
P E L L G G P
P E L L G G P
H 2 C P A P P - V A G P  
H4C P A  P E F L G G P  
B2 C V R ...................... E P
CH3-domain
w i n o r - m c D N o o M - i n N W W f f l Ni n i n N N N N N N C O C O C O O J O r - C OC O C O C O C O C O C O C O C O C O C O C O C O T O - T O - T O -
B1 A Q T S D Y A N G P G S E T
H1 P R K G S D A N G P K G Q T
H3 P R K G S D A S G P K G Q T
RA G R N G S D s N G A K G R T
H2 P R K G S D A N G P K G Q T
H4 P Q K G s D A N G P K G E T
B2 D K I G E D V D D R T R R R M
B1 = bovine lgG1, B2 = bovine lgG2, H1 = human lgG1, H2 = human lgG2 
H3 = human lgG3, H4 = human lgG4, RA = rabbit IgG, B2 = bovine lgG2
The IgGs above the bold line Inhibit binding of bovine lgG1 to 
bovine mammary epithelial cells, whereas those below the bold 
line fail to inhibit.
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substitution on human IgG3, at the human Fc-gamma-RI binding site, effectively 
destroyed receptor binding (Duncan et al., 1988). It is therefore possible that a 
Leu-234 to Phe-234 change is responsible for the inability of human IgG4 to bind 
bovine mammary epithelial cells.
Involvement of the hinge-CH2 link region (particularly Leu-234) in binding to 
the bovine mammary epithelial Fc-gamma-1 receptor is supported by the inability of 
both Fab and Fc fragments, derived from bovine IgGl by papain digestion, to bind 
the receptor (Kremler et al., 1975). This situation is similar to that observed 
with thermolysin prepared Fab and Fc fragments of human IgGl. These fragments fail 
to bind human monocytes (FcRI) despite the intact molecule serving as a ligand 
(Ratcliffe and Stanworth, 1983). Thermolysin cleaves human IgGl between residues 
234 and 235 i.e. in the region identified as the FcRI binding site on human IgGl 
(Duncan et al., 1988). Papain digestion cleaves bovine IgGl on the C-terminal side 
of the hinge disulphides between residues 233 and 234 (Wie et al., 1978) i.e. in 
the region proposed above as the site most likely to bind to the bovine mammary 
epithelial Fogamma-1 receptor.
In summary, a comparison of the sequence and binding specificities of bovine, 
human and rabbit IgGs for bovine mammary epithelial cells has been used to 
identify residues that could be exploited by the selective mechanism that 
transports bovine IgGl into colostrum. Seven residues in the CH2-domain and a 
single residue in the CH 1-domain were identified as possible candidates, provided 
that these residues are obstructed by the Fab arms and are, therefore, inac­
cessible for binding in human IgG2 and IgG4. Three additional residues (2 on the 
CH2 domain and 1 on the CHI domain) could also be involved provide that, in 
addition to these residues being inaccessible in human IgG2 and IgG4, amino acid 
substitutions are tolerated at these sites.
A comparison of the hinge-CH2 link region identified residue 234 as a the most 
likely site for binding. This residue is deleted in both bovine and human IgG2 and 
is formed by phenylalalnine in human IgG4, whereas leucine is present in all IgGs 
that inhibit the binding of bovine IgGl to bovine mammary epithelial cells. The 
involvement of Leu-234 is supported the inability of Fab and Fc fragments prepared 
from bovine IgGl by papain digestion to inhibit the binding of bovine IgGl to 
bovine mammary epithelial cells. Papain cleaves bovine IgGl between residues 233 
and 234.
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EXPRESSION OF BOVINE IMMUNOGLOBULIN cDNA.
CHAPTERS.
CHAPTER 5.
EXPRESSION OF BOVINE IMMUNOGLOBULIN cDNA.
5.1 Introduction.
Bovine Ig heavy and light chain cDNAs were simultaneously expressed in COS-1 
cells to verify that the antibody encoded by the cDNAs bound testosterone.
5.2 Construction of Full-length Heavy Chain cDNA.
The complete coding sequence for the Ig heavy chain was constructed from two 
overlapping fragments. The cDNA of clone 8 extended from the poly-A tail, through 
the 3' non-coding region, into the coding region, as far as FR-3. The cDNA of 
clone 75 extended 5' from the mid region o f the coding sequence for the CHI 
domain, through the coding sequence for the VH-domain and signal peptide, into the 
5' non-coding region. Figure 22 shows the overlap of the fragments in schematic 
form.
The overlap region contains a common unique AccI site which was utilised to 
join the fragments to produce full length cDNA. The AccI sites in the multiple 
cloning site (MCS) of pUC13 and in the cDNAs are formed from different nucleotide 
sequences and the digestion products o f these two sites cannot ligate. This 
observation was exploited in a simple forced cloning strategy to construct full 
length cDNA (Figure 24).
The cDNA of clone 8 was isolated from lambda-gtlO as a EcoRl fragment and 
ligated into the EcoRl site of pUC13, to form pUC13.8. The orientation with the N- 
terminus of the cDNA adjacent to the MCS was identified and this clone digested 
with AccI. The fragment containing the heavy chain coding sequence 3' of the AccI 
site and pUC13 DNA was isolated. The cDNA of clone 75 was isolated from a pUC13 
library in an orientation consistent with the above strategy. Clone 75 was 
digested with AccI and the fragment containing the heavy chain V-domain coding 
sequence 5* of the CHI AccI site isolated. The purified fragment of clone 75 was 
ligated into the AccI digested vector of clone 8 to produce circular pUC13 mole­
cules containing full length heavy chain cDNA (pUC13.8.75). The ligation products 
were used to transform E.coli DH5a™ to ampicillin resistance. Plasmid DNA, 
isolated from transformants (section 2.21.1), was digested to compare the 
restriction map of pUC.8.75 with that predicted for the ligation products. In 
addition, the integrity of the open reading frame was confirmed directly by DNA 
sequencing through the AccI join.
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Figure 24. Strategy for the construction of full-length  
heavy chain cD N A
p U C 13.8 A c(1)
A c(1)
p U C .75
Ac(1)
M C S  = Multiple cloning site of p l)C 1 3
E = EcoRI H -  Hind III A c(1 ) = G T G C A C  A c(2) = G T C G A C  
C = C-term inus of clone 8 cD N A . N = N-term inus of clone 7 5  cDNA .
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The light chain coding sequence was contained on a single cDNA molecule and 
required no manipulations prior to ligation into the expression vector.
5.3 Construction of Expression Vectors.
An expression vector was designed for transient expression in COS-1 cells 
(Figure 25). Bovine heavy and light chain cDNAs were placed under the control of 
the human cytomegalovirus (hcmv), immediate early promoter/enhancer element 
(Boshart et al., 1985). An SV40 origin of replication was supplied by an SV40 
early promotor region, driving transcription o f an E.coli xanthine-guanine 
phosphoribosyl transferase gene (gpt). The vector was based on pEE6 which supplied 
a bacterial ampicillin resistance marker and a bacterial origin o f replication, 
permitting the selection and propagation of the vector in bacterial hosts. pEE6 
is based on the plasmid pBR328 and therefore does not include the 'poison 
sequence' reported to be present on other plasmids, such as pBR322, which are 
believed to be responsible for inhibition of DNA replication of SV40-based vectors 
in COS cells (Lusky and Botchan, 1981). A poly-adenylation consensus sequence, 
AATAAA (Wickens and Stephenson, 1984) is located on the vector between the EcoRl 
site in the MCS and the BamHI site (Figure 25).
The hcmv promoter/enhancer element (obtained from Dr W.Schaffner and 
subsequently modified by Dr S.T.Jones) was ligated into the unique Hindlll site 
of pEE6 and the orientation that drives transcription through the MCS selected by 
analysis of the Sst I digestion products. This plasmid was designated pEE6.hcmv.
The gpt expression cassette was ligated into the unique Bam HI site of 
pEE6.hcmv and the resultant plasmid designated pEE6.hcmv.gpt (Figure 25).
The heavy chain cDNA of pUC13.8.75 was isolated as an EcoRl fragment and 
ligated into EcoRl digested pEE6.hcmv.gpt. Plasmid DNAs, isolated from 
transformants, were analysed by Sma I and Sst I digestion, to select a construct 
with the N-terminus of the heavy chain proximal to the MCS. This plasmid was 
designated pEE6.hcmv.gpt.HC.
The light chain cDNA was ligated into pEE6.hcmv.gpt at the EcoRl site to 
generate pEE6.hcmv.gpt.LC and orientated by BamHI digestion.
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Figure 25. pEE6.hcmv.gpt
B
M C S  «  M ultip le  clon ing  site S’-H in d lll-X b a l-C la l-S m a l-S s tl-E c o R I-S ’
E =  E c o R I H =  H in d lll B -  B a m H I S s  -  S stl
hcm v =  H u m a n  c y to m eg a lo v iru s  p ro m o to r/e n h a n c e r  
- ►  =  D irec tion  o f transcrip tion  
P A  =  P o ly -A  add ition  site  
gpt =  gp t exp ress io n  c a s s e tte
A m p  =  Am picillin  re s is ten ce  m a rk e r  
ori *  origin of rep lication
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5.4 Verification of testosterone binding.
Expression vectors, including heavy or light chain cDNA, were simultaneously 
introduced into COS-1 cells (section 2.42) and testosterone binding detected in 
transfected cell supernatants using an ELISA specific for bovine anti­
testosterone IgG (section 2.43). Control transfections were performed in parallel 
by applying the transfection procedure to:
1. Cells in the absence of exogenous DNA 
(cell control),
2. The expression vector in the absence of Ig DNA 
(vector control).
3. The heavy and light chain expression vectors individually 
(heavy and light chain controls).
The success of the transfection assay and transcription of the Ig cDNAs were 
monitored by Southern and Northern blot analyses (section 2.31).
Southern blot analysis.
DNA, extracted from transfected COS-1 cells, including the transfection 
controls were hybridised with a mixed probe of pEE6.hcmv.gpt.HC and 
pEE6.hcmv.gpt.LC DNA. Target DNA was blotted as both undigested and EcoRl 
digested, which removes the cDNA inserts. The gel was stained with ethidium 
bromide and photographed (section 2.19) prior to blotting. Figures 26A and 26B 
shows the results of this analysis. Figure 26a shows the gel after ethidium 
bromide staining and that similar amounts of DNA were blotted in each lane. Figure 
26b shows the hybridisation pattern obtained and, as can be seen, all cells 
transfected with vectors gave the hybridising bands expected for EcoRl-digested 
DNA (pEE6.hcmv.gpt = 5.4 kb, HC insert = 1.6 kb, LC insert = 0.96 kb), whereas 
hybridisation could not be detected in the cell control (lanes 4 and 5). Hybridi­
sation signals with higher molecular weight DNA most likely resultfrom 
hybridisation with multimeric or rearranged forms of the vector (Tsui et al., 
1982).
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Figure 26A  Souther blot analysis using D N A  
from transfected C O S-1 cells.
The gel prior to blotting.
3  4  5  6 7  8 9 10 11 12 13 14 M
kb
23
9 .6  
6 .4
4 .6
2 .3
2.0
D N A  from CO S-1 cells, transfected with Ig D N A  and controls,
w ere run as uncut (lanes 5, 7, 9 , 1 1 ,  and 13) and as EcoRl
digested (lanes 4 , 6, 8 , 1 0 ,  and 12).
All lanes included a  similar am ount of D N A  
Lanes 4  & 5  = Cell control.
lanes 6 & 7 =  Cells transfected with pEE6.hcm v.gpt (vector control). 
Lanes 8 & 9 = Cells transfected with pEE6.hcm v.gpt.LC  
Lanes 10 & 11 = Cells transfected with pE E 6.hcm v.gpt.H C  
Lanes 12 & 13 = Cells transfected with both pEE6.hcm v.gpt.LC  
and pEE6.hcm v.gpt.H C  
Lanes 3 & 14 = D N A  size m arkers, kilobase pairs (kb).
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Figure 26B . Southern blot analysis using D NA  
from transfected C O S-1 cells
1 2 3 4 5 6 7 8 9 10 11 12 13 14
The gel shown in F ig .26A  w as blotted and the filter probed  
with pEE6.hcm v.gpt.LC  and pEE6.hcm v.gpt.H C  and the  
filter w ahed at high stringency (0.1 x S S C ).
Hybridisation w as not detected in the cell control (lanes 4 & 5).
A hybridising band at 5 .2  kb (pEE6.hcm v.gpt) is present in lanes 
7 , 9 , 1 1  and 13.
A band at 1.6 kb (heavy chain cD N A ) is visible in lanes 11 & 13.
A band at 0 .96  kb (light chain cD N A ) is visible in lanes 9 & 13.
Lane 1 = EcoRl digested pEE6.hcm v.gpy.LC  
Lane 2 = EcoRl digested pEE6.hcm v.gpt.H C .
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Northern blot analysis.
Transcription of bovine Ig cDNA in transfected cells was detected by Northern 
hybridisation using RNA extracted from the same cells as was used in the Southern 
blot analysis and a mixed bovine heavy and light chain cDNA probe (Figure 27). As 
can be seen, only cells transfected with expression vectors that included Ig cDNA 
resulted in specific hybridisation (lanes 3, 4 and 5). The background 
hybridisation with ribosomal RNA (18S and 28S) seen in all lanes has a similar 
intensity, indicating that similar amounts o f RNA were present in each lane, 
including the vector and cell controls.
ELISA.
Culture media from transfected cells and control transfections were screened 
for antibodies to testosterone using an ELISA specific for bovine anti­
testosterone IgG (section 2.43). Additional controls to those performed for the 
transfection assay (i.e cell control; vector control; heavy chain control; light 
chain control) were included on each plate. A negative control was supplied by 
wells coated with chicken gammaglobulin (CGG), and a positive control by a 
dilution series of culture media from the heterohybridoma (BMT.4A).
The ELISA assay was repeated for several transfections and gave reproducible 
results. Typical ELISA results are shown as a graphical representation in Figure 
28. Bovine anti-testosterone IgG was only detected in culture media from COS-1 
cells that had been simultaneously transfected with the heavy and light chain 
cDNAs (pEE6.hcmv.gpt.HC and pEE6.hcmv.gpt.LC).
5.5 Conclusions.
Southern hybridisation demonstrated that expression vectors were being 
sucessfully transfected into COS-1 cells. Northern analysis demonstrated that Ig 
RNA transcripts could only be detected in cells traptected with vectors including 
Ig cDNA.
Functional bovine IgG anti-testosterone antibodies were only detected in 
culture media from cells simultaneously transfected with both the heavy and light 
chain expression vectors. This strongly suggested that the cloned cDNAs encode for 
the bovine anti-testosterone monoclonal antibody secreted by BMT.4A.
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Figure 27. Northern hybridisation studies using 
R N A  from transfected CO S-1 cells.
1 2 3
28 S
HC
LC
18 S
RN A  w as extracted from the sam e cells used for the Southern analysis  
(Figure 26) and hybridised to bovine Ig heavy (clone 8 .75 ) and light 
chain (182) DNA.
Background hybridisation with ribosomal RNA, seen in all lanes  
indicates that a  similar am ount of R N A  w as run in each lane.
Specific hybridisation w as only detected in lanes 3 ,4  and 5.
H C  = heavy chain transcript. LC = light chain transcript.
Lane 1 = R N A  from cell control.
Lane 2 = R N A  from cells transform ed with pEE6.hcm v.gpt 
Lane 3 = R N A  from cells transform ed with pEE6.hcm v,gpt.LC  
Lane 4 = R N A  from cells transform ed with pE E 6.hcm v.gpt.H C  
Lane 5 = R N A  from cells transform ed with both pEE6.hcm v.gpt.LC  
and pE E 6.hcm v.gp t.H C .
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Figure28 Testosterone binding in transfected C O S  
cell m edia.
Log of antibody dilution.
*  = Antibody secreted by heterohybridom a cells (B M T.4A )A = Antibody secreted by C O S-1 cells transfected with heavy  
and light chain expression vectors.
+  = N egative controls.
Negative controls gave near identical results and are  shown  
as a  single curve on the Figure.
Negative controls
Cell control (Cos-1 cells transfected without exogenous DN A ). 
Vector control (cells transfected with pEE6.hcm v.gpt).
Light chain control (cells transfected with pEE 6.hcm v.gpt.LC ). 
H eavy chain control (cells transfected with pE E 6.hcm v.gp t.H C ) 
W ells coated with C G G  in coating buffer.
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MODELLING THE ANTIGEN BINDING SITE OF THE BOVINE 
ANTI-TESTOSTERONE MONOCLONAL ANTIBODY.
CHAPTER 6.
CHAPTER 6.
MODELLING THE ANTIGEN BINDING SITE OF THE BOVINE 
ANTI-TESTOSTERONE MONOCLONAL ANTIBODY.
6.1 Introduction.
A three-dimensional molecular model of the antigen binding site of the bovine 
antibody secreted by BMT.4A was constructed to aid investigations of the molecular 
interactions between the antibody and testosterone and the design o f a higher 
affinity antibody. The model was made using the methods described in section 2.46. 
CDRs predicted to share the same or similar main chain conformation to a CDR in a 
crystal structure were modelled by side-chain replacement using the maximum 
overlap procedure (MOP) (de la Paz et al., 1986; Chothia and Lesk 1987; Chothia et 
al., 1989). CDR-H3 was modelled using the combined algorithm approach (Martin et 
al., 1989; Martin, 1990).
6.2 Modelling the CDRs.
6.2.1 CDR-L1.
The length and main chain conformation of CDR-L1 of the antibody KOL and the 
light chain dimer RHE are virtually identical (de la Paz et al., 1986). The key 
structural residues responsible for the observed conformations have been 
identified as CDR residues Gly-25, Ile-28, and Val-33, and framework residue Ala- 
71 (Chothia and Lesk., 1987). CDR-L1 of the bovine antibody is the same length as 
that of KOL and RHE, and includes identical residues at the key interacting sites 
(Table 10). CDR-L1 was therefore predicted to share the same main chain 
conformation as KOL and RHE and was modelled using KOL as a template on the basis 
of greater sequence homology.
6.2.2 CDR-L2.
The length of CDR-L2 is the same in all o f the Ig crystal structures and main 
chain conformations are almost identical, despite significant differences in 
their amino acid sequences (de la Paz et al., 1986; Chothia and Lesk., 1987; 
Chothia et al., 1989). The observed main chain conformation is dependant upon 
framework residues IIe-48 and Gly-64 (Chothia et al., 1989), which are highly 
conserved in VL-domains (Kabat et al 1987). In the bovine light chain, Ile-48 and
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Gly-64 are present. The main chain conformation for the model was selected from 
KOL as Ile-48 and Gly-64 are both present and the sequence is closest in homology 
to that of the bovine antibody.
6.2.3 CDR-L3.
The length of CDR-L3 in KOL and RHE are the same and their main chain 
conformations are very similar (Chothia and Lesk., 1987), with residues 93, 94, 
95 and 95a forming a four residue turn. The major structural determinant 
responsible for this conformation has been identified by Chothia as residue 95a, 
which is asparagine in KOL and aspartate in RHE. CDR-L3 in the bovine light chain 
is the same length as that of KOL and RHE and residue 95a is arginine. The 
conformation of CDR-L3 depends upon the class of the light chain (Chothia and 
Lesk., 1987). The majority o f Ig crystal structures include kappa light chains, 
thereby limiting the number of main chain conformations upon which a model of a V- 
iambda CDR-L3 may be made. In the absence of a crystal structure including a V- 
lambda CDR-L3 that has arginine at residue 95a, the model was based on the 
conformation of KOL as the sequence of this loop is closer than that of RHE to the 
sequence of the bovine antibody.
CDR conformations with non-identical amino acids at key structural residues 
have been grouped into single canonical families (Chothia et al., 1989). Arginine 
(95a in the bovine light chain), like asparigine (95a in KOL) and aspartate (95a 
in RHE), is a charged amino acid. CDRs with arginine at residue 95a could con- 
ceiveably be grouped into the same canonical famiiiy as KOL and RHE, provided that 
the charge on each of these amino acids is neutralised, for example, by occupying 
a position such that the charge is on the protein surface where it could interact 
with solvent molecules. In the crystal structures of KOL and RHE, this situation 
is found to be the case and substitution o f arginine at this site would not be 
expected to greatly alter the main chain conformation o f the CDRs. However, a 
direct assesment of the accuracy of this step awaits a crystal structure o f a V- 
lambda domain with arginine at residue 95a.
6.2.4 CDR-H1.
The main chain conformations o f CDR-H1 (Kabat definition) in Ig crystal 
structures are similar (de la Paz et al., 1986) The conformation of CDR-H1 in a 
model of the antigen binding site of the anti-lysozyme antibody Gloop-2 (de la Paz 
et al., 1986) has been subsequently demonstrated to be in good agreement with that 
o f the crystal structure, despite only 20% sequence homology (1 of 5 residues)
138
(Martin et al., 1989). CDR-H1 of the bovine antibody was modelled using the 
conformation of D1.3 as a template which also displays 20% sequence homology (1 of 
5 residues).
6.2.5 CDR-H2.
A model constructed of the antigen binding site of the antibody D1.3, correctly 
predicted the main chain conformation o f CDR-H2 to share a near identical 
conformation with the corresponding CDR of NEW (Chothia et al., 1986). This 
prediction was based on the presence of a glycine residue that occupies the fourth 
position of a seven residue turn. CDR-H2 of the bovine antibody is the same length 
and includes glycine at the same residue as both D1.3 and NEW. CDR-H2 was, 
therefore, modelled using the main chain conformation of D1.3 as a template as the 
sequence of D1.3 is closer to to that of the bovine antibody.
The sequences of the CDRs and '.key' interacting framework residues o f the 
bovine antibody and those of KOL and D1.3 used to construct the model are compared 
in Table 10.
6.2.6 CDR-H3
CDR-H3 was modelled using the methods of Martin et al., (1989) and Martin, (1990) as 
described in section 2.45.2.2. The database search was applied to residues 95, 96, 97, 
98, lOOe, lOOf, 101 and 102. The main chain of residues 100 and lOOa-d were rebuilt using 
CONGEN.
6.3 Selection of the Framework Regions.
Antibodies with recombinant VH and VL-domains (Jones et al., 1986; Verhoeyen et 
al., 1988; Riechmann et al., 1988) demonstrate the importance of considering the 
identity of amino acids at key interacting Framework residues when selecting a FR 
for model construction. A recombinant antibody, including a VH-domain formed from 
the FR of the human Ig NEW and the CDRs from a rat anti-'CAMPATH-l' antibody, 
together with the VL-domain of the wild-type rat anti-CAMPATH antibody, failed to 
bind antigen (Riechmann et al., 1988). Failure of this antibody to bind its 
antigen resulted from the loss o f contact between Phe-27 and Tyr-32. In the 
normal rat VH-domain, Phe-27 is predicted to form a van der Waals contact with 
Tyr-32 (Riechmann et al., 1988). In the reshaped VH-domain, serine is found at 
residue-27 and the above contact is lost. Substitution of phenylalanine at this 
site restored the ability of the recombinant antibody to bind antigen.
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Table 10. CDRs and key interacting framework residues of the bovine antibody compared 
with those used as a template for model construction.
Residues are numbered according to Kabat et al., (1987). - indicates that the amino 
acids found at these positions are identical in the two sequences. * highlights the 
key structural residues that determine the main chain conformation of the loops as 
identified by Chothia and Lesk, 1987 and Chothia et al., (1989).
RES = Residue. BOV = Bovine antibody.
Light chain
CDR--LI. FR
Res 24 25 26 27 27a 27b 28 29 30 31 32 33* 34 71*
KOL T G T S S N I G S I T V N A
BOV S - S - - - - - T Y G - E -
CDR-■L2. FR
Res 50* 51 52 53 54 55 56 48* 64*
KOL R D A M R P S I G
BOV G S N S - - - - -
CDR-•L3
Res 89 90 91 92 93 94 95 95a* 95b 96 97
KOL A S W N S S D N S Y V
BOV - A G D - - S R G A _
Heavy chain 
CDR-H1
FR CDR-H1 FR
Res 26* 27* 28 29* 31 32 33 34* 35
D1.3 G F S L G Y G V N
BOV - - - - S - A L T
CDR--H2 FR
Res 50 51 52 53 54 55* 56 57 58 71*
D1.3 M I W G D G N T D K
BOV G _ T S G _ T - Y -
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Selection of the main chain conformations for the modelled CDRs included a 
consideration of the contacts between ’key' interacting residues in both the FR 
and the CDRs themselves (Chothia and Lesk, 1987; Chothia et al., 1989). The FRs 
used to construct the model were therefore selected from the same domains that 
supplied the CDR main chain conformations, namely VH of D 1.3 and VL of KOL. Selec­
tion of these FRs maintains the same interations that are predicted to be present 
in the bovine antibody in the modelled Fv. The overall sequence homology of the 
FR of VL KOL and VH of D 1.3 with the corresponding domains of the bovine antibody 
are 69 and 70% respectively. This level of sequence homology would appear to be 
acceptable for the construction of a model of the antigen binding site of BMT.4A 
as the final recombinant antibody with a reshaped VH-domain (Riechmann et al., 
1988) retained antigen specificity, despite sequence homology over the FR of only 
51%.
6.4 Results.
The dominant feature of the surface described by the modelled CDRs is a cavity, 
which is shown in Figure 29. Visual inspection of the cavity revealed the 
following characteristics:
(i). The cavity 'walls' are formed exclusively by CDR residues (Table 11). Major 
contributions are made by 4 CDRs (HI, H2, H3 and L3). Only a single residue of 
CDR-L1 (Tyr-32) is involved and CDR-L2 does not appear to make any contribution.
(ii). The cavity 'walls' are incomplete (Figure 30) as part of the upper region 
is missing.
(iii). The dimensions of the cavity were estimated to be 10 A deep and 15 A wide 
(at the mouth).
(iv). Residues that form the walls are predominantly small with hydrophobic side 
chains, although three tyrosine residues and a single charged residue (CDR-L3, 
Arg-95a) are found. The side chain of Arg-95a extends towards the protein surface 
where the charge is available for interactions with solvent (Figure 31). One of 
tyrosines (CDR-H3, Tyr-97) forms part o f the bottom o f the cavity with the 
hydroxyl group exposed to solvent.
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Table 11. Residues that form the cavity walls of the modelled Fv.
CDR Residue s/c atoms m/c atoms
HI Ala-33 +
leu-34 - +
Thr-35 +
H2 Gly-50
IIe-51
Thr-52
Thr-56
Tyr-58
H3 Ser-95
Thr-96
Tyr-97
LI
L3
Tyr-32
GIy-91
Asp-92
Ser-93
Arg-95a
Gly-95b
Ala-96
+
+
+
+
+
+
+
+
sc = side chain atoms, 
me = main chain atoms.
+ indicates atoms involved in forming the cavity walls.
- indicates atoms not involved in forming the cavity walls.
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Figure 29.
In the model of the antigen binding site of the bovine anti-testosterone 
monoclonal antibody the CDR associate to form a cavity. Figure 29, shows a cross- 
sectional view through the cavity as visualized on an Evans and Sutherland 
Workstation.
Testosterone is predicted to bind into the cavity and form a hydrogen bond, 
through the hydroxyl group of the D-ring, with CDR-H3 Tyr 97 (Arrowed).
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Figure 30.
Figure 30, shows the a section through the 'rim' of the cavity and that the 
upper region of the 'cavity wall' is incomplete.
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Figure 31.
Figure 31, shows the relative positions of CDR-H3 Tyr-97 (Numbered as TYR 210) 
and CDR-L3 Arg-95a, Gly-95b and Ala-96 (Numbered as 97, 98 and 99, respectively). 
When testosterone binds to the antibody it is predicted to make contact with the 
L3 residues shown above and form a hydrogen bond with CDR-H3 Tyr-97. Other 
residues of the cavity (not shown) may also make contact with testosterone.
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6.5 Discussion.
The methods used to construct models of antigen binding sites assume that CDR 
replacement between antibodies does not greatly perturb their conformation and 
that the relative spatial arrangement of the CDRs does not significantly alter 
when they are supported by different framework arrangements. These assumptions 
appear to be supported by the construction of recombinant antibodies in which the 
CDRs of one antibody have been grafted on to the framework regions of another 
(Jones et al., 1986; Riechmann et al., 1988; Verhoeyen et al., 1988). Such 
recombinants have been demonstrated to retain the antigen specificity of the 
parent antibody.
The relative spatial arrangment of the CDRs in the Ig crystal structures have 
been observed to have^all but significant differences which probably result from 
different amino acids at residues that form the VL:VH domain interface (Davies and 
Metzger, 1983; Chothia and Lesk, 1986; Lascombe et al., 1989). Different amino 
acids at these sites appear to effect the way the V-domains of a Fv fragment pack 
together which inturn may effect the arrangement of the CDRs. However, evidence 
has recently been obtained (Bhat et al., 1990 and section 1.6.3) which shows that 
the VL:VH domain interface is flexible and the difference in the relative 
positions of the CDRs observed in the crystal structures may, therefore, reflect 
the inherent flexibility of Fv modules.
The relative positions of the CDRs in models constructed by Chothia et al., 
(1989) were observed to be different when compared with their positions in the 
crystal structures of the antibody being modelled. For most o f the CDRs, the 
observed differences are small and probably results from different amino acids at 
the VL:VH domain interface; however, some of their models were constructed using 
FRs of antibodies complexed with their antigen and it is also possible that the 
difference in the relative positions of the CDRs in their models result as a 
consequence of antigen binding.
In the models constructed by Chothia et al., (1989) the relative repositioning 
of CDR-H2 was observed, in some cases, to be significantly larger than for the 
other CDRs and results from a different packing arrangement of H2 with heavy chain 
framework residue 71.In the crystal structures of KOL and J539, Arg-71 packs 
against and forms hydrogen bonds to CDRs HI and H2 and as a consequence Pro-52a 
forms part of the binding surface. In HyHEL-5, alanine is present at residue-71
6.5.1 CDR Replacement and Relative Spatial Arrangment.
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and the space created by its smaller side-chain is filled by Pro-52a which results 
in both a conformational change and a relocation of CDR-H2 by 4A. The heavy chains 
o f the bovine antibody and D1.3 both have lysine at residue-71 and the 
conformations of H2 of these antibodies are predicted to be grouped in the same 
canonical family in which the contribution of residue-71 is not as important. This 
suggests that the difference in position o f CDR-H2 observed in the models of 
Chothia et al., (1989) may not be as extensive in the model o f the bovine 
antibody.
Comparison of the residues that form the VL:VH domain interface of the bovine 
antibody with those o f the modelled Fv shows that at 4 light chain residues 
different amino acids are found in these structures (Table 12). In addition, the 
model of the antigen binding site was built using the heavy chain FRs of the VH- 
domain of D 1.3 when complexed with lysozyme in which the position of the VH- 
domain, relative to the VL-domain is known to have changed on lysozyme binding. It 
is, therefore, likely that the relative positions of the CDRs in the model o f the 
antigen binding site of the bovine antibody is different to that of the bovine 
antibody when it binds testosterone and this possibility should be considered when 
predicting the nature of likely interactions between the antibody and 
testosterone.
6.5.2 Confidence in the Model.
The model was constructed to investigate the nature of the molecular 
interactions between the antigen binding site of the bovine antibody secreted by 
BMT.4A and testosterone. Before the model could be used for the above 
investigations, it was considered both necessary and desirable to obtain an 
estimate of its accuracy.
Several lines of evidence, although indirect, suggest that the overall shape of 
the antigen binding site as described by the modelled CDRs i.e. a cavity, is a 
reasonably accurate representation of the bovine antibody.
Five CDRs (LI, L2, HI, H2 and H3) were modelled using methods that have been 
vigorously tested by direct comparison with known structures and have given 
accurate reproducible results (de la Paz et al., 1986; Chothia and Lesk., 1987; 
Chothia et al., 1989; Martin et al., 1989; Martin, 1990). CDR-L3 was modelled 
using the Chothia method, although this CDR of the bovine antibody does not fit 
exactly a pattern of key structural residues which describe a canonical family 
(Chothia et al 1989); however, the difference in the nature o f key structural
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Table 12. Comparison of the FR residues that form the VL:VH interface in the bovine 
antibody and the modelled Fv.
VL-domain VH-domain
Res BOV KOL Res BOV E
36 Y - 2 V _
38 Q - 37 V -
43* G A 39 Q -
44* L P 43 K -
46* T L 45 L -
87* F Y 47 W -
98 F - 91 Y -
93 A _
The above table was compiled from Novotny and Haber, (1985); Chothia and Lesk, 
(1985); de la Paz et al., (1986). * highlights FR residues that are different between 
the two structures.
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residues of the bovine antibody from that upon which the model was based (i.e KOL) 
is minor (section 6.2.3) and a major change in the main chain conformation is 
considered unlikely.
In the original crystal structure of D1.3, in which the antibody is complexed 
with lysozyme (Amit et al., 1986), the conformation of heavy chain residue Leu-29 
is different to that observed in a more refined structure (Bhat et al., 1990) and 
the position o f Leu-29 is now believed to represent an error in the original 
structure. The atomic co-ordinates o f the original structure supplied the VH- 
domain FR for model construction and the misplaced Leu-29 in the original 
structure will therefore be similarly misplaced in the model. The position of 
Leu-29, therefore, represents a known error in the model; however, this residue 
lies outside the boundaries of the CDRs as defined by Kabat (Kabat et al., 1987) 
and in the crystal structures of D1.3 complexed with lysozyme this residue does 
not form part of the antibody paratope (Amit et al., 1986).
The high affinity of antibody secreted by BMT.4A for testosterone implies that 
a large proportion of the testosterone molecule will be in contact with the 
antibody. This situation is best served by testosterone binding into a cavity or 
slot, as is known to be the case for other small ligands, such as 
phosphorylcholine (Satow et al., 1986) and fluorocine (Lascombe et al., 1989). 
Testosterone is a relatively small hydrophobic molecule and would be expected 
predominantly to make hydrophobic contacts with the antibody. The amino acids that 
line the cavity are mostly hydrophobic. The only charged residue (LC Arg-95a) that 
participates in formation of the cavity walls occupies a position such that the 
charge is at the protein surface, where it may interact with solvent molecules 
(see Figure 31).
A correlation between the length and volume occupied by CDRs Ll and H3, with 
the nature of the surface formed by the association o f the CDRs has been 
identified (de la Paz et al., 1986). The surface of an antigen binding site formed 
by a short CDR-L1 and a relatively short CDR-H3 is relatively flat, whereas 
binding sites formed by a long CDR Ll and a long CDR-H3 present grooves or 
cavities (table 13). CDRs Ll and H3 of the bovine are relatively long, formed by 
13 and 14 residues respectively, consistent with cavity formation. In addition, 
cavity formation is enhanced by CDR residues having small side chains which 
effectively 'open up the cavity'. The side chains of residues that form the cavity 
walls are predominantly small.
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Table 13. Correlation between the residue number of CDRs LI
and H3 and the shape o f  the antigen binding site.
Crystal CDR Surface
structure LI H3 type
D1.3 11 8
HyHEL-5 10 7 Flat
HyHEL-10 11 5
Gloop-2 11 4
NEW 14 9 Shallow groove
McPC603 12 17 Cavity
KOL 13 17
6.5.3 Predicting the Molecular Interactions Between the Bovine 
Antibody and Testosterone.
The side chain of CDR-H3 Tyr-97 forms part of the bottom of the cavity and it 
is attractive to speculate that the hydroxyl group o f this residue forms a 
hydrogen bond (or hydrogen bonding network) with the hydroxyl group on the D-ring 
of the testosterone molecule (Figure 32). Binding of testosterone into the cavity 
in an orientation that satisfies the requirments of such a hydrogen bond is 
consistent with the conjugated state of the molecule when presented to the animal 
on immun isation (Groves et al., 1987a) i.e. conjugated through the A-ring carbonyl 
oxygen atom. In addition, Ala-96, Gly-95b and the hydrocarbon stem of the side- 
chain of Arg-95a of CDR-L3 presents a hydrophobic surface upon which testosterone 
may sit when within hydrogen bonding distance of Tyr-97 (Figure 31).
Based on observations of the model, the above hydrogen bond formed the major 
prediction of the interactions likely to occur between testosterone and the 
antibody. CDR-H3 Tyr-97 was, therefore, selected for mutagenesis.
150
Figure32. The structure of Testosterone.
A. As visualized on an Evans and Sutherland Workstation.
T E S T O S T E R O N E
SITE
The structure of testosterone consists of 3 six mem bered rings 
labelled A, B and C, and a five membered ring labelled D.
W hen presented to the anim al on immunisation testosterone was  
conjugated to a carrier protein (CG G ) through the A-ring carbonyl
The predicted hydrogen bond with the is through the D-ring 
hydroxyl group.
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CONSTRUCTION AND EXPRESSION OF MUTATED ANTIBODIES.
CHAPTER 7.
CHAPTER 7.
CONSTRUCTION AND EXPRESSION OF MUTATED ANTIBODIES.
7.1 Introduction.
Mutated antibodies, including specific amino acid substitutions at CDR-H3 Tyr- 
97 (Tyr-97) were constructed, in order to test the major predictions made from 
observations o f the model (section 6.6). The major predictions were that 
testosterone binds into a cavity (that is formed by the CDRs) and establishes a 
hydrogen bond with Tyr-97. The exsistence of the predicted hydrogen bond was 
tested by the substitution o f phenylalanine (Ab-14) for Tyr-97, whereas the 
contribution o f the cavity to binding testosterone was assessed by the 
substitution of glutamate (Ab-15).
The effects o f the above amino acid substitutions on the affinity o f the 
antibody for testosterone were quantitated by expressing the mutated antibodies in 
COS-1 cells and calculating their Kd.
7.2 Preparation of the Mutated Antibodies.
The heavy chain cDNA of pUC13.8.75 was cloned into the EcoRl site of M13mpl8 
and the single stranded form used as a template for site-directed mutagenesis 
(Section 2.41). After mutagenesis, the complete coding sequence of the mutated VH- 
domain was sequenced to verify that the correct nucleotide changes had been 
incorporated and that additional unwanted changes had not been introduced.
Figure 33 shows the sequence of codon-97 of the wild-type antibody (Fig.33A) 
and mutated heavy chains (Fig.33B, Ab-14 and Fig.33C, Ab-15). Additional 
nucleotide changes were not observed in the sequence of the mutated VH-domains.
7.3 Testosterone Binding by the Mutated Antibodies.
The mutated heavy chains were ligated into the EcoRl site of pEE6.hcmv.gpt and 
orientated for expression with AccI. The vectors including the mutated heavy 
chains were then introduced, individually and also in association with 
pEE6.hcmv.gpt.LC (which includes the wild-type light chain) into COS-1 cells. 
Testosterone binding was identified in culture media from transfected COS-1 cells
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Figure 33A . Sequence of codon-97 in the wild-type  
antibody secreted by B M T.4A .
G  A  T  C
C odon-97  of the wild-type antibody secreted by B M T.4A  codes  
for tyrosine.
C odon-97  of the m utated heavy chains are  shown in Figures 
33B  and 33 C .
In Figure 33B  (m utated heavy chain 14) codon-97 codes for 
phenylalanine.
In Figure 3 3 C  (m utated heavy chain 15) codon-97 codes for 
glutam ate.
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Figure 33B . C odon-97 of mutated heavy chain 15
G A T  C
Figure 33C . C odon-97 of mutated heavy chain 15
G A T  C
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using the ELISA that was used to verify the specificity of the antibody encoded by 
the unmutated cDNAs for testosterone (Chapter 5).
The ELISA results are shown in figure 34, and show that both of the mutated 
antibodies (Ab-14 and Ab-15) retain the ability to bind testosterone.
7.4 Determination of the Equilibrium Dissociation Constant 
of the Mutated Antibodies.
The equilibrium dissociation constant (Kd) of the wild-type and mutated 
antibodies was measured using a competitive RIA as described in section 2.44 with 
the data being analysed by the method of Muller, (1980).
The Kd of the wild-type antibody, when expressed by COS-1 cells, was calculated 
in order to allow for a direct comparison between the binding affinity o f the 
normal and mutated antibodies when expressed in the same system.
Light chain clones isolated from the BMT.4A cDNA library gave two different 
hybridisation patterns with a bovine lambda light chain probe after EcoRl 
digestion (Figure 15). This suggested that there may be two bovine light chains 
present in BMT.4A, both of which could be derived from a functionally rearranged 
gene. In order to verify that the antibody encoded by the cDNAs is that secreted 
by BMT.4A, the Kd of the antibody secreted by this cell line was remeasured in 
parallel.
7.4.1 Radioimmunoassay Results.
Four experiments were performed to calculate the Kd of the above antibodies 
using cell culture media from different transfections.
Experiment 1.
A ntibody dilution curve JL
An antibody dilution curve was derived as described in section 2.44 using 0.093 
pmol o f tritiated testosterone per tube. Plots o f the percentage bound of the 
added labelled testosterone against antibody dilution are shown in Figure 35, with 
the dilution that bound 50% of the label indicated in the legend. A 1/10 dilution 
of both the wild-type antibody secreted by BMT.4A and by COS-1 cells bound greater 
than 90% of the added labelled. At the same dilution,the mutated antibodies failed
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Figure 34 . Testosterone binding by the mutated antibodies.
Log of antibody dilution.
*  -  Antibody secreted bt heterohybridom a cells (B M T.4A )
A  =  Antibody secreted by C O S-1 cells transfected with heavy  
and light chain expression vectors. (C D R -H 3  T yr-97 ) 
o  = A b-14  (C D R -H 3  P he-97)
□ «  A b15 (C D R -H 3  G lu-97)
+  =  Negative controls
T he negative controls (as listed on Fig.28) gave near identical 
results and are shown above as a  single curve.
N.B. Additional negative controls of the m utated heavy chains  
expressed in the absence of the light chain w ere included.
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to bind 50% of the label as required by the Muller method of analysis. A 1/10 
dilution of Ab-14 bound only 13% of the labelled steriod, whereas Ab-15 failed to 
bind label above the non-specific binding (NSB) value.
Standard curve 1.
A standard curve (section 2.44) was derived using the wild-type antibody 
secreted by BMT.4A and COS-1 cells at the dilution that bound 50% of the added 
label (derived as above). The data are shown as a plot of the percentage bound of 
the added labelled testosterone per tube against unlabelled testosterone 
concentration (Figure 36).
The antibody secreted by BMT.4A bound 40% of the added label in the absence of 
competing unlabelled testosterone and 50% inhibition of labelled testosterone 
binding to the antibody was observed at a unlabelled testosterone concentration 
of 0.12 pmol/tube.
The wild-type antibody expressed by COS-1 cells bound 52% of the added label in 
the absence o f unlabelled testosterone and 50% inhibition was observed at a 
unlabelled testosterone concentration of 0.13 pmol/tube.
M uller analysis.
The Kd of the wild-type antibody when expressed by BMT.4A and by COS-1 cells 
were both calculated using the Muller equation (section 2.44) to be 4.3 x 10'"11 
M.
Experiment 2.
A ntibody dilution curve.
Experiment 2 was performed using a much smaller amount (0.0143 pmol/tube) of 
labelled testosterone. The dilutions of the wild-type antibody when expressed by 
COS-1 cells and that of Ab-14 that bound 50% of the added label were determined as 
above in experiment 1; however, culture media containing Ab-15 again failed to 
bind 50% of the added testosterone (Ab-15 bound only 9% of the label when used 
undiluted) and the Muller analysis for this antibody could not be performed.
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Figure 35. Experim ent 1. Antibody dilution curve 1.
Log of antibody dilution.
* W ild-type antibody secreted by B M T .4A  
A  W ild-type antibody secreted by CO S -1 cells, 
o  A b-14. Mutated with Phe replacing Tyr at 
C D R -H 3  residue-97  
D ata  for A b-15 is not shown.
Th e  wild-type antibody secreted by B M T.4A  bound 5 0 %  of the  
added testosterone at a  dilution of 1 /100.
The wild-type antibody secreted by transfected C O S-1 cells 
bound 5 0 %  of the added testosterone at a  dilution of 1 /26 .
A b-14  bound only 13%  of the added testosterone at a  dilution of 1 /10 . 
A b-15  failed to bind above the NSB.
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Standard curve 2.
The standard curve data is shown in Figure 37. The wild-type antibody expressed 
by COS-1 cells bound 55% of the added label in the absence of competing unlabelled 
testosterone, with 50% inhibition o f labelled testosterone binding to antibody 
observed at an unlabelled testosterone concentration of 0.026 pmol/tube.
Ab-14 bound 50% of the added label in the absence of competing unlabelled 
testosterone and 26% in the presence o f the lowest unlabelled testosterone 
dilution (10 pmol/tube). The concentration of unlabelled testosterone that 
inhibited the binding of the added label by 50% was, therefore, determined by 
extrapolation of the data and was estimated to be 13 pmol/tube (Figure 37).
Muller analysis.
The Kd of the wild-type antibody expressed by COS-1 cells and Ab-14 were 
calculated using the Muller equation to be 1.3 x 10-11 M, and 1.9 x 10“ 8 M, 
respectively.
Experiments 3 and 4.
A more accurate determination of the Kd of Ab-14 was obtained in further 
experiments using an extended range o f unlabelled testosterone concentration 
(0.0078-100 pmol/tube). Experiments 3 and 4 were performed using 0.0153 and
0.0137 pmol of labelled testosterone per tube respectively.
Antibody dilution curves 3 and 4.
The dilution that bound 50% of the added label was determined from a plot of 
the percentage bound label against antibody dilution as described above in 
experiment 1; however, in both of these experiments, antibody-15 again failed to 
bind 50% of the added label and the Kd was not determined.
Standard curves 3 and 4.
Antibody-14 bound 44% and 40% of the total labelled testosterone added in the 
absence o f unlabelled antigen in experiments 3 and 4 respectively. The 50% 
inhibition concentrations were measured as 9 pmol/tube and 46 pmol/tube for 
experiments 3 and 4 respectively.
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Muller analysis.
The affinity (Ka) of Ab-14 was calculated to be 1.3 x 10“ 8 M and 7.1 x 10“ 8 M 
using the data of experiments 3 and 4 respectively.
7.5 Summary of Results.
The affinity for testosterone of the antibody encoded by the non-mutated cDNAs 
was calculated to be identical to that o f the antibody secreted by the 
heterohybridoma (BMT.4A), thus confirming that the cDNAs isolated from the library 
encode for the identical antibody.
Replacement of the normal heavy chain of the anti-testosterone antibody with a 
mutated chain carrying phenylalanine (in place of tyrosine) at CDR-H3 residue-97, 
led to the production o f an antibody (Ab-14) with an affinity for testosterone 
that was reduced by nearly 3 orders of magnitude.
The affinity of the mutated antibody including glutamate in place of tyrosine 
(Ab-15) could not be measured under the assay conditions. The Kd results are 
summarised in table 14.
Table 14. Kd of the wild-type antibody and mutated Ab-14.
Exp Antibodv Kd M
WT(BMT,4A) 4.3 x 10
WT(COS-l) 4.3 x 10
WT(COS-l) 1.3 x 10
Ab-14 1.9 x 10
III Ab-14 1.3 x 10
IV Ab-14 7.1 x 10
The number of the experiment is shown in the left hand colum.
WT (BMT.4A) = Wild-type antibody secreted by the heterohybridoma. 
WT (COS-1) = Wild-type antibody expressed by COS-1 cells.
Ab-14 = Antibody including the Tyr ->  Phe substitution in CDR-H3.
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7.6 Discussion.
Site-directed mutagenesis has been used as a means to test the major 
predictions made of the likely interactions between the bovine anti-testosterone 
monoclonal antibody and testosterone. The major prediction were;
1. Testosterone binds into a cavity that is formed exclusively by the CDRs.
2. CDR-H3 Tyr-97 (Tyr-97) is located at the bottom of the cavity and on 
testosterone binding it establishes a hydrogen bond, through its hydroxyl group, 
with the hydroxyl group on the D-ring of testosterone.
Tyr-97 was therefore selected for mutagenesis. The exsistence of the predicted 
hydrogen bond was tested by substituting phenylalanine for Tyr-97 (Ab-14), whereas 
the contribution of the cavity was assessed by the substitution of glutamate (Ab- 
15). Both o f the mutated antibodies were demonstrated to retain the ability to 
bind testosterone using an ELISA. The effects of the substitutions on the affinity 
of the antibody for testosterone were quantitated by calculating the binding 
equilibrium dissociation constant (Kd) of the wild-type and mutated antibodies.
The Kd of the mutated antibody which had phenylalanine in place of Tyr-97 (Ab- 
14) was reduced by nearly 3 orders of magnitude. The Kd of the mutated antibody 
with glutamate in place of Tyr-97 (Ab-15) could not be measured under the assay 
conditions. The most likely explanation for this observation is that the affinity 
of Ab-15 for testosterone is weak and removal of free testosterone into the 
dextran coated charcoal at phase separation (section 2.44) results in the 
dissociation of the antibody-testosterone complex and, therefore, antibody bound 
label.
Definitive statements as to how the above mutations at Tyr-97 effect the 
conformation of the antibody and its interactions with testosterone cannot be made 
as the structure of the antibody and its complex with testosterone are unknown. 
However, by refering to the model and considering possible enthalpy (AH) and 
entropy (AS) changes that may occur on testosterone binding by the wild-type and 
mutated antibodies it is possible to offer a molecular explanation for the 
observed reduction in affinity associated with die mutated antibodies.
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Enthalpy (H) and entropy (S) are related by the equation;
AG = AH-TAS
where,
AG = The Gibbs free energy change 
AH = Enthalpy change 
AS = Entropy change 
T = Kelvin
The Gibbs free energy change is a measure o f the feasibility o f a reaction or 
physical change occuring spontaneously, without the provision of external energy. 
A change is more likely to occur if there is a decrease of free energy i.e. AG is 
negative.
Case 1. Testosterone binding bv the wild-tvoe antibody.
When testosterone is not bound to the antibody, the hydroxyl groups of Tyr-97 
and the D-ring of testosterone will be hydrogen bonded to water. When testosterone 
binds to the antibody, a hydrogen bond is established between Tyr-97 and the D- 
ring hydroxyl group and the above hydrogen bonded water will be displaced to bulk 
water where it is free to hydrogen bond to other water molecules. The magnitude of 
the enthalpy change associated with the interaction between the antibody and 
testosterone is unknown; however, the same number and types of hydrogen bonds are 
broken and formed by the interaction o f the antibody with testosterone and 
formation of the antibody-testosterone complex may, therefore, be considered to be 
essentially isoenthalpic i.e. AH = 0 (Fersht et al., 1985).
The contribution of the hydrogen bond to the binding energy of the antibody- 
testosterone interaction arises from entropy; water molecules hydrogen bonded to 
the antibody and testosterone are more restricted than when in bulk water and 
therefore have a lower entropy. Release o f the hydrogen bonded water on 
testosterone binding, therefore, increases the entropy of the system and helps 
drive the interaction.
Case 2. Testosterone binding by the mutated antibody 
with phenylalanine in place of Tvr-97.
Deletion of the hydrogen bonding potential o f Tyr-97, by substitution of 
phenylalanine, means that water molecules that were hydrogen bonded to Tyr-97 in 
the wild-type antibody are likely to be in contact with hydrophobic residues. When
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testosterone binds to the antibody it will break its bonds with hydrogen bonded 
water and its hydrophillic hydroxyl group may replace the water that is in contact 
with phenylalanine. As in the case o f testosterone binding to the wild-type 
antibody, the displaced water is free to hydrogen bond with bulk water. Therefore, 
the same number of hydrogen bonds are also broken and formed on testosterone 
binding and the interaction between the mutated antibody and testosterone may also 
be considered to be isoenthalpic; however, in the case of the mutated antibody, 
the loss of the hydroxyl group of Tyr-97 increases the entropy of the water that 
is in contact with the mutated antibody, relative to the entropy o f the water that 
hydrogen bonds to wild-type Tyr-97. Therefore, the entropy gained by the system on 
forming the mutated antibody-testosterone complex will be less than that gained by 
forming the complex between the wild-type antibody and testosterone
i.e. ASWT-Ab > ASAb_14.
where, WT-Ab = Wild-type antibody with Tyr-97
Ab-14 = Mutated antibody with phenylalanine in place of Tyr-97.
Since, AS associated with the binding of testosterone by the mutated antibody 
is less than AS for binding by the wild-type antibody, then -TaS for the mutated 
antibody will be less negative and the interaction between the mutated antibody 
and testosterone will be less favourable.
The binding energy associated with the reduction o f Kd of Ab-14 can be 
calculated from the equation,
AG = -RT InKd
where, a G = The Gibbs free energy change (J mol’1) 
R = The ideal gas constant (8.314 J K ’1 mol'1) 
K = Kelvin
Kd= The equilibrium dissociation constant (M)
Therefore, the change in AG (a a G) associated with the substitution of 
phenylalanine for Tyr-97 may be calculated from the equation;
A aG = -RT lnKdAb_14 - -RT lnKdWT__AjD
where, KdWT_Ab = The equilibrium dissociation constant of the wild-type antibody 
KdAb_ i4 = The equilibrium dissociation constant of mutated antibody 
with phenylalanine in place of Tyr-97.
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Since,
T = 111
KdAb-14 = 3-4x10'8 
Kdwi-Ab = 3-3 * 10-11
then, A AG = (-8.3) (277) (6.9) = 15.8 KJ mol-1 
since, 1 calorie = 4.186 J 
then, A AG = 3.8 kcal mol” 1
A binding energy o f this amount is within the range (4.0 - 0.5 Kcal mol” 1) 
determined for a single hydrogen bond (Fersht et al., 1985; Bartlett and Marlowe, 
1987; Tronrud et al., 1987).
The binding energy of a hydrogen bond appears to reflect the degree by which 
the hydrogen bonding components are fixed before the bond is established. The 
binding energy of a hydrogen bond that is formed between uncharged components that 
are held in the same orientation in the absence and presence of the hydrogen bond 
has been determined to be 4.0 Kcal mol” 1 (Bartlett and Marlowe, 1987; Tronrud et 
al., 1987), This value is greater than that determined (0.5 - 1.5 Kcal mol” 1) for 
a hydrogen bond between uncharged components that are on flexible amino acid side 
chains that have rotational and translational energy before the hydrogen bond is 
established (Fersht et al., 1985). The hydrogen bond predicted to >exist between 
the antibody and testosterone may be considered to be intermediate between the 
above examples as it involves a hydroxyl group on an amino acid side chain (Tyr- 
97) and a relatively inflexible hydroxyl group on testosterone. The existence of 
the predicted hydrogen bond can only be proven by the crystallographic structure 
of the antibody-testosterone complex; however, the reduction in affinity observed 
for the antibody on removal of the hydrogen bonding potential of Tyr-97 (3.8 kcal 
mol” 1) is remarkably consistent with that expected for a hydrogen bond between the 
components involved in the predicted hydrogen bond.
As previously stated, the structure o f the antibody-testosterone complex is 
unknown, therefore, it is possible that the calculated change in the binding 
energy o f the mutated antibody with phenylalanine in place of Tyr-97 includes a 
contribution from the loss of contact(s) between the aromatic ring of Tyr-97 and 
testosterone. This situation could arise if a water molecule remains trapped at 
the mutated antibody-testosterone interface in the space created by removal of the 
hydroxyl group of Tyr-97 and prevents contact(s) between testosterone and the
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aromatic ring of phenylalanine from being made.
Case 3. Testosterone binding bv the mutated antibody with 
glutamate in place of Tvr-97.
The side chain of glutamate, like tyrosine may participate in forming hydrogen 
bonds; however, unlike tyrosine, glutamate is a charged amino acid and the 
introduction of the charge into the cavity may result in a perturbation o f the 
antigen binding site; for example, by causing the VH and VL-domains to move apart. 
Disruption o f the conformation o f the antigen binding site may result in less 
exacting complementarity between the antibody and testosterone and as a 
consequence less water may be displaced from the antibody surface on testosterone 
binding. This situation would result in less entropy being gained by the system 
when testosterone binds to the mutated antibody with glutamate at CDR-H3 residue- 
97 than when testosterone binds the wild type antibody. Testosterone binding to 
the mutated antibody will, therefore, be less favourable and result in a decrease 
in affinity for testosterone. Several other explanations may also account for the 
apparent reduction in affinity of the mutated antibody with glutamate in place of 
Tyr-97, but the above explanation allows for the observation that this mutated 
antibody retained the ability to bind testosterone in the ELISA.
A discussion of the above data would not be complete without also considering 
the possibility that the observed reductions in affinity for testosterone 
associated with the mutations results, not directly from the substitutions, but 
results from a conformational change that is propagated from residue 97 to other 
residues o f the antibody that make direct contact with testosterone. This 
explanation can only be proven by direct evidence i.e. a crystal structure of the 
antibody-testosterone complex. However, the ability of the mutated antibody with 
phenylalanine in place of Tyr-97 (Ab-14) to bind testosterone with a reasonable 
affinity (Kd 3.4 x 10“ 8 M) implies that any conformational change(s) associated 
with the tyrosine to phenylalanine substitution are likely to be small.
In conclusion, a combination of molecular modelling and site-directed 
mutagenesis has successfully been used to identify CDR-H3 Tyr-97 as a residue 
critical for the affinity of the bovine antibody for testosterone. Several lines 
o f indirect evidence which support the findings of the model have been discussed 
in Chapter 6. The mutagenesis data presented above adds further to that evidence 
and supports the major prediction made from observations of the model that CDR-H3 
Tyr-97 forms a hydrogen bond with the hydroxyl group on the D-ring of 
testosterone. Examined together, the accumulated evidence suggesed that the
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overall shape o f the modelled antigen binding site is correct and furthermore, 
that the residues that line the 'walls' o f the modelled cavity are those most 
likely to form the antibody paratope. It was, therefore, concluded that the model 
of the antigen binding site of the bovine antibody formed a good base upon which 
rational amino acid substitutions could be chosen in attempts to increase the 
affinity of the antibody for testosterone.
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GENERAL DISCUSSION. SUMMARY AND PROPOSALS 
FOR FURTHER INVESTIGATIONS.
CHAPTER 8.
CHAPTER 8.
GENERAL DISCUSSION, SUMMARY AND PROPOSALS FOR 
FUTURE INVESTIGATIONS.
8.1 The cDNA and Derived Protein Sequence of the Bovine 
Anti-testosterone Monoclonal Antibody.
cDNAs that encode for the heavy and light chains of a bovine anti-testosterone 
monoclonal antibody secreted by a mouse x bovine heterohybridoma (Groves et al., 
1987a) have been cloned and sequenced. The proteins encoded by the cDNAs were 
identified as Ig chains by sequence homology with Ig of other mammalian species. 
The heavy chain was identified as bovine C-gamma-1 by a comparison of the derived 
protein sequence for the C-terminus of the CH3-domain with the protein sequence of 
this region in bovine C-gamma-1 and C-gamma-2 heavy chains (Milestein and 
Feinstein, 1968). The light chain was identified as a lambda isotype by the 
presence of highly conserved residues that are unique to lambda light chains 
(Kabat et al., 1987).
The cDNAs are the first to be described for functionally rearranged Ig genes 
from the bovine species. A J-region has been identified at the C-terminus of the 
VL and VH-domains. In addition, CDR-H3 is 14 residues long which implies that a D- 
segment contributes to the coding region of this CDR (Kabat et al., 1987). Identi­
fication of JL, JH and probably a D-segment strongly imply that both the germline 
organisation of V-region DNA and its assembly into V-exons are likely to be 
similar to that of other mammalian species (Tonegawa, 1983).
8.1.2 The heavy chain.
The nucleotide and derived protein sequences of the hinge region and those of 
the C-domains o f the heavy chain are in complete agreement with those o f the 
coding sequence of a recently reported bovine germline C-gamma-1 gene (Symons et 
al., 1989). The heavy chain cDNA of the bovine antibody, therefore, confirms the 
splice sites proposed for RNA transcripts derived from the bovine C-gamma-1 gene.
The CH2 domains include the sequence motif Gln-318, Lys-320, Lys-322, which has 
been identified as the binding site for Clq on human and murine IgGs (Duncan and 
Winter, 1988). The presence of a Clq binding site on bovine IgGl is consistent
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with the ability of this isotype to activate homologous complement (Howard and 
Brownlie, 1979).
The hinge-CH2 link region o f bovine IgGl includes the sequence 
(234-Leu-Pro-Gly-Gly-Pro-238), that differs at only a single residue (residue-235) 
from that of the known human monocyte Fc-gammma receptor (FcRI) binding site on 
human IgGl [234-Leu-Leu-Gly-Gly-Pro-238. (Duncan et al., 1988)]. Bovine IgGl 
binds human monocytes, albeit with reduced affinity when compared to human IgGl 
(Nash et al., 1990). It is, therefore, possible that the Leu-235 to Pro-235 
substitution results in a functional binding site for human FcRI but binds with a 
weaker affinity; however, bovine IgGl also binds human B-cells which do not 
express FcRI (Anderson and Looney, 1986; Hogg, 1988). Bovine IgGl may, therefore, 
bind human monocytes and B-cells through an Fc-gamma receptor that is common to 
both of these cell populations. Consistent with the latter possibility, both human 
monocytes and B-cells express Fc-gamma-RII receptors. Bovine IgG2 also binds human 
monocytes, but does not bind human B-cells (Nash et al., 1990). The hinge-CH2 link 
region o f bovine IgG2 is shorter than those o f other mammalian IgGs and the 
residues that bind the human monocyte FcRI receptor have been deleted (Symons et 
al., 1990). It is, therefore, unlikely that bovine IgG2 binds human monocytes 
through interactions with FcRI. The sequences of bovine C-gamma-1 and C-gamma-2 
heavy chains and the binding specificities of bovine IgGl and IgG2 isotypes (and 
their proteolytic fragments) for human Fc-gamma receptors (FcRII and FcRIII), may, 
therefore, aid the identification o f regions on human IgGs involved in binding 
these receptors.
8.1.2 The light chain.
The complexity of the lambda light chain locus in the genome of mammalian 
species appears to correlate with the appearance of lambda light chains in their 
Igs i.e. the greater the number of C-lambda genes the greater the incidence of 
lambda light chain containing Igs. In the mouse, in which only approximately 5-10% 
of Igs have lambda light chains, the organisation is relatively simple: only two 
V-lambda germline gene segments have been identified, each associated with its own 
cluster of two J-lambda - C-lambda units (Tonegawa, 1983). In the rat, like the 
mouse, only a small percentage of Igs have lambda light chains and the 
organisation is similar to that of the mouse, except that only a single V-segment 
and two C-genes have been identified. In man, in which approximately 33% of Ig 
have lambda light chains, six distinct C-lambda genes have been identified, 
suggesting that at least this many genomic V-lambda and J-lambda segments are 
available for recombination. The Igs of cattle appear to have only lambda light
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chains, as light chains of the kappa class have not been identified. The absence 
o f kappa light chains in bovine Igs suggests that the bovine genome may contain 
several C-lambda light chain genes. Hybridisation studies, using a murine C-lambda 
light chain probe, have identified the presence of at least two C-lambda genes in 
bovine liver DNA (Figure 12) as none of the enzymes used in this analysis cut 
within the CL-domain coding sequence of the cloned bovine light chain cDNA. The 
analysis using Hind III (Figure 12, lane 3) suggests that as many as 4 C-lambda 
genes may be present as 4 bands of specific hybridisation are seen.
8.2 Testosterone Binding by the Antibody Encoded by the cDNAs.
Full-length heavy chain cDNA was constructed from 2 overlapping clones and the 
integrity of the translational reading frame verified by DNA sequencing through 
the joining site. The heavy and light chain cDNAs were expressed, individually and 
simultaneously in COS-1 cells. Testosterone binding antibodies were only detected 
in cell culture medium from cells cotransfected with expression vectors including 
both the heavy and light chain cDNAs.
8.3 Selective Transport of bovine IgGl into Colostrum.
The selective transport o f IgGl into colostrum is a property unique to 
ruminants (Butler, 1983). In cattle, the selective transport mechanism is known to 
involve determinants on the heavy chain of IgGl and the appearance of Fc receptors 
specific for IgGl on the surface o f mammary epithelial cells at and near 
parturition (Kremler et al., 1975; Sasaki et al.,1977). Binding the bovine mammary 
epithelial IgGl receptors is a property shared by heterologous IgGs (Kremler et 
al., 1975). The sequences and binding specificity of bovine IgGl and IgG2, as 
well as those of human and rabbit IgG isotypes for the bovine mammary epithelial 
IgGl receptor, have been compared in an attempt to identify a region(s) on bovine 
IgGl that is involved in receptor binding. This analysis identified the hinge-CH2 
link region (particularly Leu-235) as the most likely site on bovine IgGl that may 
be involved in receptor binding. The involvement of this region is supported by 
the inability of Fab and Fc fragments, derived from bovine IgGl by papain 
digestion, to inhibit the binding o f bovine IgGl to bovine mammary epithelial 
cells (Kremler et al., 1975). Papain cleaves bovine IgGl between residues 234 and 
235 (Wie et al., 1978).i.e immediately adjacent to the residue proposed as the 
major determinant in receptor binding.
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8.4 Interaction of the wild-type and mutated antibodies with testosterone.
A three-dimensional molecular model of the antigen binding site of the bovine 
anti-testosterone monoclonal antibody, secreted by a bovine x mouse 
heterohybridoma (BMT.4A), has been made. The model was constructed to aid 
investigations of the interactions between the antibody and testosterone and the 
rationale design of an antibody with higher affinity.
The major structural feature described by the model was a hydrophobic cavity 
formed exclusively by residues of five of the CDRs (excluding LI), CDR-H3 Tyr-97 
(Tyr-97) occupied the bottom of the cavity with its side chain orientated such 
that the hydroxyl group was available for interactions with solvent molecules. 
Based on these observations, testosterone was predicted to fit into the cavity on 
formation of the antibody-testosterone complex and establish a hydrogen bond, 
through the hydroxyl group of the D-ring, with the hydroxyl group of Tyr-97. In 
addition, CDR-L3 Ala-96, Gly-95b and the side chain of Arg-95a present a 
hydrophobic surface with which testosterone could form an interface when bound in 
the cavity in an orientation that satisfies the above hydrogen bond. Several lines 
of indirect evidence have been presented in support of the major findings of the 
model (section 6.5.2) which suggested that the modelled structure represented a 
good base upon which to undertake investigations of the molecular interactions 
between the antibody and testosterone. Site-directed mutagenesis of Tyr-97 was 
selected as the first experiment, to test the above predictions.
Mutated antibodies, in which either phenylalanine (Ab-14) or glutamate (Ab-15) 
replaced Tyr-97, were constructed and expressed in COS-1 cells. Testosterone 
binding activity was retained by the mutated antibodies as demonstrated by an 
ELISA specific for bovine anti-testosterone IgG. The effect of the mutations on 
the interaction between the antibody and testosterone were quantitated by 
calculating the Kd of the wild-type and mutated antibodies. The Kd of Ab-14 was 
reduced by nearly 3 orders o f magnitude compared to the wild-type antibody, 
whereas the affinity o f Ab-15 appeared to be greatly reduced and could not be 
calculated under the assay conditions used. Definitive statements o f the effects 
o f the mutations on the structure o f the antibody and its interactions with 
testosterone cannot be made as these structures are unknown; however, with 
reference to the model, a possible explanation that considers the enthalpy (AH) 
and entropy (A) changes that may occur on testosterone binding by the wild-type 
(WT-Ab) and mutated antibodies has been proposed to account for the changes in Kd 
associated with the mutations.
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The binding energy associated with the reduction in Kd of Ab-14 was estimated 
to be 3.8 kcal mol""1 which is remarkably consistent with the reduction in binding 
energy that may be expected for the loss of a single hydrogen bond between 
components, one of which is on a flexible side chain (Tyr-97) and the other which 
is relatively fixed (The hydroxyl on testosterone. (Fersht et al., 1985; Bartlett 
and Marlowe, 1987; Bash et al., 1987)).
The results of the site-directed mutagenesis experiments added further to the 
evidence in support of the major findings of the model and the predicted 
interaction between the antibody and testosterone. Examined together, the evidence 
suggested that the model represented a good base upon which to design an antibody 
with enhanced affinity for testosterone.
8.5 Increasing the Affinity of the bovine Anti-testosterone Monoclonal Antibody.
Increasing the affinity of this particular anti-testosterone antibody may prove 
difficult (see below) as its affinity is already relatively high (Kd = 2.5 x 10” 
11 M). Nonetheless, an ovine anti-testosterone monoclonal antibody with a higher 
affinity (Kd = 7.5 x 10” 12 M) has been produced (Groves et al., 1988b), which 
implies that anti-testosterone antibodies with higher affinity than the monoclonal 
antibody secreted by BMT.4A are feasible. In addition, ovine polyclonal antisera 
with avidities in the 10” 14 range have been raised against both oestradiol (which 
has a similar structure to testosterone) and fluorescein iso-thiocyanate 
(B.A.Morris, personal communication) which suggests that antibodies with 
affinities even higher than 10“ 11 M are possible.
Several studies have demonstrated that the affinity of an antibody for its 
specific antigen may be increased by the introduction of amino acid substitutions 
in the CDRs (Allen et al., 1987; Roberts et al., 1987; Allen et al., 1988). In 
these studies, the increases in affinity obtained by the intoduction o f a single 
amino acid substitution ranged from 3 fold to 12.9 fold. The studies of Allen et 
al., (1988) identified at least two unspecified substitutions that are responsible 
for an observed increase in affinity of 100 fold. These changes are required 
together in combination with each other since the individual mutations do not 
result in antibodies of higher affinity. Similarly, a combination of two amino 
acid substitutions in a anti-lysozyme monoclonal antibody have been demonstrated 
experimentally to be responsible for an 8-9 fold increase in affinity (Roberts et 
al., 1987); however, in this case, both o f the individual substitutions resulted 
in an antibody with higher affinity. The results of these studies demonstrate that 
improvements in the affinity o f an antibody for its antigen may be made by
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introducing single amino acid substitutions and that the effects o f multiple 
substitutions on affinity may be additive. In each case, the antibodies in 
question originally had affinities for their antigen that were at least 3 orders 
of magnitude lower than that of the bovine antibody investigated in this study. In 
addition, some of the antibodies used in these studies were germline encoded and, 
therefore, have not been exposed to somatic hypermutation mechanism. The 
testosterone-sensitised B-cell used to construct the heterohybridoma (BMT.4A) was 
derived from a secondary immune response and the V-exons, therefore, may have 
already been extensively mutated.
The affinity of an antibody for its antigen depends on both the dimensions of 
the buried surface area and the nature o f specific interactions at the antibody- 
antigen interface. The contribution of specific interactions to binding energy has 
been demonstrated by crystallographic studies o f thermolysin complexed with 
inhibitors of its catalytic activity (Bartlett and Marlowe, 1987; Tronrud et al., 
1987). Incorporation of one additional hydrogen bond into the enzyme-inhibitor 
interface results in an increased affinity for inhibitor by 840 fold.
The above discissions suggest that the routes to an antibody with enhanced 
affinity may involve specific amino acid substitutions that:
1. Increase the dimensions of the surface area buried at the antibody-antigen
interface.
2. Increase the number of specific interactions at the antibody-antigen interface.
3. Result in the interacting surfaces of the antibody and antigen moving closer 
together, thereby increasing the strength of both van der Waals contacts and 
specific interactions.
Testosterone is a relatively small molecule and the existing high affinity of 
the bovine antibody (Kd = 2.5 x 10” 11 M. (Groves etal., 1987a)) implies that a 
large proportion of the surface area of the testosterone molecule already makes 
contact with the antibody. In addition, the only site available for specific 
interactions on the testosterone molecule (i.e. the hydroxyl group on the D-ring) 
has been strongly implicated to form an existing hydrogen bond with CDR-H3 Tyr-97. 
These observations suggest that improving the affinity of the bovine antibody may 
prove difficult; however, the model revealed a structural feature o f the cavity 
that, if real, has the potential to be exploited in attempts to design an antibody 
with higher affinity.
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In the model of the antigen binding site the 'wall' o f the cavity is 
incomplete as part of the upper region is not filled by protein structure (Figure 
30). Closing this ’gap' may, therefore, allow for the surface area of the antibody 
that is in contact with testosterone to be increased. CDR-H2 Gly-50 and CDR-H1 
Ala-33 are positioned in the lower region o f the cavity and are orientated such 
that their side chains point towards the gap in the cavity wall. Replacement of 
these residues by non-polar amino acids with larger side chains (e.g alanine or 
valine for CDR-H2 Gly-50 and valine or isoleucine for CDR-H1 Ala-33) may, 
therefore, result in a larger contacting surface. In addition, replacement of 
these residues by an amino acid including an aromatic side chain (e.g 
phenylalanine or tyrosine) may result in a greater increase in affinity as the 
'fused' carbon atoms of the aromatic ring may result in a reduction in the loss of 
conformational entropy that could occur on complex formation (Padlan, 1990). 
Furthermore, the side chain of CDR-H3 Asp-100b runs along the 'rim'of the cavity 
with its charge on the protein surface where it may interact with solvent 
molecules. It may, therefore, also be possible to close the gap in the cavity wall 
by substituting an amino acid with a longer side chain at this site. However, it 
is possible that the 'gap' in the cavity wall may be a structural requirment for 
the entry of testosterone into the cavity and mutations that reduces its size may 
preclude binding.
A second possible route to obtaining an antibody with greater affinity may be 
by introducing specific amino acid substitutions that result in closer contact 
between the antibody and testosterone. Closer contact between the antibody and 
testosterone may improve the strength of both hydrophobic interactions and the 
predicted hydrogen bond between CDR-H3 Tyr-97 and the hydroxyl group of 
testosterone, thereby resulting in an antibody with higher affinity. On 
inspection the model, the side chains of residues positioned adjacent to CDR-H3 
Tyr-97, namely CDR-L3 Ala-96 and CDR-H3 Thr-96, appeared to protrude further into 
the cavity than the other amino acids in the immediate surrounding area. Reducing 
the volume occupied by these residues and/or removal of the hydroxyl group of CDR- 
H3 Thr-96 may allow for closer contacts between testosterone and the antibody. A 
reduction in the volume occupied by alanine may be achieved by substitution of 
glycine, whereas reducing the volume of threonine may be achieved by substition 
of alanine. The hydroxyl group of CDR-H3 Thr-96 may be replaced by a methyl group, 
with little change to the volume occupied by the this residue by the substitution 
of valine at this site.
As stated above, the effects of single amino acid changes on the affinity of an 
antibody for its antigen may be additive and it is, therefore, suggested that
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introducing the above changes in various combinations should be considered.
The design o f specific amino acid substitutions aimed at increasing the 
affinity of the antibody for testosterone may be further aided by modelling a 
molecule o f testosterone into the cavity. Such a model should consider the 
flexible nature o f the VL:VH interface and, therefore, the possibility that the 
relative spatial arrangement of the CDRs in the modelled antigen binding site may 
differ from that in the bovine antibody.
In the absence o f a crystal structure, a combination of molecular modelling and 
site-directed mutagenesis has been sucessfully used to identify a tyrosine residue 
that is critical for the high affinity o f a bovine anti-testosterone monoclonal 
antibody. In future experiments, it is envisaged that the predictions o f the 
interaction between the antibody and testosterone will be further tested by the 
introduction of specific amino acid substitutions at CDR residues. For example, in 
the model CDR-L1 does not form part o f the cavity and is predicted not to make 
contact with testosterone. Introducing mutations into CDR-L1 should, therefore, 
have little or no effect on the affinity o f the bovine antibody for testosterone. 
The evidence in support of the predicted hydrogen bond between the hydroxyl groups 
of CDR-H3 Tyr-97 and the D-ring of testosterone would be further supported by 
calculating the Kd of the wild-type antibody for a testosterone molecule in which 
the D-ring hydroxyl group has been replaced by a hydrogen atom.
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